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ABSTRACT 
The neuro-inflammatory mechanisms in chronic neuropathic pain are poorly 
understood, particularly in the central nervous system (CNS), and represent 
important targets for the development of novel analgesics. Inflammation 
associated with nerve injury produces a number of pathogenic chemical 
mediators of which prostanoids are a potent component. Recent studies 
show that inflammatory processes may contribute to neuropathic pain. 
Cyclooxygenases (Cox-1 and Cox-2) are the enzymes responsible for 
prostanoid production. Cyclooxygenase-2 (Cox-2) sensitise sensory 
neurones via the EP1 receptor. We have investigated EP1 and EP4 
receptors, Cox-1 and Cox-2 expression and glial activation in human nerves, 
dorsal root ganglia (ORG) and in the chronic constriction injury (CCI) rat 
model, using immuno-histological and autoradiographic methods. T cell 
mediated immune response (Cathepsin S and lymphocytes) were 
investigated in human injured peripheral nerves. EP1 and Cox-2 were also 
investigated in the human CNS. Since plasticity and neuro-degenerative 
processes are thought to play an important role in generating chronic pain, 
particularly de-afferentation pain, inhibitory mechanisms on axonal 
regeneration (Nogo and its receptor) were also investigated. 
Human and rodent tissues were immunostained with antibodies to EP1, EP4, 
Cox-1, Cox-2, cathepsin S, CDS and CD4 (lymphocyte markers), Nogo-A 
and Nogo-66 receptor (myelin associated protein and receptor), prior to 
image analysis. To assess macrophage/microglial cells, antibodies to CD68 
(human macrophage marker), OX-42 (rat microglial marker), ferritin 
(microglia/macrophage-IIke cell marker) or radioligand PK11195 (marker of 
glial activation) were used. 
In human nerves, Cox-1 and Cox-2 immunoreactivity was detected in cells 
with morphology and distribution similar to microglia/macrophage-IIke cells. 
EP1 and Cox-2 expression was significantly Increased in human nerve 
proximal to injury. While there was a rapid Increase in EP1-fibres and CD68 
positive macrophages, Cox-2 increase was apparent later reaching a peak at 
4 - 6 weeks after injury, but was persistent in human painful neuromas for 
years. Cox-1 expressing cells appeared after the transient Cox-2 peak and 
remained present over many years. Sensory neurones in injured human 
DRG showed a significant acute increase of EP1-IR intensity. EP4-IR was 
found to be increased in injured peripheral nerves (acute, chronic and 
neuromas) while decreased in injured DRG sensory neurones (acute and 
chronic) suggesting a translocation of the protein from the soma on to the 
proximal nerve axon after injury. Cathepsin S levels were increased 
immediately after injury and lasted only for a period of 2 weeks with the 
gradual appearance of lymphocytes thereafter. 
In the rat CCI model, at 40 days after injury, microglia-like cells with Cox-2-IR 
were increased significantly in the injured nerve, and ipsilateral dorsal spinal 
cord. PK11195 binding results were similar than for Cox-2-IR in chronic 
injured human nerve and rat tissues. 
In the CNS studies, EP1 and Cox-2 expressing microglia/macrophage-like 
cells were found present in the human spinal cord and more so in 
neurological conditions with neuroinflammation and neurodegeneration. 
Diseased human spinal cord showed increased expression of Nogo-A and of 
Nogo-66 receptor compared to controls. 
Different stages of infiltration and activation of macrophages may thus be 
observed in the peripheral and central nervous system following peripheral 
nerve injury. EP1 receptor level increase in sensory neurones, and 
macrophage infiltration, appears to precede increased Cox-2 expression by 
macrophages. The findings suggest that Cox-2-immunoreactive cells could 
play a role in processes associated with Wallerian degeneration, nerve 
regeneration, and the development of persistent pain. Selection of patients 4 
to 6 weeks after nerve injury would be more likely to show any efficacy of 
Cox-2 inhibitors. EP1 antagonists may show therapeutic effects in acute and 
chronic neuropathic pain, in addition to inflammatory pain. Finally, the data 
supports blockade of Nogo-A and its receptor as being potentially therapeutic 
in neurodegenerative and neuro-inflammatory disorders, and deserves trials 
in chronic pain states. 
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Introduction 
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1.1. Inflammatory and neuropathic pain 
Peripheral and central neuro-inflammatory and non-neuronal mechanisms of 
neuropathic chronic pain are poorly understood, and represent important 
targets for the development of novel analgesics. Neuropathic and 
inflammatory pain present distinct features, and have therefore been 
classified in separate categories, with only a small area of overlap 
representing the neuroimmune interactions (Taylor, 2001). However, current 
knowledge of pain mechanisms has somewhat blurred the margins of this 
overlap, and instead of a strict categorical distinction between neuropathic 
and inflammatory pain processes, a continuum, with each on either end of 
the spectrum, has been suggested (Backonja, 2003). 
Inflammatory pain such as in rheumatoid arthritis (RA) and osteoarthritis 
occurs in response to non-neuronal tissue damage with the release of 
various inflammatory agents and cells such as local macrophages. This 
response can trigger excitatory changes in the periphery at the site of injury 
and in the central nervous system (CNS) resulting in a hypersensitivity of the 
inflamed and surrounding tissue (hyperalgesia). Additionally a secondary 
response occurs when non-noxious stimuli such as light touch begins to 
cause pain (allodynia). Finally central mechanisms also become involved 
such as central sensitisation (Woolf and Costigan, 1999). 
The current definition of neuropathic pain, as proposed by the International 
Association for the Study of Pain, is "pain initiated or caused by a primary 
lesion or dysfunction of the nervous system" (Merskey et al., 1994). This 
definition is currently under debate, partly due to its focus on the nervous 
system, and neglect of the possible contributions of the immune system 
(DeLeo and Yezierski, 2001, Watkins and Maier, 2002, Sommer and Kress, 
2004). Neuropathic pain caused by peripheral nerve or CNS damage is 
associated with a number of pain syndromes (Table 01.01) and mechanisms 
(Koltzenburg and Scadding, 2001, Jensen et al., 2003). Clinical trials have, 
nevertheless, mainly focused on postherpetic neuralgia (PHN) or painful 
diabetic neuropathy (PDN). The underlying pathophysiological mechanisms 
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and therapeutic strategies in these two peripheral neuropathic pain 
syndromes have been generalised to others; however, the extent to which 
pathophysiological mechanisms and pharmacological treatments are shared 
remains to be determined (Dworkin et al., 2003). 
Table 01.01. Listing of most common neuropathic pain syndromes. 
Peripheral Neuropathic Pain Syndromes 
Metabolic Neuropathies (e.g., Painful Diabetic Neuropathy; PDN) 
Neuropathies due to Nutritional Deficiencies [e.g.. Vitamin B1 
(Thiamine), Vitamin B6 (Pyridoxine)] 
Toxic Neuropathies (e.g.. Alcohol, thallium poisoning, mercury 
poisoning, Antiretroviral drugs) 
Autoimmune Neuropathies 
Human HIV-associated painful peripheral neuropathy 
Postherpetic neuralgia (PHN) 
Complex regional pain syndrome (CRPS) 
Nerve compression and Entrapment Neuropathies 
Polyneuropathies such as chronic inflammatory demyelinating 
polyneuropathy (CIDP) 
Phantom Limb Pain 
Central Neuropathic Pain Syndromes 
Central Poststroke Pain 
Multiple Sclerosis Pain 
Parkinson Disease Pain 
Spinal Cord Injury Pain 
For instance, clinical studies have demonstrated that within one diagnostic 
group of patients, drug treatment can vary (Galer et al., 1993, Byas-Smith et 
al., 1995, Dellemijn et al., 1998, Fields et al., 1998). The coexistence of 
multiple pain mechanisms within patients, that may vary between patients, 
could explain the heterogeneous patterns of symptoms and signs seen within 
one syndrome (Dworkin, 2002). Hence current research and treatment 
strategies efforts are more directed towards the identification of specific 
pathophysiological mechanism of a patient's pain with treatment focused to 
that specific mechanism (Woolf and Max, 2001, Dworkin et al., 2003). A 
considerable body of evidence has been generated in support of the trend 
towards a mechanism-based classification of pain (Craig, 2003) challenging 
the conventional disease-based evaluation of neuropathic pain, i.e. 
classification based on injury to nervous system aetiology or on anatomical 
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distribution of the pain (Woolf and Mannion, 1999, Woolf, 2004b). However, 
a consensus has been reached across different pain research sectors that 
currently it is not possible to evaluate a specific mechanism in a given 
patient, leaving the mechanism-based treatment approach still on a 
conceptual level (Woolf and Max, 2001). Consequently, for the time being, a 
more clinically oriented approach is more realistic and pragmatic (Bouhassira 
et al., 2004). 
1.2. Clinical symptoms in neuropathic pain 
Two main broad types of pains have been characterised when assessing 
clinical symptoms in neuropathic pain - stimulus-dependent pain or stimulus-
evoked pain, and stimulus-independent pain or spontaneous pain. A number 
of underlying pathophysiological mechanisms may be responsible for these 
different types of pain (Bolay and Moskowitz, 2002). A brief description of 
these different types of pain is given below. 
1.2.1. Stimulus-evoked pain 
Stimulus-evoked pain (also called stimulus-dependent pains) refers to 
abnormal pain sensations caused by external stimuli such as gentle touch, 
pressure of clothing or hot and cold temperatures (Dworkin et al., 2003). 
The various types of evoked pain, characterised by hypersensitivity of the 
nervous system, include allodynia and hyperalgesia (Jensen et al., 2001, 
Dworkin, 2002). Allodynia refers to pain in response to a normally non-
painful stimulus (Merskey et al., 1994). Hyperalgesia refers to the lowering 
of the pain threshold or the increased pain in response to a normally painful 
stimulus (Merskey et al., 1994). Several types of allodynia and hyperalgesia 
have been distinguished and defined according to the stimulus used in their 
evaluation. These include thermal, vibration, dynamic, and static (punctuate 
or blunt; Jensen et al., 2001, Dworkin, 2002). Furthermore, findings suggest 
that each type of hypersensitivity can be mediated by different nerve fibres. 
For example, dynamic mechanical allodynia was found to be mediated by 
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low threshold Ap fibres whilst heat hyperalgesia appears to be more 
mediated by the sensitisation of C nociceptors (Koltzenburg et at., 1992, 
Torebjork et al., 1992, Ochoa and Yarnitsky, 1993, Kilo et al., 1994, Baron, 
2000). A consensus has been reached that painful and non-painful 
responses irrespective of the type of stimuli are activated by different 
neurophysiological mechanisms. In general, A^-fibre mechanoreceptors 
appear to be mostly triggered by non-painful mechanical stimuli whilst A5-
and C-fibre nociceptors more by painful stimuli (Dworkin, 2002). Finally, 
allodynia has more a qualitative attribute in the perception of pain, whilst 
hyperalgesia is more quantitative (Suzuki and Dickenson, 2000). 
1.2.2. Spontaneous pain 
Spontaneous pain or stimulus-independent pain is characterised by its 
occurrence in the absence of any association with external stimuli. This type 
of pain has been described by patients as being either continuous or 
intermittent, and as having different qualities such as burning, throbbing or 
shooting. Spontaneous pain can be continuous pain or tonic, with varying 
intensity. On the other hand, spontaneous intermittent pain is often 
paroxysmal, short in duration and described as shooting, stabbing or electric-
shock-like in quality (Woolf and Mannion, 1999, Taylor, 2001, Dworkin, 
2002). Paroxysmal pain appears to occur more in tic douloureux, in 
entrapment neuropathies and in amputees (Jensen et al., 2001). 
1.2.3. Negative & positive symptoms 
Negative symptoms (or negative phenomena) refer to loss of sensory and/or 
motor input due to nerve damage. Afferent nerve impairment results in area 
of sensory deficit and is often experienced by patients as numbness. 
Efferent nerve impairment results in motor deficit mostly experienced by 
patients as weakness (Taylor, 2001). 
Positive symptoms (or positive phenomena) refer to enhanced, abnormal or 
disagreeable sensations. Patients report these positives symptoms or signs 
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in addition to spontaneous or stimulus-evoked pain and are often described 
as non-painful but disturbing (Backonja, 2003). They include paraesthesia, 
an abnormal but non-painful spontaneous or evoked sensation such as pin 
and needles. Spontaneous bursts in Ap-fibres are thought to be responsible 
for this type of sensations. Hyperaesthesia represents heightened but non-
painful appreciation of sensation. Finally, dysaesthesia refers to abnormal 
unpleasant sensations but not necessarily painful which can be spontaneous 
or stimulus-evoked. These latter sensations are most likely generated by 
sensitised C-nociceptors and evoked dysesthesia appears to show no 
qualitative difference with evoked hyperalgesia (Stewart John, 2000, Jensen 
et al., 2001, Dworkin, 2002). 
1.3. Treatment in neuropathic pain 
Antidepressants and anticonvulsants have become the most commonly used 
drugs in treating neuropathic pain, since conventional analgesics such as 
aspirin, acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) 
have shown little effectiveness in alleviating chronic neuropathic pain 
(MacFarlane et al., 1997, Sindrup and Jensen, 1999, Attal, 2000, 
Koltzenburg and Scadding, 2001). They have been in use for over 30 years 
in the management of chronic neuropathic pain (McQuay, 2002). Other drug 
classes of established efficacy are used in the pharmacologic treatment of 
peripheral neuropathic pain i.e., local anaesthetics and derivatives, opioids, 
capsaicin, and N-methyl-D-asparate (NMDA) antagonists (Attal, 2000, 
Koltzenburg and Scadding, 2001, Wallace, 2001, Dworkin et al., 2003). It is 
essential to understand the underlying pathophysiological mechanisms 
whenever possible when treating neuropathic pain. Chronic pain caused by 
injury to peripheral nerves can often be severe, disabling and difficult to treat 
(German et al., 1998). The effectiveness of available drugs to treat 
neuropathic pain has been extensively reviewed (McQuay et al., 1996, 
Kingery, 1997, Sindrup and Jensen, 1999, Attal, 2000, Collins et al., 2000, 
Sindrup and Jensen, 2000, Wiffen et al., 2000, Wallace, 2001, McQuay, 
2002). Clinical trials have mainly been carried out with postherpetic 
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neuralgia, diabetic polyneuropathy or HIV-related neuropathy. Their main 
shortcomings were small number of patients with treatment efficacy 
overestimation as a result, too little power to detect adequate statistical 
significance levels, too few studies used parallel group design and only the 
most common drugs have been investigated (Koltzenburg and Scadding, 
2001). 
1.3.1. Antidepressants 
Tricyclic antidepressants (TCAs) demonstrated their effectiveness in 
numerous clinical trials and remain the most effective treatment regime in 
many various types of neuropathies. The analgesic effects of this class of 
drugs are not fully understood and their mechanisms of action remain to be 
determined. It is hypothesised that they have effects based on their sodium 
channel antagonistic abilities and that they also exert their action at the 
descending inhibitory serotoninergic nociceptive system. The most 
commonly prescribed TCAs are imipramine, clomipramine, amitriptyline, 
desipramine, nortriptyline and maprotiline. Comparatively in trials, these 
TCAs showed no significance difference in efficacy over each other (Attal, 
2000, Koltzenburg and Scadding, 2001, Shembalkar and Anand, 2003). A 
newer class of antidepressants, the serotonin specific reuptake inhibitors 
appear to have little analgesic effects in neuropathic pain but too few 
systematic clinical trials in humans have been carried out so far (Jett et al., 
1997, Mattia et al., 2002). The impetus behind the search for more selective 
drugs such as noradrenaline and/or serotonin inhibitors emerged because of 
the side-effect profile from TCAs. Most TCAs are sedatives and pain relief is 
often not achieved without side-effects (Attal, 2000, Wallace, 2001). 
1.3.2. Antiepileptics 
Antiepileptics have been in use to treat neuropathic pain for at least 30 
years, since Ellenberg treated successfully with phenytoin more than 70% of 
patients with diabetic polyneuropathy (Ellenberg, 1968). The sodium 
channel blockers appear to be effective in reducing lancinating pain, 
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paraesthesia and dysaesthesia predominantly caused by abnormal ectopic 
neuronal firing in peripheral nerves fibres of dorsal root ganglion (Swerdlow 
and Cundill, 1981, Tanelian and Brose, 1991). Use of antiepileptics such as 
carbamazepine has proved to be a challenge mostly due to their high side-
effects profile (drowsiness, dizziness and somnolence) when administered at 
higher dosages to increase efficacy. Newer antiepileptics such as 
gabapentin, with lower side-effects profile have therefore become the focus 
of attention in neuropathic pain treatment. Gabapentin is considered to act 
via a calcium channel (Taylor et al., 1998). Numerous clinical trials in a 
broad range of neuropathic pain conditions have been conducted with 
gabapentin, showing its effectiveness in reducing pain (Attal, 2000, Backonja 
and Glanzman, 2003, Bennett and Simpson, 2004). 
1.3.3. Local anaesthetics and derivatives 
Systemic lidocaine and other related local anaesthetics are effective in 
reducing spontaneous pain and mechanical allodynia caused by peripheral 
nerve lesions, diabetes and the herpes related painful neuropathy, but they 
have been less successful in reducing central pain (Attal, 2000). Lidocaine 
can suppress ectopic discharges generated by injured peripheral nerves 
(Tanelian and Brose, 1991, Tanelian and Maclver, 1991). Topical 
anaesthetic treatment such as EMLA cream (prilocaine/lidocaine mixture) 
has also showed some effectiveness in patients with paroxysmal pain and 
mechanical allodynia (Attal et al., 1999). This type of treatment is mostly 
useful where the area of pain is limited (Attal, 2000). 
1.3.4. Opioids 
General consensus accepts the efficacy of opioids (i.e. morphine, codeine, 
fentanyl or oxycodone) in the treatment of neuropathic pain. Predominantly 
centrally acting analgesics, they are generally prescribed to patients with 
moderate to severe acute pain states or that present side effects to TCAs 
and antiepileptics (Attal, 2000, Jensen et al., 2003, Ossipov et al., 2004). 
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1.3.5. Capsaicin 
Capsaicin is the active component of chilli peppers and is responsible of the 
burning and heat sensation. Applied topically it was found to be useful in 
treating chronic pain caused by peripheral nerve damage (Mason et al., 
2004a). Its efficacy is however limited due to its short-lived effect and is 
predominantly used as adjuvant therapy. The underlying mechanism of 
action was thought to occur at C-nociceptive fibres where substance P 
depletion and loss of nociceptor fibres appears (Attal, 2000). 
1.3.6. NIVIDA (N-methyl-D-asparate) antagonists 
NMDA antagonists such as ketamine when given intravenously or 
subcutaneously have demonstrated some effects in reducing pain, however, 
their use is limited due to a high side effect profile such as sedation, 
decreased reaction time and hallucinations (Attal, 2000). 
1.3.7. Non-steroidal anti-inflammatory drugs (NSAIDs) 
One of the most frequent and widely used class of drugs in our society, the 
NSAIDs are well known for their analgesic, antipyretic and anti-inflammatory 
properties (Steinmeyer, 2000, Flower, 2003, Sawynok, 2003). Since the 
seventies it was understood that the mechanism of action of NSAIDs was to 
inhibit the formation of prostaglandins (PGs) via the cyclooxygenase (Cox) 
enzyme of which two forms (Cox-1 and Cox-2) have been well characterised 
and further developed in subsequent sections (Vane, 1971, Ferreira, 1972, 
Sirois et al., 1992, Vane et al., 1998). The proposed mechanism of action of 
the NSAIDs was by either covaiently modifying the enzyme or by competitive 
inhibition (Vane and Botting, 2003). It was shown that aspirin-like drugs act 
not only peripherally but also at a central level (Carlsson et al., 1986, 
Carlsson et al., 1988) including the spinal cord (Malmberg and Yaksh, 
1992a). A better understanding of NSAIDs action at the spinal and 
supraspinal levels has dissociated their analgesics effects from their anti-
inflammatory effects (Yaksh et al., 1998). 
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This impetus to develop better NSAIDs was mostly driven in an attempt to 
minimise some of the side effects that they have in common. NSAIDs 
indiscriminately inhibit both Cox enzymes. Since Cox-1 is constitutively 
expressed in the stomach and l<idneys and responsible for maintaining tissue 
integrity, prolonged inhibition of Cox-1 enzyme can lead to destruction of the 
stomach lining or, at very high doses, to kidney failure. Hence the focus was 
to find specific inhibitors to the Cox-2 enzyme, induced by inflammation 
(Vane et al., 1998). A new generation of NSAIDs - selective Cox-2 inhibitors 
(Coxibs) - has seen the light and are available on the market. They include 
Celebrex (celecoxib) (Penning et al., 1997) - others such as Vioxx 
(rofecoxib) (Prasit et al., 1999) and Bextra (Valdecoxib) (Talley et al., 2000) 
have recently been withdrawn from the market because of concerns with 
cardiovascular complications with prolonged use. Cox-2 inhibitors are 
predominantly used for the treatment of pain due to inflammation, and were 
shown to be effective in conditions such as osteoarthritis or rheumatoid 
arthritis (Clemett and Goa, 2000, Pertusi, 2004). 
NSAIDs such as aspirin or acetaminophen (paracetamol) or Cox inhibitors 
have shown little effectiveness to date in alleviating chronic neuropathic pain 
(MacFarlane et al., 1997, Sindrup and Jensen, 1999, Attal, 2000, 
Koltzenburg and Scadding, 2001, Bingham et al., 2004). Animal research 
has established the presence of prostaglandins peripherally and centrally 
following nerve injury. However, while administration of Cox inhibitors 
(mostly selective Cox-2 inhibitors) showed diminution of hyperalgesia and 
allodynia in various rat models of inflammation, this was not observed in 
neuropathic pain (Wallace, 2001). A novel Cox-2 inhibitor (GSK) showed to 
be effective in animal models of neuropathic pain, now in clinical trials, but its 
mechanism of action remains still to be established. This compound may 
have possibly different CNS properties. However in general, currently 
prescribed Cox-1 and Cox-2 inhibitors do not affect animal model or clinical 
neuropathic pain. 
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Few systematic studies have been conducted to investigate a role for Cox 
inhibitors in the treatment of neuropathic pain in humans (Wallace, 2001). 
One case report demonstrated effectiveness using ketorolac, a non selective 
Cox inhibitor, when administered subcutaneously in patients with refractory 
cancer pain (Ripamonti et al., 1996). Another strategy to minimise side 
effects was the development of topical NSAIDs. In general, topical NSAIDs 
given by gel, spray or patch were found to be effective and safe in treating 
mostly acute painful conditions for one week (Sawynok, 2003, Mason et al., 
2004b). While there is increasing evidence of a role for inflammatory 
mechanisms, particularly in the CNS, in neuropathic pain, the currently 
assumed lack of effectiveness of Cox inhibitors deserves an explanation 
(e.g. Lack of CNS penetration or alternative pathways that produce 
inflammatory agents). Neuropathic pain management advancement with 
respect to neuro-inflammatory mechanisms in the peripheral nervous system 
(PNS) and CNS will thus dependent on further clinical and basic research, 
leading to a better account of symptoms and pathophysiological mechanisms 
involved in neuropathic pain (Taylor, 2001). 
1.3.8. Other agents 
Other pharmacological agents and treatment strategies have been 
investigated. A GABA-ergic agonist, baclofen, demonstrated some efficacy 
in trigeminal neuralgia (Fromm et al., 1984), levodopa (Ertas et al., 1998) 
and vitamin supplements (Nash, 1999) in the treatment of painful diabetic 
neuropathy. Transcutaneous electrical nerve stimulation (TENS), 
acupuncture, spinal cord stimulation, cognitive-behavioural rehabilitation or 
surgery have all shown various degree of pain relief in different chronic pain 
states (Jensen et al., 2003). 
1.3.9. Concluding remarks 
The results of published clinical trials and clinical experience provide some 
guide lines for first line treatment and second line treatment options for 
neuropathic pain (Dworkin et al., 2003, Namaka et al., 2004). Nevertheless, 
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apart from some success of pain relief witli carbamazepine in trigeminal 
neuralgia and with gabapentin and TCAs in diabetic neuropathy and 
postherpetic neuralgia, adequate treatment remains still to be determined to 
a vast number of patients with established neuropathic pain. Neuropathic 
pain management advancement will be dependent on further clinical and 
scientific research leading to a better account of symptoms and 
pathophysiological mechanisms involved in neuropathic pain (Taylor, 2001). 
1.4. Animal Models 
Most current understanding of the specific mechanisms that underlie 
neuropathic pain symptoms (spontaneous pain, hyperalgesia and allodynia) 
and the therapeutic effects of new drugs stems from the development of 
neuropathic pain-like animal models. Study of the chronic constriction injury 
(CCI) model of peripheral nerve injury, for example, has led to a better 
understanding of nociception, and the events contributing to the onset and 
development of chronic pain states in patients (Taylor, 2001, Backonja, 
2003). Several animal models have been developed to cover the vast range 
of symptoms expressed in neuropathic pain. The models can be divided into 
three categories 1) peripheral mononeuropathy, 2) peripheral 
polyneuropathy, and 3) central neuropathic pain with human clinical 
correlates for each category respectively - peripheral nerve injuries, diabetic 
peripheral neuropathy and spinal cord injury (Wallace, 2001). Since the 
focus of this project is on chronic persistent pain resulting from peripheral 
nerve injuries only the models from the first category will be addressed. 
1.4.1. Peripheral mononeuropathy models 
Several models of sciatic nerve injury have been developed inducing tactile 
and thermal hypersensitivity. Some of the main models are listed below with 
a brief description (Figure 01.01): 
1) Complete sciatic nerve transection or total sciatic nerve axotomy (Wall et 
al., 1979a) - widely used model to investigate degeneration, regeneration 
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and chronic persistent pain. This model was proposed as a surrogate to 
the human clinical correlate - anaesthesia dolorosa. In this condition 
pain was referred to an area that had no sensory input. Self-mutilation of 
the injured foot (autotomy) was observed and interpreted as a pain 
measure. 
2) Spinal nerve ligation (SNL or Chung model): Tight complete ligation of L5 
or both L5 and L6 spinal nerve (Kim and Chung, 1992, Kim et al., 1997). 
3) Chronic constriction injury model (CCI or Bennett model) where 4 loose 
ligation are placed around the sciatic nerve generating allodynia and 
thermal hyperalgesia in a similar fashion as seen in painful human 
peripheral neuropathies (Bennett and Xie, 1988). The CCI model is 
thought to be principally mediated by a chemical inflammatory response 
generated from the chromic gut sutures (Maves et al., 1993, Meller et al., 
1994). 
4) Partial ligation of the sciatic nerve (PLSN or Seltzer model): a % to % of 
the sciatic nerve is ligated with silk suture (size 6) (Seltzer et al., 1990). 
5) Sciatic cryoneurolysis (SCN model): in this model, the common sciatic 
nerve is exposed and frozen with a cryoprobe proximal to its primary 
trifurcation (DeLeo et al., 1994). 
6) Ischaemic sciatic nerve lesion (Gazelius model): here, the lesion is 
induced photochemically using low power laser. Allodynia was more 
rapid than in the CCI model, lasted longer and was more prominent 
(Gazelius et al., 1996). 
7) Spared nerve injury model (SNI or Woolf model): ligation and section of 
the tibial and common peroneal nerves. This model appears to produce 
a robust and long-lasting increase in tactile and cold sensitivity 
(characteristic in neuropathic pain), in the absence of decreased thermal 
threshold (not characteristic in neuropathic pain) that best mimics 
neuropathic pain in humans (Decosterd and Woolf, 2000). 
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Figure 01.01. Schematic representation of animal models of peripheral 
nerve injury. Wallerian degeneration in the tibial nerve and its branches 
ensues from lesion at 4. Lesions at 2 and 3 would produce Wallerian 
degeneration in the tributaries of the sciatic nerve. A lesion at 1 produces 
transient hyperalgesia, but would not lead to Wallerian degeneration. (1) 
Spinal nerve ligation or Chung model. (2) Chronic constriction injury model 
or Bennett model. (3) Partial sciatic nerve ligation or Seltzer model. (4) 
Spared nerve injury model or Wooif model (From Taylor, 2001). 
1.4.2. Evaluation of the models 
One of the problems of the complete sciatic nerve transaction was that it had 
to rely on a spontaneous outcome measure, in this case autotomy or self-
mutilation of the toe, to assess pain levels, since due to the sensory input 
loss, no response was obtainable with an applied stimulus (Wall et al., 
1979b). Till today no consensus has been reached on whether autotomy 
reflects pain levels or is merely the result of excessive grooming in the 
absence of any sensory feedback (Rodin and Kruger, 1984, Coderre et al., 
1986, Kauppila, 1998). This model is rarely used nowadays as a model of 
neuropathic pain caused by peripheral nerve injury since a complete lesion is 
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usually only observed after amputation where pain modality is of a different 
nature, phantom limb pain (Decosterd and Woolf, 2000). 
The Chung, Seltzer and Bennett models represent the main commonly 
studied peripheral mononeuropathy animal models of pain, that best mimic 
the human clinical correlate of peripheral nerve injuries. One main 
advantage of the newer models compared to the previous model involving 
complete section of the sciatic nerve, is that these models leave a large 
proportion of the motor fibres intact allowing behavioural measurements. 
Another advantage of animal models is that, following peripheral nerve injury, 
biochemical, anatomic and physiological changes in both peripheral and 
central nervous system can be investigated (Taylor, 2001). However these 
models have their limitations, as key differences exist between the model 
and the human clinical - variability and temporal progression (Taylor, 2001). 
For instance, animal models have been developed to produce hyperalgesia 
and allodynia in a highly consistent manner - not all patients following 
peripheral nerve injury exhibit these phenomena. Furthermore, ethical 
considerations limit animal studies to a period of weeks, whereas the clinical 
course of neuropathic pain in humans extend beyond the period of weeks, 
and may persist over many years (Bridges et al., 2001). Finally, ligation 
models depend mainly on the competence of the experimenter in inducing 
adequate degree of damage and level of hypersensitivity required by the 
different model. Due to the human factor (variation in ligament placements), 
some variability in the number of responders and in pain behaviour can 
consequently occur with these models. This leaves transection models such 
as the Woolf model with an advantage over ligation models (Decosterd and 
Woolf, 2000). 
All in all, all three models when compared appear to produce similar onset 
and development of behavioural hypersensitivity but the models differed in 
the intensity of pain each produced. For instance, the Chung model showed 
the highest levels of mechanical allodynia whilst the CCI model had the 
lowest. Ongoing pain was also measured and the CCI model appeared to 
show the highest levels compared to the other models. Despite showing 
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different pain beliaviour characteristics, it was concluded that all three 
models were valuable models of neuropathic pain (Kim et al., 1997). 
As already mentioned, neuropathic pain present a mixture of symptoms, 
which are most likely, evoked by different underlying mechanisms. These 
models, although sharing many similar features also differ in some 
characteristics, possibly reflecting the various types of pain reported in 
patients. Consequently, all together, these models might contribute to a 
better understanding of the underlying pathophysiological mechanisms 
involved in neuropathic pain resulting from peripheral nerve damage 
(Kauppila, 1998). 
1.5. Pathophysiological Mechanisms 
Some main mechanisms involved in neuropathic pain have been identified. 
Damaged tissue cause an inflammatory response at the site of injury with the 
release of inflammatory mediators from non-neuronal cells that in turn can 
result in several changes to normal nociception function such as 
neurochemical changes (post-translational and transcriptional changes), and 
structural changes, such as synaptic connectivity changes in the dorsal horn 
of the spinal cord (Woolf and Mannion, 1999). These changes can 
dramatically alter threshold, excitability (ectopic excitability) and transmission 
properties of nociceptors, contributing to pain hypersensitivity and 
spontaneous pain (Scholz and Woolf, 2002). Changes in pain transmission 
can occur peripherally at the nerve terminals, at the site of axonal injury 
(peripheral sensitisation), or at the central synapse (central sensitisation). 
Post-translational changes such as reduction in nociceptor threshold are 
rapid, whilst transcriptional changes are more gradual and long-lasting, as 
they require activation of signal transduction cascades, changes in 
transcription and then orthograde transport of proteins to the peripheral or 
central terminals (Svensson and Yaksh, 2002). The identification of these 
mechanisms, in which animal models played a key role, is relevant with 
respect to novel treatment strategies. A better understanding of these 
mechanisms will facilitate the development of improved animal models, 
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which represent pathologies observed in the clinic, increasing the 
predictability of efficacy of novel analgesics. It will also help Identify suitable 
patients and end-points for future proof of concept trials with novel 
analgesics, with or without CNS access. 
1.5.1. Post-transiational changes 
Fundamental molecular and cellular mechanisms that operate in sensory and 
nociceptive pain transmission has been extensively reviewed in the literature 
(McCleskey and Gold, 1999, Millan, 1999, Waxman eta!., 2000, Hill, 2001, 
Hunt and Mantyh, 2001, Julius and Basbaum, 2001, Mantyh et al., 2002, 
Millan, 2002, Patapoutian et al., 2003). Briefly, physiological pain begins at 
the peripheral terminals of unmyelinated C-fibres and thinly myelinated AG-
fibres nociceptors where noxious stimuli of different modalities (mechanical, 
chemical or temperature) are transformed into electrical activity by specific 
transducer receptor or ion channel complexes. The activation of these 
transducer receptors generates a depolarisation creating a current that is 
conducted to the spinal cord and to supraspinal pathways through the 
thalamus to the somatosensory cortex and, associated areas, where the 
sensation of pain is experienced (Hunt and Mantyh, 2001). Normal 
nociception is mainly characterised by high threshold levels of nociceptors 
for activation - high enough so not to interfere with normal activities but low 
enough to generate a response before tissue damage occurs. Pain normally 
has an adaptive value and serves as an early warning to protect the body 
from tissue injury or as an aid in repair after tissue damage. Pain becomes 
maladaptive when pain states occur with no immediate protective or 
reparative role. Shifts in pain threshold and responsiveness are an 
expression of neural plasticity, the neurobiological means by which changes 
in the nervous system can modulate the response to any stimulus. Such 
plasticity or modifiability of the sensory system essentially characterizes 
clinical pain syndromes (Woolf and Salter, 2000, Scholz and Woolf, 2002). 
The plasticity responsible for abnormal pain such as hypersensitivity or 
allodynia has two forms - modulation and modification. The modulation of 
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the pain system will be discussed first. Modulation is characterised by 
reversible changes in the transduction, conduction and transmission of 
sensory neurones near the site of injury but also in the CNS. These changes 
are mediated via post-translational modifications of transducer receptors 
such as reduction of threshold and increase of excitability mostly occurring 
after inflammation or after repeated noxious stimuli. Inflammatory mediators 
such as prostanoids remain the main effectors of post-translational changes. 
These bind to receptors at nociceptors peripheral terminals and induce 
activation of protein kinases A and C (PKA and PKC) that in turn 
phosphorylate the receptor. This heightened state of sensitivity is referred to 
as peripheral sensitisation. A similar phenomenon can take place in the 
dorsal horn - central sensitisation. It had been proposed that the release of 
neurotransmitter (e.g. glutamate, substance P or Brain Neurotrophic Derived 
Factor) at C fibre central terminals bind to receptors on the dorsal horn 
neurones and activate protein kinases that phosphorylate membrane bound 
NMDA and a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) 
receptors, altering their functional properties (increase of membrane 
permeability), and thereby inducing central sensitisation (Woolf and 
Costigan, 1999, Scholz and Woolf, 2002). 
1.5.2. Transcriptional changes 
Modification is, on the other hand, characterised by long-term changes in 
receptor/ion channel expression or in their structure (transcriptional 
changes), as well as in connectivity and survival of neurones (see next 
section 1.5.3), resulting in significant alterations in the neuronal response to 
stimuli (Woolf and Salter, 2000). Activity-dependent signal transduction 
cascades and downstream signalling pathways in the dorsal root ganglion 
(DRG) and dorsal horn neurones act to modify transcription in nociceptor 
neurones. Nerve growth factor (NGF) increases following inflammation, 
increases in calcium influx through voltage-gated calcium channels, 
nociceptor activity and inflammatory mediators can all set off transcriptional 
changes in sensory neurones. Transcriptional changes constitute mostly of 
increasing constitutively expressed genes. However, novel genes can also 
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be induced. Large myelinated A(3 fibres can begin to express substance P 
and brain neurotrophic derived factor (BNDF) primarily only produced by 
unmyelinated C fibres. Ap fibres, by switching phenotype, can thus also 
conduct stimulus-induced hypersensitivity and contributing to central 
sensitisation (Woolf and Costigan, 1999) 
1.5.3. Structural reorganisation 
Altered connectivity in the dorsal horn of the spinal cord is another 
mechanism through which abnormal pain plasticity can take place. C fibres 
project normally into lamina I/I I whereas Ap fibres project into lamina 11 I/IV 
where the signal is relayed via the spinothalamic tract to the brain. After loss 
of C fibres following peripheral nerve injury, A|3 fibres sprout into the lamina II 
region vacated by central terminals of C fibres. This re-wiring causes 
innocuous stimuli to be now interpreted as noxious and therefore possibly 
contributing to the touch-evoked allodynia seen in patients with chronic 
neuropathic pain (Taylor, 2001, Bolay and Moskowitz, 2002) 
1.5.4. Decreased inhibition 
Finally, central sensitisation can be further conveyed by a reduction of 
inhibitory mechanism due to a loss of interneurones. Inhibitory mechanisms 
in the CNS play an important role in the transmission of information to the 
brain, which is actively controlled by inhibitory interneurones. Reduced 
function or loss of these inhibitory interneurones increase information input. 
Peripheral nerve injury was found to decrease the synthesis of the inhibitory 
neurotransmitters y-aminobutyric acid (GABA) and glycine in interneurones. 
Furthermore, the increased levels of excitotoxic amino acid glutamate 
following nerve damage had a direct impact on interneurones loss (Scholz 
and Woolf, 2002) 
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1.5.5. Ectopic excitability 
Ectopic excitability or discharges are thought to be responsible to generate 
spontaneous sensations such as paraesthesia, dysaesthesia and burning 
pain (Woolf, 2004a). Findings from electrophysiological studies have 
demonstrated that non-injured unmyelinated nociceptors innervating sites of 
injury as well as injured peripheral nerve begin to develop evoke ectopic 
action potential discharges (Wu et al., 2001, Liu et al., 2002a). This 
spontaneous activity was blocked with local anaesthetics (Wu et al., 2001). 
Spontaneous activity can also appear at the cell bodies of myelinated axons. 
It was shown that ectopic discharges not only occur peripherally but also at 
the somata of the injured peripheral nerve. Furthermore, some of this activity 
was also generated by non-injured nerves that have their somata in ganglia 
containing injured neurone cell bodies (Michaelis et al., 2000). It was shown 
that the intensity of these discharges was directly dependent on local blood 
flow changes (Habler et al., 2000). 
1.5.6. Inflammatory response 
1.5.6.1. Peripheral inflammatory response 
Across the various peripheral nerve injury animal models, there appear to be 
a consensus in the literature that tissue damage caused by peripheral nerve 
injury generates an acute inflammatory response resulting in rapid infiltration 
of immunocompetent immune cells, mostly macrophages, to the site of injury 
with release of inflammatory mediators such as prostaglandins that in turn 
causes hyperalgesia and pain (Bonney et al., 1979, Said and Hontebeyrie-
Joskowicz, 1992, Perry et al., 1993a, Tracey and Walker, 1995, Wagner et 
al., 1998, DeLeo and Yezierski, 2001). Macrophages are predominantly 
involved in removal of intracellular content leakages into extracellular fluid 
due to tissue damage and in tissue regeneration (Brown et al., 1991, Myers 
et al., 1993, Perry et al., 1993b, Clatworthy et al., 1995, Miyauchi et al., 
1997). It was also suggested that infiltrating macrophages are involved in 
myelin debris removal and subsequently play a role in wallerian degeneration 
- axonal breakdown (Perry et al., 1993a). Wallerian degeneration has been 
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extensively reviewed in the literature (Bruck, 1997, Kury et al., 2001, Hi rata 
and Kawabuchi, 2002, Stoll et al., 2002, Koeppen, 2004, Coleman, 2005). 
A brief overview of peripheral nerve anatomy will be first given. A nerve 
trunk is composed of numerous fascicles. Each fascicle is surrounded by 
tissue called the perineurium and the entire nerve trunk by the epineurium. 
Connective tissue within the fasciculus is referred to as endoneurium (Figure 
01.02). Small blood vessels irrigate the nerves providing nutrients and 
through which immune cells can gain access (Olsson, 1990, Watkins and 
Maier, 2002). The endoneurium contains a number of different resident cells 
types such as fibroblasts, macrophages, mast cells, dendritic cells, 
endothelial cells and Schwann cells. The access of haematogenous factors 
such as immunocompetent cells, antibodies or other plasma protein is mostly 
restricted by the blood-nerve barrier but not exclusively (Ho et al., 1998). 
Upon activation of those resident cells, recruitment of other 
immunocompetent cells can follow (Olsson, 1990). Activation of resident 
macrophages with the recruitment of haematogenous macrophages as well 
as lymphocytes to the site of injury after peripheral nerve injury has been a 
focus of attention as rapid removal of damaged myelin and cellular debris 
facilitate neuronal regeneration whilst long-standing immune response could 
result in pathological state such as chronic pain (Avellino et al., 1995, 
Watkins and Maier, 2002) 
Large infiltration of inflammatory cells at the site of injury after peripheral 
nerve damage has been demonstrated using mostly animal models of 
peripheral nerve injury. For instance, in this particular study, the rat sciatic 
nerve was severed resulting in a neuroma and distribution of macrophages 
was observed using immunohistochemical staining after 3 days to one years 
post operation. Findings showed an extensive infiltration of macrophages 
into the neuroma the first two weeks after injury. From 3 weeks, 
macrophages were found at sites of focal demyelination, to be in direct 
contact with axonal membranes and containing myelin protein fragments in 
their vacuoles. Macrophages were observed to be present at one year and 
to spread beyond the site the injury (Frisen et al., 1993). 
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Figure 01.02. Schematic representation of a cross section of a nerve. The 
nerve is surrounded by dense connective tissue referred to as the 
epineurium and each smaller nerve fascicle (fasciculus) within the larger 
nerve is invested in connective tissue - perineurium. Each axon within each 
fascicle, each individual axon and its surrounding neurolemmal cell is 
covered by a delicate layer of connective tissue - endoneurium (From 
www. anatomy, dal. ca/ Human_Histology/Lab4/99DL.html). 
Another study, to generate nociceptive behaviour and endoneural pathology 
characteristic of experimental nerve injuries, administered a local sciatic 
injection of the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-
a). This study demonstrated that TNF-a injection generated thermal 
hyperalgesia and mechanical allodynia for 3 days post-injection in 
association with nerve oedema, splitting of myelin lamellae with 
vacuolisation, Schwann cell injury, fibroblast and macrophage activation, and 
phagocytosis of lipid debris (Wagner and Myers, 1996). The same authors 
further demonstrated recruitment of macrophages in CCI rats at 2 and 5 days 
post-operation (Wagner et al., 1998). 
A further study demonstrated significant increased numbers of various types 
of immune cells in the injured nerve from several animal models of 
neuropathic pain. Four rat models of mononeuropathy were used in this 
study (Total nerve axotomy, Gazelius, Bennett and Seltzer models). 
Expression of various immune cells (monocytes/macrophages, neutrophils, 
natural killer cells and T lymphocytes) and cytokines (IL-6, IL-1-P and TNF-a) 
in the sciatic nerve were investigated using immunohistochemical staining 
and cell counting as methods. The main findings of this study showed 
significant increases of all immune cells in the injured sciatic nerve at 14 
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days post-surgery. Furthermore, in this study, animals from the Bennett and 
Seltzer models were separated into two groups according to the presence or 
not of allodynia. When compared on macrophage expression, the allodynic 
rats showed twice as much positive cells of macrophage morphology in the 
sciatic nerve as the non-allodynic rats suggesting that the presence of 
macrophages in the peripheral nerve must play some role in the 
development of tactile allodynia. Another interesting result of interest was 
that fewer macrophages were observed after complete injury than after 
partial injury. Finally, a 2- to 3-fold increase in the number of positive 
macrophages was shown in injured nerves from Seltzer and Bennett 
allodynic rats and from Gazelius rats compared to total sciatic nerve axotomy 
rats challenging the positive relationship between increase of macrophages 
and the degree of Wallerian degeneration (Cui et al., 2000). 
The last study investigating infiltration of macrophages near the site of injury 
analysed rat nerve tissue (Seltzer model) by standard immunohistochemistry 
method at different time points (3 days, 1,2,4 weeks, 3 and 7 months). A 
rapid increase was observed in Cox-2 expressing macrophages with a peak 
at 2 weeks and reclining from 3 months to disappear at 7 months (Ma and 
Eisenach, 2003a). 
Only a few studies have investigated macrophage infiltration in human 
inflamed tissue. One study found significant increase in number of 
macrophages present in the peritoneal fluid of women with endometriosis 
compared to control (Karck et al., 1996). The second study demonstrated 
the presence of macrophages within lesions of patients with multiple 
sclerosis where acute axonal damage takes place defined by the 
accumulation of amyloid precursor protein (APR). APR expression in 
damaged axons was positively correlated with the number of macrophages 
(Bitsch et al., 2000). 
1.5.6.2. Central inflammatory response 
In addition to these peripheral changes following peripheral nerve injury, 
changes in central neuronal processes may also occur inducing rapidly a 
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glial response around central primary terminals (Figure 01.03) of peripherally 
damaged nerves in the spinal cord (Aldskogius et al., 1999). The 
inflammatory response is, therefore, not restricted to the primary site of injury 
but can also extend retrogradely to remote projection areas in the CNS 
(Tracey and Walker, 1995, Kreutzberg, 1996, Aldskogius and Kozlova, 1998, 
Graeber et al., 1998, Banati, 2002, Vela et al., 2002). Microglial activation 
has been reported in numerous CNS conditions including peripheral nerve 
injury, and may contribute to chronic pain states (Streit et al., 1999, Banati, 
2002, Watkins and Maier, 2002). Microglia (the intrinsic immunoeffector cell 
of the CNS) became the focus of attention over the last decade with the 
appearance in the literature of numerous reviews with a particular emphasis 
placed on their role in fundamental processes determining neuronal 
regeneration and degeneration (Banati and Graeber, 1994, Barron, 1995, 
Kreutzberg, 1996, Moore and Thanos, 1996, Streit and Graeber, 1996, 
Benveniste, 1997, Bruce-Keller, 1999, Streit et al., 1999, Rosenstiel et al., 
2001, Rezaie and Male, 2002, Nakajima and Kohsaka, 2004, van Rossum 
and Hanisch, 2004). 
Spinal cord and dorsal root ganglion 
Dorsal Horn 
Low-threshold 
mechanoreceptors 
(Ap fibres) 
Dorsal Root 
Dorsal Root Ganglion (DRG) 
Temperature and 
pain receptors 
(AS and C fibres) 
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X . l 
Proprioceptors 
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(motor) 
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Figure 01.03. Schematic representation of afferent and efferent peripheral 
nerves into the spinal cord. Sensory neurones are pseudo unipolar cells with 
their perikarya in the dorsal root ganglion while motor neurones cells bodies 
are located in the ventral horn (lamina IX). A^, A5 and C fibres project 
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centrally to dorsal horn interneurones in laminae l-IV (From Patapoutian et 
al., 2003). 
1.5.6.2.1. Microglia 
Microglia are phagocytic, cytotoxic and antigen-presenting cells that upon 
activation are involved in a pattern of cellular responses, including 
proliferation, recruitment to the site of injury and increased expression of 
immunomolecules (Kreutzberg, 1996). The brain has, traditionally, always 
been considered as an "immunologically privileged site", implying that the 
CNS was separated from the general immune system by a barrier - the 
blood-brain-barrier (BBB), and that the CNS had no intrinsic protective 
system. This former consensus, however, has been challenged. Research 
has demonstrated perivascular immune competent cell infiltration in the CNS 
through the BBB. It is currently well accepted that activated mononuclear 
phagocytes and activated T lymphocytes and, more recently, B cells, cross 
with ease the BBB, even if this trafficking remains limited (Cross et al., 2001). 
Microglia have an important function in the recruitment process of these 
haematogenous immune competent cells (Kreutzberg, 1996). The brain 
compared to the rest of the organs remains nevertheless different as its 
immunologic properties are concerned. A fully fledged immune response 
comes at a cost. While responding to invading micro-organisms, 
surrounding healthy tissue can also sustain damage from the numerous toxic 
agents released by the different immune competent cells. Due to their 
fragility and mostly to their limited regenerative capabilities, neurones could 
not withstand such an immune response. The immunologic competence of 
microglia is considered much less effective than peripheral immune effector 
cells. Microglial immune functions are kept under control in the CNS via the 
release of inhibitory factors by neurones (Moore and Thanos, 1996, Harrison 
et al., 1998, Neumann et al., 1998, Streit et al., 2000). 
There has been a great deal of controversy surrounding the origin of 
microglia. A minority view claimed that microglia originated from the true glia 
of neuroectodermal lineage. However, the general consensus has accepted 
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the view that microglia derive from circulating blood monocytes or their 
precursors and, that they colonise the CNS during foetal life and within the 
first few weeks post-natally (Barron, 1995, Kaur et al., 2001). During brain 
development nearly half of the neurones die causing an infiltration of blood 
circulating monocytes with phagocytic capabilities. These cells are able to 
cross the BBB with ease. At that stage the BBB is still in an immature state 
with tight junctions not formed as yet. It is proposed that once the BBB 
reaches maturity (fully formed tight junctions), the remaining trapped 
monocytes in the brain will form the network of intrinsic immune cells in the 
CNS (Moore and Thanos, 1996). 
There are at least five anatomically (and most likely functionally) distinct 
resident mononuclear phagocytes populations in the CNS, including 
microglia. Others include meningeal macrophages, supraependymal 
macrophages (Cerebrospinal fluid-ependyma border), macrophages of the 
choroids plexus (Kolmer cells) and perivascular macrophages - bounded by 
a basement membrane, lying within blood vessels (Goldsby, 2003). 
Functionally, microglia are the principal immune effector cells population in 
the brain (Banati et al., 1993). Research on microglia suggested that 
microglia formed a network of antigen-presenting cells in the CNS 
parenchyma with a primary function in immune surveillance. They represent 
5-15% of the total cellular composition of the CNS and are a stable 
population of cells with an increase with aging however (Aldskogius and 
Kozlova, 1998). They are uniformly distributed throughout the grey matter 
and between fibre tracts in the white matter but are less numerous in the 
white matter (Barron, 1995, Moore and Thanos, 1996, Stoll and Jander, 
1999). 
Many phenotypic markers and effector molecules are shared between 
microglia and haematogenous macrophages making their differentiation in 
pathological events difficult (Stoll and Jander, 1999). There are as yet no 
definitive antigenic markers specific to microglia alone. Research 
demonstrated that microglia possess one property not shared by any other 
mononuclear phagocytes, i.e., their expression of an inward-rectifying 
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potassium channel but no outward current channels. This renders them 
sensitive to depolarisation since relatively small changes in membrane 
potentials trigger large inward currents. This unique collection of membrane 
channels was directly related to their rapid responsiveness to any changes in 
the brain's structural integrity and also to ion homeostatic discrepancies 
triggered in pathological events. This inward rectifying channel is shared by 
microglia with only one population of precursor cells within the bone marrow 
- possibly microglial precursors. Moreover, microglial ion channels can be 
linked to P2 purinoceptors that may become activated by adenosine 
5'triphosphate (ATP) released from damaged cells. Finally, microglia 
possess several other receptors allowing them to react to other CNS 
signalling molecules such as calcitonin gene-related peptide (CGRP), 
acetylcholine (ACh) and noradrenaline. This ability to respond selectively to 
molecules implicated in neurotransmission permits microglia in their 'resting' 
state to constantly monitor the CNS environment and subsequently, react 
quickly to any CNS pathological disturbances. This collection of receptors 
gives microglia the capabilities to phagocytose neurones (neuronophagia) 
and to detach synaptic terminals from axons ("synaptic stripping") for 
regeneration (Kreutzberg, 1996). 
Microglia have been demonstrated to react promptly to a wide range of 
injuries in the CNS. Some of their functions are to play a part in the repair of 
neuronal tissue, in reducing astrocytic proliferation and in scar formation 
(astrogliosis) after injury. Microglia were shown to participate, in tissue 
reconstruction after lesions by releasing neurite outgrowth (such as 
plasminogen, brain-derived fibroblast growth factor, NGF), in remodelling 
(plasticity), in synaptogenesis, in the control of the BBB integrity, in the 
regulation of haematogenous cells infiltration and migration, and in removal 
of pro-inflammatory cytokines such as IL-1 (Kreutzberg, 1996, Moore and 
Thanos, 1996, Aldskogius and Kozlova, 1998). Microglia have also the 
ability to transform themselves into large phagocytes and thereby act as 
scavengers by destroying invading micro-organisms and by removing any 
potentially harmful tissue debris (Stoll and Jander, 1999). Their ability to 
mop up debris from degenerating nerve fibres (Wallerian degeneration) has 
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been found however to be less effective than PNS phagocytic macrophages 
(Reichert and Rotshenker, 1996). Their phagocytic efficacy appears to be 
suppressed in the CNS limiting their function as phagocytes. This decreased 
phagocytic efficacy has an impact on neuronal regeneration by limiting the 
sprouting of injured neurones (Zeev-Brann et al., 1998, Aldskogius, 2001, 
Gebicke-Haerter, 2001). Cytotoxic properties add to their function as 
"guardians" in the brain. Microglia secrete a range of bioactive substances 
ranging from NGF to cytokines. These cytotoxic properties can be regulated 
by cytokines and/or directly by neurotransmitters. Microglia have also been 
found to produce toxic substances such as amino acids or oxygen and 
nitrogen intermediates of detrimental impact on neurones (Moore and 
Thanos, 1996). Finally, in addition to their phagocytic and cytotoxic roles, 
microglia are also antigen-presenting cells, enabling them to interact directly 
with immunocompetent cells such as T lymphocyte cells (Stoll and Jander, 
1999). Microglia have been shown however to have weak antigen 
presenting cells properties compared to other CNS parenchyma cells types 
or other peripheral antigen presenting cells (Carson et al., 1998, Carson et 
al., 1999, Flugel et al., 1999). It is thought that this weakness is not critical 
since the CNS parenchyma contains other specialised CNS antigen 
presenting cells mostly perivascular macrophages which offer an interface 
between the CNS and circulating haematogenous immune cells (Streit, 
2002). Thus, microglial activation presents a double-edged response - a 
cytotoxic effector role and a protective role. 
The morphology of microglia cells changes upon activation. Microglial 
response occurs to injury in stages: (i) resting, (ii) primed, (iii) fully active 
phagocytes (Figure 01.04). Resting microglia are characterised by their 
small somata and their well-ramified processes. Upon activation, the somata 
become rounder and the processes shorter. At the phagocytic stage, 
microglia display an amoeboid-like morphology and resemble peripheral 
phagocytic cells (Kreutzberg, 1996, Streit et al., 1999). 
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Figure 01.04. Microglia morphology. Gradual transformation of microglia 
from a resting state (left) to a phagocytic state (From Kreutzberg, 1996). 
1.5.6.2.2. Microglial activation and markers 
Research using the rat facial nerve axotomy paradigm contributed to our 
present knowledge of microglial activation (Graeber et al., 1988, Streit, 2002, 
Moran and Graeber, 2004). Microglial activation was mostly associated with 
a marked upregulation of surface molecule markers such as complement 
type-3 receptor (CR3; CD11b/Mac-1 complex), MHC class-l and Class II 
antigens, co-stimulatory molecules such as B7-1, TNF- a, microsialin 
(CD68), IgG Fc-receptor (CD64), and other adhesion molecules such as 
thrombospondin (Kreutzberg, 1996, Stoll and Jander, 1999). Recent 
investigations have focused on the expression of the CD40 also found to be 
upregulated following brain injury. The ligand of CD40 (GDI54) is mainly 
found on T CD4 lymphocytes. Compelling evidence demonstrated the 
implication of this receptor in chronic inflammation and several 
neurodegenerative diseases and that blocking this receptor could result in 
reduced neurotoxicity (Tan et al., 2002, Benveniste et al., 2004, Townsend et 
al., 2005). Most of these markers are not specific to microglia and are also 
expressed on the surface of haematogenous macrophages. Consequently, 
they cannot be used as distinctive and reliable marker for microglia in the 
CNS injury paradigm (Stoll and Jander, 1999). 
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Figure 01.05. Molecular structure of [^^C] (R)-PK11195. The radioligand 
[^^C] (R)-PK11195 molecule bound to activated microglia via PBBS. [Images 
reproduced by permission of Dr R. Banati]. 
Recently a group of scientists has focused on quantitatively measuring 
microglial activity in order to isolate in vivo sites of pathology in brain 
disorders (Banati et al., 1997, Banati et al., 1999, Banati et al., 2000b, 
Cagnin et al., 2001, Gerhard et al., 2003, Gerhard et al., 2005). The ligand 
isoquinoline PK11195 (1-[2-chlorophenyl]-A/-methyl-A/-[1-methyl-propyl]-3-
isoquinoline carboxamide) was found to have the property to bind to 
peripheral benzodiazepine binding sites (PBBS) predominantly expressed on 
activated microglia and macrophages (Figure 01.05) and within the cell 
PBBS are primarily located in the mitochondrial membrane (Banati et al., 
2004), themselves only found in regions of active pathology in brain (Kassiou 
et al., 2005). Recent immunohistochemical findings confirmed that, in the 
absence of any haematogenous macrophages infiltration and with an intact 
BBB, PBBS expression was rapid upon CNS injury and that in lesions de 
novo PBBS expression was restricted to activated microglia (Banati et al., 
1997). In the mammalian brain, two types of benzodiazepine receptors have 
been isolated - the central benzodiazepine receptor (CBR) and the 
peripheral benzodiazepine receptor (PBR). The CBR and the PBR differ in 
their anatomical and cellular distribution and in their pharmacological effects. 
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The CBR is expressed in the CNS and is part of the receptor for the 
inhibitory neurotransmitter GABA. The CBR has been considered to be the 
main binding site for anxiolytics and anticonvulsants. For instance, 
Clonazepam has been shown to bind with this receptor (Itzhak et a!., 1993). 
The PBR, on the other hand, was first described as a diazepam-binding site 
and is mainly found in peripheral tissues such as heart, lung, kidney, and 
testes (Gavish et al., 1999). PBR expression was only found at low levels in 
the brain under non-pathological conditions. However, PBR expression has 
been demonstration in tissue samples of a number of CNS disorders 
including gliomas, thiamine deficiency disorders, Huntington's disease (HD), 
Alzheimer's disease (AD) and transient forebrain ischaemia. Thus, as the 
PBR was found to be expressed in an array of CNS disorders, researchers 
have selected this receptor as a potential marker for CNS injury (Gavish et 
al., 1999). Although, the precise physiology and physiological role of this 
receptor has yet to be understood, it was demonstrated that the ligand 
isoquinoline carboxamide derivative, PK11195, has high affinity for this 
receptor and that activated microglia were the principal contributors to the 
lesion-induced increase of PK11195 binding in vivo (Vowinckel et al., 1997, 
Banati et al., 2000a). This line of research increased confidence that 
PK11195 was a well-suited marker to detect microglial activation in areas of 
subtle brain pathology where neither disruptions of the BBB nor the 
infiltration of immune effector cell were indicative of an on-going disease 
process. 
The procedure used to quantitatively measure microglial activation was to 
radiolabel the ligand PK11195 with a positron-emitting such as tritium [^H] or 
carbon-11 ^C ] . The radioligand [^H] (R)-PK11195 or T^C] (R)-PK11195 
could then be used in autoradiographic or positron emission tomography 
(PET) studies (respectively) to view accumulation of microglial activation 
(Banati et al., 1997, Banati et al., 1999). 
1.5.6.2.3. Microglial activation and pain 
Glial activation (Figure 01.06) can be induced by substances released from 
neurones such as prostaglandins, nitric oxide, fractalkine, substance P, 
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excitatory amino acids and adenosine tripliosphate (ATP; Watl<ins et al., 
2001), and in turn, result in the production and release of numerous 
inflammatory agents such as cytokines, growth factors, kinins, purines, 
amines, prostanoids and ions (Woolf and Costigan, 1999, Boddeke, 2001, 
Mantyh et al., 2002). These inflammatory mediators all together are 
sometimes referred to as the 'inflammatory soup' (Scholz and Woolf, 2002). 
Inflammatory mediators have been shown to activate and/or enhance the 
sensitivity of primary afferents and spinal cord neurons (Shu and Mendell, 
1999, Woolf and Costigan, 1999, Watkins and Maier, 2000) and to alter 
neuronal excitability by facilitating pre- and post-synaptic signalling of 
excitatory neurones, and by reducing inhibitory transmission (Yamagata et 
al., 1993, Kaufmann et al., 1996, Woolf and Salter, 2000, Scholz and Woolf, 
2002). For instance, prostaglandins (PGs) such as PGE2 (Prostaglandin Ea), 
which activate the EP1 receptor expressed on sensory fibres may play an 
important role in the development of hypersensitivity following peripheral 
nerve injury (Syriatowicz et al., 1999, Ma et al., 2002); PGs generated by 
Cox-2 in the spinal cord have been shown to contribute to the maintenance 
of hyperalgesia (Seybold et al., 2003). Some of these mediators (protons, 
ATP, serotonin or lipids) have been shown to activate and/or enhance the 
sensitivity of primary afferents and spinal cord neurons by directly interacting 
with ion channels on the nociceptor surface. Some others such as 
bradykinin and NGF mediated their effects indirectly through second 
messenger signalling cascades by binding to metabotropic receptors (Julius 
and Basbaum, 2001). For instance bradykinin and PGs have been found to 
sensitise mechanoreceptive injured (Michaelis et al., 1998, Omana-Zapata 
and Bley, 2001) and intact (Khasar et al., 1998) axons following peripheral 
nerve injury. Consequently it was suggested that glial activation may play a 
substantial role in nociceptive processing (Shu and Mendell, 1999, Woolf and 
Costigan, 1999, Watkins and Maier, 2002, Sommer and Kress, 2004). 
However, some studies report a lack of correlation of neuropathic pain 
behaviour with levels of microglial activation in animal models suggesting 
that microglial activation is not the sole component involved in the 
development and the maintenance of hyperalgesia, mechanical allodynia or 
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chronic inflammatory pain in animal models (Watkins et al., 2001). Microglial 
activation was shown, for instance, to be instantaneous in the ipsilateral 
spinal ventral and dorsal horns following spinal nerve cryoneurolysis and 
chronic constriction injuries. However pain behaviour appeared only 9 days 
post injury (Colburn et al., 1997). Moreover, manipulating the in vivo 
macrophage environment with the modified Chung model (see section 1.4.1), 
a limited role of peripheral macrophages in the development and 
maintenance of mechanical allodynia was demonstrated. Depletion or 
deactivation of macrophages near the site of injury did not alter pain 
behaviour in rat with partial ligation of the sciatic nerve. It was further found 
that microglial activation was not directly linked with mechanical allodynia 
(Rutkowski et al., 2000). 
PTN: NO, PGs, 
fractal kine 
Viruses and bacteria 
Activated 
glia 
Primary afferent: 
Substance P, EAAs, ATP, 
fractal kine 
IL-1. TNF, IL-6, ROS, NO, 
PGs, EAAs, ATP 
Enhance PTN 
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Figure 01.06. Schematic representation of glial induced pain. Glial cells can 
be activated by three different sources: viruses and bacteria, pain 
transmission neurones (PTN) and primary afferent via the release of several 
bioactive substances. The proposed pathway of interest is the one where 
PTN release nitric oxide (NO), PGs and fractalkine resulting in activation of 
glial cells that in turn are responsible for PTN hyperexcitability caused by the 
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exaggerated release of a number of mediators such as interleul<in-1 (IL-1), 
tumour-necrosis factor (TNF), IL-6 reactive oxygen species (ROS), NO, PGs, 
excitatory amino acids (EAA) or ATP (Pathway of interest in blacl<; from 
Watkins and Maier, 2003). 
Using different animal models of neuropathic pain contrasting evidence was 
found. For instance, peripheral L5 spinal nerve transection in rats lead to an 
increase in positive cells of macrophage-like and T-cell-like morphology in 
the dorsal horn mainly 3 to 14 days post-spinal nerve transection. It was 
suggested that since a relationship was shown between leukocyte trafficking 
at these specific time points (3-14 days) and the occurrence of mechanical 
allodynia, central neuroinflammation might play a role in the development or 
maintenance of persistent neuropathic pain (Sweitzer et al., 2002). 
Moreover, depletion of peripheral macrophages resulted in alleviation of 
thermal hyperalgesia with a model of partial sciatic nerve ligation or Seltzer 
model (Liu et al., 2000). 
To account for these conflicting data, it was suggested that the different pain 
modalities i.e., mechanical allodynia and thermal hyperalgesia depended 
upon distinctive mechanisms; that a greater peripheral inflammatory 
component might be involved in thermal hyperalgesia compared to 
mechanical allodynia; that macrophages might play different roles in the 
development of thermal hyperalgesia and mechanical allodynia or that 
macrophages respond differently in the sciatic tight ligation and transection 
models (Rutkowski et al., 2000). Some evidence demonstrated that 
allodynia was more dependent on supraspinal descending pathways (Bian et 
al., 1998). Wallerian degeneration in the PNS appears to be more a 
macrophage-dependent event with macrophage activation, recruitment, 
production and release of inflammatory mediators (Wagner et al., 1995). 
Human studies have also demonstrated microglial activation following 
peripheral nerve injury. For instance, activated microglia have been 
observed in the contralateral thalamus in patients with painful post-traumatic 
neuropathy. Significant increased binding of f ^C] (R) PK11195 was found in 
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the thalamus contralateral to the side of injury up to two decades after the 
event (Banati et al., 2001). It was proposed that peripheral nerve injury could 
lead to microglial activation in retrograde and anterograde projection areas 
remote from the primary lesion focus. This response could be related to the 
emergence of central sensitisation or the plasticity phenomena considered to 
play a role in the development or maintenance of hyperalgesia in chronic 
pain states (Aldskogius et al., 1999, Banati, 2002). 
Most studies, to date, investigated the involvement of microglia/macrophage-
like cells in the development of chronic neuropathic pain. Other immune 
cells such as Schwann cells, oligodendrocytes, fibroblasts, neutrophils, or 
endothelial cells might also play some role in the inflammatory response and 
the aetiology of persistent pain (Aldskogius and Kozlova, 1998, Rutkowski et 
al., 2000). Nevertheless, immune cells/ inflammatory agents may be 
involved in pain caused by nerve injury; however their exact nature or role 
still remains to be fully determined. 
1.6. Prostanoids and pain 
Recent evidence suggests that CNS non-neuronal processes may contribute 
to pain phenomena. Peripheral nerve injury generates a local inflammatory 
response, resulting in rapid infiltration of immune cells, mostly macrophages, 
which express Cox-2 and other enzymes, with release of inflammatory 
mediators such as prostanoids - these contribute to peripheral nerve 
terminal sensitisation via the receptor EP1 (Bonney et al., 1979, Karck et al., 
1996, Ito et al., 2001, Svensson and Yaksh, 2002). Prostaglandins (PGs) 
such as PGE2are also produced and released in the spinal cord following 
peripheral nerve injury where they may play an important role in the 
development of hypersensitivity following peripheral nerve injury (Ma et al., 
2002, Seybold et al., 2003), thus establishing both peripheral and CNS links 
between prostaglandin production and hypersensitivity (Dirig and Yaksh, 
1999, Yaksh et al., 2001). 
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1.6.1. Prostaglandin biosynthesis 
The enzymes involved in the production of PGs are cyclooxygenases of 
which Cox-1 was at first thought to be the only enzyme present. 
Cyclooxygenase was first purified in 1976 and cloned in 1988 by three 
different groups (DeWitt and Smith, 1988, Merlie et al., 1988, Yol^oyama et 
al., 1988). Subsequently, it was found that Cox activity could be induced by 
inflammatory cytokines, suggesting the existence of a second isoform. This 
was confirmed by the isolation of a second cyclooxygenase gene encoding 
Cox-2 in 1991 (Sirois et al., 1992). It was Habenicht and colleagues' work 
that at first suggested the existence of an endogenous enzyme, Cox-1, and 
an inducible enzyme, Cox-2 (Habenicht et al., 1985). The classical view that 
Cox-1 was constitutive and that Cox-2 was exclusively a pro-inflammatory 
inducible enzyme was challenged since both isoforms are present in different 
tissues and sites of inflammation, and induced differentially (O'Neill and 
Ford-Hutchinson, 1993, Harris et al., 1994). A further enzyme "Cox-3" had 
been recently described (Chandrasekharan et al., 2002). Cox-2 protein is 
up-regulated in a number of non-neuronal cell types such as macrophages, 
human monocytes, synoviocytes, and microglia in CNS inflammation (Bauer 
et al., 1997, Minghetti et al., 1999). Data indicate that Cox-2 is strongly 
involved in different processes of central nervous modelling and regulated by 
different signalling pathways. The explicit roles of the constitutive enzyme in 
pain and inflammatory processes remain to be fully determined (Hoffmann, 
2000). Evidence that prostanoids could sensitise the peripheral nerve 
terminals (Yaksh et al., 2001) has triggered new research in the Cox 
enzymes involved in the biosynthesis of PGs to develop inhibitors (Coxibs) of 
potential therapeutic value. 
1.6.1.1. Cyclooxygenase (Cox) biology 
Cyclooxygenase enzymes (Cox-1 and Cox-2) also known as prostaglandin H 
synthase (PGHS) or prostaglandin endoperoxide H synthase are membrane 
associated enzymes with a 70 kDa and 72-74 kDa molecular weight 
(respectively) and a 60-65% amino acid sequence identity (Vane et al., 1998, 
Hawkey, 1999). Both enzymes are located on the luminal surfaces of the 
59 
endoplasmic reticulum (ER) and on the inner and outer membranes of the 
nuclear envelope (Otto and Smith, 1994). They are attached to the 
membrane with the substrate-binding pocket oriented outwards so to take up 
released AA (Funk, 2001). Some evidence associated Cox-2 principally with 
the nuclear envelope (Morita et al., 1995). It was suggested that this 
preferential proximity to the nucleus of Cox-2 might give it some specific 
nuclear related enzymatic activities (Smith et al., 1997). However this 
segregation remains challenged since the enzyme was observed in 
neurones to be present in distal dendrites (Kaufmann et al., 1996). Also, 
using other methods of investigation, Cox-2 was found to be located on the 
nuclear membrane as well as on the ER (Regier et al., 1995). Nevertheless, 
both enzymes were found to have some activity within the nucleus (Coffey et 
al., 1997, Parfenova et al., 1997, Neeraja et al., 2003) but little is known 
about their extraluminal activity as yet (O'Banion, 1999, Simmons et al., 
2004). Both enzymes are approximately 600 amino acids in size in all 
species and are integral membrane glycoproteins composed of a homodimer 
with an associated heme group (Smith et al., 2000, Simmons et al., 2004). 
Moreover, both enzymes show short catalytic life spans (less than 1-2 min) 
when exposed to exogenous arachidonic acid (AA) and Cox enzyme reaction 
does not require ATP (Simmons et al., 2004). Finally, Cox-1 and Cox-2 are 
coded by 2 distinct genes located on human chromosome 9 and 1, 
respectively (Tanabe and Tohnai, 2002) 
Cox-1 and Cox-2 present similar cyclooxygenase active site structures, 
catalytic mechanisms, products, and kinetics which has been reviewed at 
length (Garavito and DeWitt, 1999, Smith et al., 2000). For instance, all Cox 
enzymes reveal a homodimer profile and have the same four functional 
domains, the amino-terminal signal peptide domain, the dimerization domain, 
the membrane binding domain and the catalytic domain composed of the 
peroxidase active site and the cyclooxygenase active site that consist of a 
long hydrophobic channel (Smith et al., 2000, Simmons et al., 2004). Two 
main structural differences between Cox-1 and Cox-2 subsist however with 
significant pharmacological and biological implications (Kulkarni et al., 2000). 
First, Cox-2 has a 20% larger cyclooxygenase active site than Cox-1 which is 
60 
also more accommodating (Smith et al., 2000). A substitution of isoleucine 
523 in Cox-1 for a valine in Cox-2 is responsible for this structural difference 
between the Cox enzymes' active sites (Figure 01.07). This single difference 
opens a hydrophobic out-pocketing in Cox-2 that some Cox-2-selective 
drugs can access (Kurumbail et al., 1996). Aspirin was shown to block 
cyclooxygenase activity by a covalent modification via acetylation of Ser-350 
in Cox-1 and Ser-516 in Cox-2 (Lecomte et al., 1994, Mancini et al., 1994, 
Wennogle et al., 1995). Selective Cox-2 inhibitors do not bind to Arg120, 
which is used by the carboxylic acid of the substrate AA and by the Cox-1 
selective or non-selective NSAIDs (Mancini et al., 1995, Bhattacharyya et al., 
1996). The second difference between the two Cox enzymes is a small 
variation in kinetic property. Cox-1 was found to show negative allosterism 
at low arachidonate concentrations which might allow Cox-2 to compete 
more effectively for newly released AA when both isoenzymes are expressed 
in the same cell (Smith et al., 2000). 
Cox-2 
pocket 
C O O H # 
Figure 01.07. Schematic representation of an arachidonic acid molecule 
inside a Cox-2 molecule. The Cox-1 isoenzyme contains a side pocket that 
can be blocked by an isoleucine residue inactivating the enzyme. NSAIDs 
bind to the Arg 120 residue in the Cox-2 isoenzyme (From Vanegas and 
Schaible, 2001). 
Other differences between the two isoforms have been reported. For 
instance, Cox-2 will accept a wider range of fatty acids as substrates than 
Cox-1 (Otto and Smith, 1995). Also, Cox-2 will oxygenate other fatty acid 
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substrates such as eicosapentaenoic acid, v-'inolenic acid, a-linolenic acid 
and linoienic acid more efficiently than Cox-1 (Vane et al., 1998). Finally, 
another stril^ing structural difference between the two isoforms had been 
observed but of unknown significance as yet. For instance, in comparison to 
Cox-1, Cox-2 present the absence of a sequence of 17 amino acids from the 
N terminus and the insertion of a sequence of 18 amino acids at the C 
terminus (Otto and Smith, 1995, Herschman, 1996). 
Cox-1 and Cox-2 were identified as the major enzyme involved in the 
biosynthesis of prostanoids. The main steps in the production of prostanoids 
involve first the cleavage of AA from cell membrane phospholipids by the 
action of phospholipase A2 (PLA2) and phospholipase C (PLC) enzymes. 
Phospholipases are themselves activated by a variety of intercellular and 
intracellular stimuli (Axelrod et al., 1988). Once liberated, AA can be 
metabolised by three different pathways: cyclooxygenase, lipoxygenase and 
cytochrome P450 mono-oxygenase pathway (Stack and DuBois, 2001). The 
second step involves the conversion of AA into unstable prostaglandin 
intermediate, PGH2, by Cox enzymes. This is two-step process achieved by 
the same enzyme and only possible because of its bi-functional activity 
(Sirois et al., 2004). The structural characteristic of Cox enzymes is their 
dual hydroperoxidase and cyclooxygenase active sites (Marnett et al., 1999). 
First, AA is catalysed into PGG2 via an oxygenase activity (cyclooxygenase 
reaction), then PGG2 is reduced into PGH2 via a peroxidase reaction 
(Minghetti, 2004). The AA molecules fits into a long narrow channel with a 
slightly cocked cul-de-sac at the end (Figure 01.07) where it is transformed 
into the five-carbon ring of PGs (Hawkey, 1999). Finally tissue-specific 
isomerases and oxidoreductases (PG synthase) metabolise PGH2 into 
various PG isoforms PGE2, PGD2 and PGF2, prostacyclin (PGI2) or 
thromboxane A2 (TXA2: Smith et al., 2000; Figure 01.08). 
Cox enzymes can be induced by several physiological and pro-inflammatory 
stimuli (Nishikawa et al., 1977, Morrison et al., 1978). Inducers of Cox-1 
gene expression include transforming growth factor beta (TGF-P), bradykinin, 
IL-1 or vascular endothelial growth factor. Cox-2 gene expression inducers 
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include lL-1, TNF-a, lipopolysaccharides , TGF-p, epidermal growth factor, 
platelet-derived growth factor, or fibroblast growth factor (Dubois et al., 1998, 
Smith et al., 2000, Tanabe and Tohnai, 2002). In the brain, Cox-2 is induced 
by NMDA (Yamagata et al., 1993). Cox-2 induction is generally transient 
with a return to baseline levels within 24 to 48 hours. Cox-2 expression can 
be downregulated by anti-inflammatory cytokines and glucocorticoid 
hormones (Williams et al., 1999). Several signalling pathways have been 
found to be involved in the Cox-2 gene expression of which the mitogen-
activated protein kinase (MARK) cascade was considered to be the most 
important one (Tanabe and Tohnai, 2002). 
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Figure 01.08. Biosynthesis pathway of prostaglandins (From Sirois et al., 
2004). 
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1.6.1.2. Distribution of cyclooxygenases and role of prostaglandins 
Cox-1 is constitutively expressed in most tissues (Smith et al., 2000). In the 
rat brain, Cox-1 was found in regions like the midbrain, pons and medulla but 
mostly localised in the forebrain where PCs may be involved in complex 
integrative functions, such as modulation of the autonomic nervous system 
and sensory processing (Yamagata et al., 1993). Cox-2 levels, on the other 
hand, are typically low to undetectable in most tissues. However, Cox-2 is 
constitutively expressed in the kidney macula densa cells of rodents, testes 
and the brain (Seibert et al., 1994, Dubois et al., 1998, Smith et al., 2000). 
For instance, localisation studies have found Cox-2 to be expressed in both 
the macula densa cells of the juxtaglomerular apparatus in the renal cortex of 
the rat kidney (Harris et al., 1994) and interstitial cells of the medulla (Guan 
et al., 1997). The macula densa is mainly involved in mediating the 
interaction among glomerular filtration, proximal reabsorption, and regulation 
of rennin release (Harris, 1996), which in turn regulates sodium balance and 
body fluid volume (Dubois et al., 1998). In the brain, Cox-2 mRNA 
(messenger ribonucleic acid) and immunoreactivity was found to be 
constitutively expressed in dentate gyrus granule cells, pyramidal cell 
neurons in the hippocampus (O'Neill and Ford-Hutchinson, 1993, Yasojima 
et al., 1999), the piriform cortex, superficial cell layers of neocortex, the 
amygdala, and at low levels in the striatum, thalamus, and hypothalamus 
(Yamagata et al., 1993, Breder et al., 1995, Brederand Saper, 1996). It was 
suggested that Cox-2 may play a role in synaptic activity since Cox-2 was 
found in dendrites and Cox-2 levels increased rapidly during seizures or 
ischaemia (Yamagata et al., 1993, Kaufmann et al., 1997, O'Banion, 1999). 
The main physiological function attributed to Cox-1 is a housekeeper role 
such as cytoprotection of the stomach, in maintaining glandular architecture 
integrity (Dubois et al., 1998) and platelet aggregation (Smith et al., 2000). 
Furthermore, Cox-1 is responsible for production of prostaglandins in the 
kidney, where it maintains renal plasma flow and glomerular filtration during 
systemic vasoconstriction (Palmer and Henrich, 1995). Cox-1 is therefore 
mainly involved in various homeostatic regulatory and maintenance functions 
(Smith et al., 2000). 
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Figure 01.09. Prostaglandin pathways and actions. The pathway of interest 
is where PGH2 is converted by PGE synthase into PGE2 (Green) which 
exerts their actions on EP1-4 receptors (From Funk, 2001). 
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In humans, Cox-2 products play important roles in numerous biological 
processes involved in inflammation but also in normal human physiology 
(Figure 01.09). Action of Cox-2 derived prostaglandins, especially their 
proliferation-promoting effects, have been associated with many cellular 
processes such as liver regeneration (Rudnick et al., 2001), angiogenesis 
(Cao and Prescott, 2002, Iniguez et al., 2003), cytotoxicity associated with 
inflammation (Seibert et a)., 1995, O'Banion, 1999), brain function regulation, 
nerve development and adaptation (Dubois et al., 1998), induction of labour 
(Funk, 2001), modulation of immune response (Tilley et al., 2001), ovulation 
in response to the luteinizing hormone surge, the renal response 
hypernatremia, regulation of cerebral blood flow, fever response/pathway, 
hypothalamic control of the stress hormone, the sleep/wake cycle, blood 
clotting, kidney development, bone metabolism, maintenance of 
gastrointestinal integrity, wound healing, blood vessel tone, apoptosis 
(inhibitory role), mitogenesis, and pain perception (Vane et al., 1998, 
O'Banion, 1999, Kulkarni et al., 2000, Smart et al., 2000, Smith et al., 2000, 
Funk, 2001, Stack and DuBois, 2001, Cao and Prescott, 2002). 
1.6.1.3, Cox expression in animal models of inflammatory and 
neuropathic pain 
Experimental manipulations using various animal models of inflammatory 
and neuropathic pain were able to demonstrate the induction of spinal 
cyclooxygenases, mostly Cox-2 however. 
Very few increases of Cox-1 expression have been observed in the literature. 
Cox-1 mRNA levels have been investigated in cultures of rat DRG neurone 
cells. DRG cells were exposed to IL-1p, a cytokine considered to be a main 
mediator during inflammation and hyperalgesia, to induce the release of 
Substance P via the prostanoid pathway. No increases of Cox-1 expression 
above constitutive levels were reported (Inoue et al., 1999). Cox-1 mRNA 
has also been looked at in an animal model of inflammatory pain. 
Inflammation was induced in rats with an intraplantar injection of Complete 
Freund's Adjuvant (CFA) in one hindpaw. Only basal levels of Cox-1 mRNA 
in the spinal cord were observed (Beiche et al., 1996, Hay and de 
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Belleroche, 1997, Beiche et al., 1998a, Hay and de Belleroche, 1998). Cox-
1 expression remained unchanged in a model of acute arthritis following 
injection of kaolin and carrageenan into the rat knee joint cavity (Ebersberger 
et al., 1999). One particular study, however, using inducible nitric oxide 
synthase (iNOS) gene deficient (iNOS-/-) mice and wild-type mice, showed 
after thermal hyperalgesia induction an increase in spinal Cox-1 mRNA 
expression (Guhring et al., 2000). Furthermore, a modest increase of Cox-1 
protein expression was shown in rat spinal cord at 12 hours post mechanical 
injury (compression) to the spinal cord (Tonai et al., 1999). Also, 
microglia/macrophages Cox-1 immunoreactive positive cells were increased 
in rat spinal cord after injury (spinal cord lesion model) and remained 
elevated up to 4 weeks (Schwab et al., 2000). Finally, Cox-1 expression was 
found to be increased after peripheral nerve injury in the rat spinal cord. Two 
models of peripheral nerve injury were used in this particular study, the 
partial sciatic nerve transsection (PSNT) model (Seltzer et al., 1990) -
modified Seltzer model - and the spinal nerve ligation (SNL) model (Kim 
and Chung, 1992). PSNT resulted in a considerable increase at 4 weeks 
post-surgery of the number of Cox-1 immunoreactive cells, which were of 
glial morphology, in the superficial laminae of the ipsilateral spinal dorsal 
horn of L4-L6 spinal cord. Similar patterns were demonstrated with the SNL 
model at 2 weeks post-surgery. It was suggested that Cox-1 expression 
changes in the spinal cord after peripheral nerve injury play an important role 
in central sensitisation and could present a window of therapeutic opportunity 
for specific Cox-1 inhibitors in alleviating neuropathic pain related symptoms 
(Zhu and Eisenach, 2003). This view was further consolidated by the same 
team using a different animal model - postoperative pain following surgery 
(Zhu et al., 2003). 
Most of the studies mentioned above in relation to Cox-1 had also 
investigated Cox-2 expression. Inoue and colleagues (1999) demonstrated a 
significant increase in Cox-2 mRNA levels in DRG cells after 1-hour 
incubation with IL-1(3. Cox-2 expression was inhibited with an IL-lr 
antagonist, the Cox inhibitor NS398 and dexamethasone - a synthetic 
adrenocortical steroid (Inoue et al., 1999). Significant increased levels of 
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Cox-2 mRNA expression in tine rat lumbar spinal cord were demonstrated 
following peripheral inflammation induction (6 hours) with the CFA-induced 
arthritis rat model. In this model, inflammation was generated by an 
unilateral intraplantar injection of Complete Fround's Adjuvant in the rat's 
hindpaw causing rapid swelling (oedema) followed by altered pain response 
in the ipsilateral paw such as hyperalgesia and allodynia (Beiche et al., 
1996). A time course of spinal Cox-2 expression was further investigated 
using the same adjuvant-induced arthritis rat model. In this study, in addition 
of the use of reverse transcription-polymerase chain reaction (RT-PCR), 
Western blotting confirmed increased levels of lumbar spinal Cox-2 mRNA 
expression 6 hours following induction of peripheral inflammation, to return at 
baseline levels at day 3 and to increase again at day 22 (Beiche et al., 
1998a). Further reports demonstrated rapid significant increases of Cox-2 
mRNA levels (2-4 hours) and prostaglandins (8 hours) following a hindpaw 
CFA-induced peripheral inflammation (Hay et al., 1997). Another study 
showed the anti-inflammatory effects of a glucocorticoid - dexamethasone 
after unilateral intraplantar CFA injection. Dexamethasone attenuated 
oedema, induction of Cox-2 mRNA and levels of prostaglandins in the rat 
lumbar spinal cord (Hay and de Belleroche, 1998). Finally, this particular 
study demonstrated elevated Cox-2 expression after unilateral intraplantar 
CFA injection in both sides of the spinal cord (ipsilateral and contralateral) as 
well as in the cervical spinal cord (Goppelt-Struebe and Beiche, 1997). 
Carrageenan-induced hyperalgesia animal model demonstrated increased 
levels of spinal Cox-2 mRNA and prostaglandins in the surrounding tissue 
which was associated with the development of hyperalgesia and successfully 
attenuated with the Cox-2 selective inhibitor DuP 697 (Hay and de 
Belleroche, 1997). Zymosan-induced hyperalgesia was also associated with 
increased Cox-2 mRNA expression (Guhring et al., 2000). Moreover, 
Kaolin/carrageenan induced knee inflammation caused increased Cox-2 
expression 3 hours post-inflammation in the spinal cord and ongoing as well 
as an marked increased of spinal prostaglandins (PGEa) mostly in dorsal and 
ventral horn (Ebersberger et al., 1999). Finally, bilateral Cox-2 mRNA 
expression was observed in the rat spinal cord after peripheral inflammation 
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and mostly isolated in non-neuronal cells within the grey and white matter 
(Ichitani et al., 1997). 
Rapid elevated levels of Cox-2 protein expression, with a peak at 24hours, 
were demonstrated following mechanical injury to the spinal cord in rats 
(Resnick et al., 1998). Another study showed similar increases of Cox-2 
mRNA after rat spinal cord compression. The induction of Cox-2 was 
associated to the second phase (8 hours) and Cox-2 immunoreactivity was 
mainly found in glial cells within the spinal cord (Tonai et al., 1999). Finally 
spinal Cox-2 mRNA and protein were isolated rapidly following traumatic 
spinal cord Injury. Cox-2 immunoreactivity was mainly found in endothelial 
cells (Adachi et al., 2005). Finally, using a model of neuropathic pain (L5 
and L6 spinal nerves ligation; Chung model), Cox-2 protein expression was 
demonstrated to rapidly increase in the rat dorsal spinal cord after one day 
post-operation (Zhao et al., 2000). 
Several studies have investigated cyclooxygenase expression in human 
tissue (Minghetti, 2004). A strong upregulation of Cox-2 mRNA was found in 
amyotrophic lateral sclerosis (ALS) spinal cord compared to Alzheimer's 
disease, Parkinson's disease (PD), cerebrovascular disease, and normal 
spinal cords while Cox-1 mRNA showed only a trend to increase (Yasojima 
et al., 2001). Increased levels of the pro-inflammatory prostaglandin PGE2 
were demonstrated in cerebrospinal fluid (CSF) from ALS patients (Aimer et 
al., 2002) and increased AA metabolites levels were observed in CSF from 
MS subjects (Greco et al., 1999). Cox-2 activity was further investigated by 
assessing Cox-derive product PGE2 levels in human spinal cord from 
patients with sporadic ALS. Using commercial enzyme immunoassay kit, 
ALS spinal cord tissue samples showed increased levels of PGE2 (Aimer et 
al., 2001). Furthermore, expression and localization of Cox-1 and Cox-2 was 
investigated by immunohistochemical method in human sporadic ALS. 
Perinuclear and cytoplasmic Cox-2-1R was observed in motoneurones and 
interneurones as well as in glia (astrocytes). A significant increase in 
number of positive neurones (motoneurones and interneurones) was seen in 
ALS spinal cords even with an overall reduction in total number of neurones. 
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Cox-2-IR was also observed in non-neuronal cells such as astroglial 
morphology but not in microglia-type cells. Cox-1, on the other hand, was 
observed in microglial-type cells and not in neurones (Maihofner et al., 
2003). Cox-2 expression was also found to be increased in substantia nigra 
dopaminergic neurones in post-mortem tissue samples from PD patients 
(Teismann et al., 2003). Cox-2 expression in AD has generated over the last 
decade conflicting results. Some reports demonstrated increased levels of 
Cox-2 whilst others decreased. Cox-2 expression may vary with disease 
stages. Recent studies appear to associate Cox-2 elevated levels with 
earlier stages of the disease (Bazan et al., 2002, Minghetti, 2004). 
1.6.1.4. Prostaglandin E synthase 
Prostaglandin E synthase (PGES) converts Cox-derived PGH2 to PGE2, the 
most common prostanoid. PGES was only purified and cloned recently 
(Jakobsson et al., 1999b, Mancini et al., 2001). To date three forms have 
been cloned and characterised, two perinuclear membrane-bound forms of 
PGES (mPGES-1 &-2) (Jakobsson et al., 1999b, Watanabe et al., 1999) and 
a cytosolic form of PGES (cPGES; Tanioka et al., 2000) which lead to the 
isolation of two distinct pathways of PGE2 biosynthesis within a cell (Figure 
01.10); the constitutive Cox-1-cPGES pathway and the inducible Cox-2-
mPGES pathway (Murakami et al., 2000, Tanioka et al., 2000). 
Part of the MAPEG (membrane-associated proteins involved in eicosanoids 
and glutathione) superfamily proteins, mPGES can be induced by various 
stimuli such as IL-1|3 (Jakobsson et al., 1999b) and TNF-a (Thoren and 
Jakobsson, 2000, Stichtenoth et al., 2001). mPGES is an inducible enzyme 
up-regulated by pro-inflammatory stimuli and down-regulated by anti-
inflammatory glucocorticoids, often in a similar fashion as Cox-2 (Murakami 
et al., 2000, Thoren and Jakobsson, 2000, Mancini et al., 2001, Stichtenoth 
et al., 2001). mPGES is preferentially coupled with Cox-2. It was therefore 
suggested that mPGES may play a role in inflammation, pain and fever 
(Jakobsson et al., 1999a, Murakami et al., 2000). mPGES was found to be 
upregulated in a rat model of adjuvant-induced arthritis (Mancini et al., 2001) 
as well as in chondrocytes from patients with osteoarthritis (Kojima et al.. 
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2004, Masuko-Hongo et al., 2004). A pathogenic mechanism was proposed, 
attributing mPGES-1 an important role in the vicious circle of inflammation 
associated with arthritis (Kojima et al., 2005). Based on several 
observations, the authors argued that the mPGES-1 upregulation, initiated by 
IL-1 via the downstream cascade of PGE2 biosynthesis, is further enhanced 
by PGE2 in rheumatoid synovial fibroblasts by increasing cAMP through 
activation of EP2 and EP4 receptors (Kojima et al., 2005). 
On the other hand, cPGES was coupled with Cox-1. This enzyme may 
therefore play a role in the maintenance of homeostasis (Tanioka et al., 
2000, Chandrasekharan et al., 2005) 
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Figure 01.10. Schematic representation of multiple pathways involved in the 
biosynthesis of PGE2 within a cell coupling Cox with PGE2 (From Murakami 
et al., 2002). 
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1.6.2. Prostaglandins and their receptors 
Prostaglandins are potent bioactive lipid messengers derived from fatty acids 
stored in cellular membranes. PGs are not stored but are synthesised de 
novo. They are fatty acids with a cyclopentane ring between two side 
chains, one of which holds the carboxyl group. Furthermore, PGs possess 
two double bonds in theirs side chains, and thus carry in their names the 
subscript '2' (Simmons et al., 2004). In general, PGs (AA metabolites) belong 
to a larger group of hormonally active, oxygenated Cis, C20, C22 fatty acids 
collectively known as eicosanoids that are derived from w3 and w6 
polyunsaturated fatty acid including also prostacyclin and thromboxanes 
(Smith et al., 2000, Stack and DuBois, 2001). 
Prostaglandins, formed in the endoplasmic reticulum, are shipped out rapidly 
from the cytosol across the plasma membrane. The release of PGs from 
cells is facilitated by prostaglandin transporters (PGT), part of the organic 
anion transporter polypeptide family (Schuster, 2002). PGs have low 
permeability and without these active carriers they would poorly diffuse 
across the membranes (Schuster, 1998). Once released, prostaglandins 
have a relatively short half-life and exert their effects locally in both autocrine 
and paracrine patterns (Dubois et al., 1998, Cao and Prescott, 2002) on a 
family of prostaglandin receptors EP1-4, DPI-2, FP, IP, and TP (Funk, 2001, 
Hull et al., 2004). Two classes of PGs receptors have been identified - the 
G-coupled cytoplasmic receptor class and the nuclear peroxisome 
proliferator activated-receptor class. The latter acts directly as a transcription 
factor (Stack and DuBois, 2001). PGE2, for instance, signals via a seven-
transmembrane-domain G-protein-coupled receptor (GPCR), of which four 
different receptors (EP1-4) have been currently identified (Coleman et al., 
1994). Subtypes were allocated according to their response to a number of 
agonists and antagonists. All four EP subtypes (Table 01.02) were cloned 
and each EP subtype was characterised by a different molecular structure, a 
different signal transduction pathway and a different genetic encoding (Boie 
et al., 1997, Kiriyama et al., 1997). 'Knock-out' mouse models have greatly 
contributed in the understanding of the pharmacology and the physiological 
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role of each EP subtypes. Findings have been extensively reviewed 
(Coleman et al., 1994, Narumiya et al., 1999, Sugimoto et al., 2000, 
Narumiya and FitzGerald, 2001, Kobayashi and Narumiya, 2002, Tsuboi et 
al., 2002). EP receptors subtypes diversity may account for the various 
biological responses exerted by PGE2 (Breyer, 2001, Breyer et al., 2001). 
Although most prostaglandin receptors are localised on the cell membrane, 
some could be found on the nuclear envelop where they can activate nuclear 
hormone receptors (Bhattacharya et al., 1998). 
Table 01.02. EP receptors characteristics summary (From Tsuboi et al, 2002 
and Hull et al., 2004). 
Receptor G Protein 2"^  messenger signal Spliced Isoforms 
EP1 Gq Phospholipase C/inositol 
triphosphate 
2 rats 
EP2 Gs Increased cAMP None 
EP3 Gi, Gs, Gq Decreased cAMP 3 Mouse, 8 human, 4 
bovine and 4 rat 
EP4 Gs Increased cAMP None 
cAMP: cyclic adenosine monophosphate 
1.6.2.1. Prostaglandin receptor EP1 
The mouse and human EP1 receptor have been cloned at the beginning of 
the nineties (Funk et al., 1993, Watabe et al., 1993). This receptor subtype 
has been originally described as a smooth muscle constrictor (Kennedy et 
al., 1983). The cDNA (copy deoxyribonucleic acid) of human EP1 receptor 
was found to encode a 402-amino-acid polypeptide with a predicted 
molecular mass of 41,858 kDa (Funk et al., 1993) while the cDNA of the 
mouse EP1 encoded a 405-amino-acid sequence polypeptide (Watabe et al., 
1993). A rat EP1 receptor has also been cloned and was found to be 96% 
homologous to the mouse EP1 receptor and 86% to the human EP1 receptor 
(Funk et al., 1993, Bole et al., 1997). Member of the CGRP superfamily, the 
amino acid chain of this receptor crosses the plasma membrane 7 times in a 
serpentine fashion and is comprised of an extracellular ligand binding site 
and an intracellular carboxyl terminal (C-terminal). Only differences in the 
intracellular c-terminal tail accounts for the variant spliced isoforms of the 
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receptor while the rest of the structure is conserved (Breyer et al., 2001). 
The EP receptors have been classified according to their intracellular 
signalling transduction pathways (Muallem et al., 1989, Toh et al., 1995). 
The EP1 receptor with FP and TP receptors belong to a group of receptors 
referred to as 'contractile receptors. Activation of EP1 was associated with a 
rise in inositol triphosphate and cytosolic levels of free Ca "^". EP1 does not 
modulate cyclic adenosine monophosphate (Wang et al., 2005). Specific 
agonist to this receptor have been developed however they also present 
some significant affinity to other subtypes mostly EPS. The recent discovery 
of various EP subtypes and the difficulties to synthesise prostanoid 
analogues rendered the development of specific agonists to the human EP1 
receptor only partially successful to date (Ungrin et al., 2001). 
Localisation studies have mostly investigated expression at the mRNA level 
due to the lack of well-characterised EP1 antibodies. In addition, expression 
was mostly investigated in the gastrointestinal (Gl) tract (Hull et al., 2004) 
and the kidney (Morath et al., 1999, Breyer and Breyer, 2000, Breyer and 
Harris, 2001). EP1 receptor mRNA was found predominantly in the kidney 
but also in the gastric muscularis mucosae and in the adrenal glands 
(Watabe et al., 1993, Okuda-Ashitaka et al., 1996, Guan et al., 1998). EP1 
and EPS mRNA was mostly found in the internal muscular portion of the 
intestinal wall whilst EP4 in the intestinal mucosal layer suggesting that Gl 
function could be modulated by PGE2 via at least S receptors each with a 
distinct role (Stack and DuBois, 2001). EP1 mRNA was also found to be 
expressed in rat ORG neurones (Oida et al., 1995, Hasumoto et al., 1997, 
Donaldson et al., 2001). Finally, EP1 protein expression was observed using 
immunohistochemical techniques in Purkinje cells in the rat cerebellum 
(Candelario-Jalil et al., 2005). 
1.6.2.2. Prostaglandin receptor EP4 
Before 1995, this receptor was generally referred to as EP2 receptor 
(Nishigaki et al., 1995). The human EP4 receptor was cloned in 1994 and 
forms a 488 amino acid long polypeptide with a predicted molecular mass of 
approximately 53 kDa (Bastien et al., 1994). The mouse, rabbit, rat and cow 
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EP4 receptor have also been cloned (Honda et al., 1993, Bastien et al., 
1994, Nishigaki et al., 1995, Breyer et al., 1996, Bole et al., 1997). The EP4 
receptor belongs to the "relaxant" group receptors with the IP, DPI, EP2 
receptors and signals via a Gg-mediated increase in intracellular cyclic 
adenosine monophosphate (cAMP). Two pathways were proposed to induce 
Cox-2 transcription (Figure 01.11), the cAMP/protein kinase A dependent 
pathway and the phosphatidylinositol 3-kinase (PI3K) dependent pathway 
(Breyer et al., 2001, Regan, 2003). 
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Figure 01.11. Schematic representation of EP4 receptor activation by PGE2. 
Proposed intracellular signalling pathways leading to the induction of Cox-2 
transcription (From Regan, 2003). 
EP4 and EP3 are the most widely distributed prostanoid receptors (Sugimoto 
et al., 2000). Thymus, lung, ileum, spleen, adrenal and kidney tissue 
expressed EP4 receptor mRNA (Honda et al., 1993, Bastien et al., 1994, 
Breyer et al., 1996). EP4 as well as EP1 and EP3 mRNAs were found to be 
expressed in DRG primary sensory neurones (Sugimoto et al., 1994, Oida et 
al., 1995). Gene knockout studies showed that the activation of this receptor 
was an effective vasodilator, reduced inflammation and was responsible for a 
decrease in cytokine (IL1-P and IL-6) production. Cytoprotective bicarbonate 
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secretion, important mechanisms to protect against acid-based disturbances, 
was found to be mediated by PGE2 via the EP4 receptor only in the second 
part of the second part of the human duodenum (Larsen et a!., 2005). The 
particular role in inflammation and immune function favours this receptor as a 
candidate target of potential therapeutic value (Regan, 2003). 
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1.7. Aims 
The main objective of this project was to investigate peripheral and central 
neuronal-inflammatory interactions in injured human nerves and DRG from 
patients with post-traumatic painful neuropathies, spinal cord and an 
associated robust animal pain model (the chronic constriction injury model). 
While there is increasing evidence of a role for inflammatory mechanisms, 
particularly in the CNS, in neuropathic pain, the currently assumed lack of 
effectiveness of Cox-inhibitors deserves an explanation (e.g. lack of CNS 
penetration, or alternatie pathways that produce inflammatory agents). Site-
specific neuro-inflammatory pathway changes over time, particularly 
prostanoids produced by Cox-2, and their receptor EP1, would be correlated 
with pain behaviour in the rat CCl model, and in tissues from patients with 
peripheral nerve injury. Site-specific inhibition of key correlates in these 
pathways would ameliorate pain behaviour. Any outcomes will contribute to 
the understanding of CNS mechanisms involved in chronic neuropathic pain, 
and may provide targets for novel analgesics. 
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1.8. Hypothesis 
We hypothesize that nerve injury in humans and animal models is associated 
with increased levels of Cox-2 at the site of injury, expressed in non-neuronal 
cells, and that these peripheral changes drive further neuro-inflammatory 
processes in the CNS. These central changes in turn contribute to the 
maintenance of hypersensitivity and chronic neuropathic pain. 
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CHAPTER II 
Materials and methods 
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2.1. Human tissue 
Fully informed consent was obtained for all human tissues, which were 
collected with approval of the Local Ethics Committee. All human tissues 
were snap frozen in liquid nitrogen and stored at -70°C until use. 
2.1.1. Peripheral nerve 
Injured nerve specimens (proximal and distal to site of injury) were obtained 
during surgery for brachial plexus repair at the Royal Orthopaedic Hospital 
(Stanmore, UK) by Mr Rolfe Birch. Briefly, the brachial plexus is a somatic 
nerve plexus responsible for the motor innervation to the upper limb. It also 
supplies most of the cutaneous innervation of the upper limb. Brachial 
plexus injuries (BPI), in adults, are caused by high-energy forces, usually 
involving motor vehicles. In the infants, BPI are usually obstetrical injuries 
caused from excessive traction on the plexus during complex or difficult 
delivery (Terzis and Papakonstantinou, 2000, Birch, 2002). The result of 
these types of injuries can leave patients with severe loss of motor and/or 
sensory function in the arm in conjunction with severe pain states, in some 
cases persistent over many years (Berman et al., 1998, Carlstedt et al., 
2000). Lesions in the brachial plexus have been classified into two main 
categories - postganglionic or preganglionic, and then further subdivided into 
more subcategories according to the level of injury. Figure 02.01 shows a 
schematic representation of a normal innervation of the dorsal and ventral 
roots into the spinal cord (Figure 02.01 .A), then a rupture of the peripheral 
nerve exposing a proximal and distal stumps which represents a 
postganglionic lesion (Figure 02.01.B) and finally in C (Figure 02.01.C) an 
avulsion of both ventral and dorsal roots (preganglionic lesion). Treatment 
by nerve grafting can be effective with postganglionic lesions and nerve 
transfer or any other reconstructive procedure is considered as the treatment 
of choice for preganglionic lesions (Nagano, 1998). 
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Figure 02.01. Schematic representation of brachial plexus injuries. A. 
Normal, B. Rupture (postganglionic lesion), C. Avulsion (preganglionic lesion; 
from Berman et ai, 1998). 
Painful human limb neuromas were obtained during surgery for peripheral 
nerve repair at Broomfield Hospital (Chelmsford, UK) by Mr David Elliot. A 
damaged or cut peripheral nerve, in an attempt to regenerate, grows multiple 
fine unmyelinated sprouts from the transected axon end. Not all 
regenerative nerve sprouts grow in the distal part of the cut nerve. Most 
grow randomly in all directions to form a tangled mass in the adjacent 
connective tissue. The sprouts may extend up to 2 mm from the parent axon 
into the connective tissue with some curving back into the nerve of origin. 
This formation is referred to as a neuroma (Kline and Nulsen, 1972, Wall and 
Gutnick, 1974b, Zimmermann, 2001). Following transection, the axon within 
a neuroma often develops abnormal electrical hyperexcitability most likely 
responsible for the abnormal dysaesthetic sensations (tingling, itching or 
electrifying) experienced by patients. Surgical excision of the neuroma is 
considered to be the most effective for neuroma-associated pain 
(neuromatous pain) relief or nerve regeneration (England et al., 1998, 
Zimmermann, 2001). 
All collected injured peripheral nerve tissue samples were obtained from 
young adults and adults. The mean pain scores on a visual analogue scale 
(VAS) were all > 4 out of 10 at the time of surgery, and patients reported this 
or a higher level of pain usually continuously since the time of injury. 
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Samples were sub-divided into 2 groups, acute and chronic, according to the 
delay between the date of injury and the date of tissue collection at surgery. 
On occasion, the chronic group was further sub-divided into two groups, 
short-term chronic and long-term chronic. Acute was defined as less than 21 
days and chronic as more than 21 days of injury duration. Short-term 
chronic was defined as greater than 21 days but less then 3 months and 
long-term chronic greater than 3 months of injury duration. 
Tissue for the control group was obtained during surgery for limb amputation 
for non-neurological tumours, in patients with no neurological symptoms or 
signs. 
2.1.2. Dorsal Root Ganglia (ORG) 
Avulsed dorsal root ganglia were obtained during surgery for brachial plexus 
repair. Control, post-mortem DRG were obtained from Netherlands Brain 
Bank with a post-mortem delay of less than 12h. 
2.1.3. Spinal Cord 
Post-mortem spinal cord specimens from patients with brachial plexus nerve 
injury are not available, and therefore CNS inflammatory processes, 
neuronal loss or regeneration inhibition cannot be studied within this group of 
patients. Post-mortem spinal cord from patient with multiple sclerosis (MS) 
and amyotrophic lateral sclerosis (ALS) were chosen instead, as post-
mortem tissue was available. Both conditions present elements of 
neuroinflammation and neurodegeneration. Segments of deep frozen 
human spinal cord were obtained from the rapid autopsy system of the 
Netherlands Brain Bank and Medical Research Council (MRC) Brain Bank, 
King's College London. All MS tissues were classified according to the 
following criteria: 1) Preactive lesions - expression of CD68, CD45 on 
clusters of perivascular microglial cells in white matter with no loss of myelin, 
2) Active demyelinating lesions, characterized by the presence of 
macrophages with luxol fast blue or myelin basic protein - positive 
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inclusions, and glial fibrillary acidic protein (GFAP; astroglial marker) positive 
reactive astrocytes with long processes, in demyelinating regions, 3) 
Chronic active - hypocellular demyelinated centre of the lesions containing 
a small number of CD68-positive macrophages, with reactive astrocytes 
localised mainly at the edge of the lesion, or 4) Chronic non-active lesions 
- hypocellular demyelinated lesion with gliosis (De Groot et al., 2001, 
Nijeholt et al., 2001). ALS lumbar spinal cord was obtained post-mortem 
from patients with clinically and pathologically confirmed sporadic ALS. 
Segments of deep frozen human control (no neurological signs or symptoms) 
and diseased spinal cord were obtained from the Netherlands Brain Bank 
and MRC Brain Bank, King's College London. 
2.2. Rat tissue 
All procedures involving the use of animals were approved by the UK Home 
Office and were carried out in accordance with the requirements of the 
project licence. Rat tissues were snap frozen in 2-methyl butane cooled in 
liquid nitrogen and stored at -70°C until use. All surgical procedures were 
carried out at GlaxoSmithKline (Harlow, UK) by qualified personnel. 
Adult male Sprague-Dawley rats (200-250 g) were used in this study. CCI 
animals had the left sciatic nerve loosely ligated with chromic gut sutures to 
cause a constriction injury as previously described (Bennett and Xie, 1988). 
Control, sham-operated animals underwent identical surgical procedures but 
without nerve constriction. Animals were placed at proximity to the surgery 
room the night before to reduce stress on the day of surgery. The animal 
was first anaesthetised with isoflurane by a technician. The left thigh was 
then shaved at mid thigh level and the exposed skin was disinfected with 
antibacterial skin cleanser. The rat was placed on its right side on the 
surgery table by the technician. A different person was responsible to carry 
out the surgical procedure. First an incision was made through the skin and 
blunt scissors were used to separate muscle fibres of the biceps femoris. 
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Once the common left sciatic nerve was exposed using forceps, four loose 
ligatures of chromic gut (4.0) were tied loosely around the nerve with a 
spacing of 1 mm between each. The wound was then closed and secured 
with suture clips. The surgical procedure was identical for the sham-
operated animals except the sciatic nerve was not ligated. The animals were 
left individually in a cage with a heat source (lamp or warm pad) and were 
constantly monitored till fully recovered from the anaesthesia before housed 
back to their original cage. They received standard post-operative care for 5 
days where weight was monitored daily and a mashed diet was given. CCI-
induced decrease in mechanical paw withdrawal threshold was measured 
using an algesymeter (Ugo-Basile, Comerio, Italy) as previously described 
(Randall and Selitto, 1957). To determine threshold, an increasing weight 
was applied to the dorsal surface of the left and right hindpaw until the rat 
attempted to withdraw the paw. Behavioural testing showed mechanical and 
thermal (heat) hypersensitivity in affected paw from 7 days until 40 days after 
ligation of nerve, as expected. At different time-points post-operation (04, 
21, 30 and 40 days), animals were sacrificed and tissues harvested: lesioned 
and intact contralateral sciatic nerve and DRG (L4 and L5), and lumbar 
spinal cord were collected. 
2.3. Methods 
2.3.1. Immunohistochemistry 
Tissues were supported in optimum cutting tissue (OCT) medium to allow 
best orientation (transverse for spinal cord, longitudinal for nerve). Frozen 
sections (12(jm thick) were collected onto poly-L-lysine coated glass slides 
and post-fixed in freshly prepared, 4% w/v paraformaldehyde in 0.15M 
phosphate buffered saline (PBS) pH 7.4 for 20 minutes. Sections were 
rinsed in PBS. Endogenous peroxidase was blocked by incubation in 
industrial methylated spirit (IMS) containing 0.3% w/v hydrogen peroxide for 
20 minutes also. Sections were rinsed twice in PBS. After rehydration, 
sections were incubated overnight at room temperature with primary 
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antibody. A full listing of all primary antibodies used in this work can be 
found in the table below (Table 02.01). Slides are placed by three or by four 
in a Petri dish containing a moist paper towel. Sites of primary antibody 
attachment were revealed using nickel-enhanced, avidin-biotin peroxidase 
(ABC; Vector Laboratories, Peterborough, UK) as formerly described (Shu et 
al., 1988). Briefly, sections are first rinsed then incubated with biotinylated 
(biotin labelled) secondary antibodies for 40 minutes (Table 02.02). In the 
meantime, avidin and biotinylated enzyme complex are mixed and left for 30 
minutes to form the avidin/biotinylated enzyme complex. Avidin has four 
binding sites for biotin. Sections are rinsed and incubated with ABC 
(avidin/biotin complex) for at least one hour. Followed by a rinse, sections 
are immersed in a nickel salt rich solution (DAB solution). Ammonium and 
glucose is added to the DAB solution and to start the reaction glucose 
oxidase is finally added. Sections are left to develop for 8-10 minutes. 
Finally, sections were counter-stained for nuclei in 0.1% w/v aqueous neutral 
red. The dehydration process consisted of the immersing the slides in a 
succession of solution containing a gradually increasing percentage of IMS 
(30%, 70%, 90% and 100%) to finish in xylene for 4 minutes. Slides were 
mounted in a xylene-based mountant (DPX) prior to photomicrography. 
Negative controls included omission of primary antibodies and specificity of 
immunoreaction confirmed by preincubation of primary antibodies with 
homologous primary peptide antigen (whenever available) at 10 "Mo 10 
mg/ml diluted antibodies prior to immunostaining or confirmation with a 
similar commercially available antibody but from a different company (see 
Appendix 1 for list of chemicals and Appendix 6 for list of buffer solution 
used). 
Table 02.01. List of primary antibodies. 
Antibodies to Donor 
species Source Reference Titration 
Cox-1 Goat Santa-Cruz Biotechnology Inc, Santa Cruz, CA.USA C-20 1:1000 
Cox-1 Mouse Cayman Chemical, Bingham, UK 160110 1:100 
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Cox-2 Mouse Transduction Laboratories, Cowley, UK Clone 33 
1:50 & 
1:250 
Cox-2 (C-20) Goat Santa-Cruz Biotechnology Inc, Santa Cruz, CA,USA C-20 1:500 
Cox-2 (M-19) Goat Santa-Cruz Biotechnology Inc, Santa Cruz, CA,USA M-19 1:500 
CD68 (human 
macrophage 
marker) 
Mouse Dako, Ely, UK Clone EBM11 1:1000 
CD68 Rabbit Santa-Cruz Biotechnology Inc, Santa Cruz, CA,USA H-255 1:200 
CD11b (rat 
macrophage 
marker) 
Mouse Serotec, Kidlington, UK Clone MRC 0X42 1:1000 
EP1 Receptor Rabbit Cayman Chemical, Bingham, UK 101740 1:500 
EP1 Receptor Rabbit 
Alpha Diagnostic 
International, San 
Antonio, Texas, USA 
EP11-A 1:500 1:1000 
EP4 Receptor Rabbit Cayman Chemical, Bingham, UK 101775 1:750 
Cathepsin S Goat Santa-Cruz Biotechnology Inc, Santa Cruz, CA,USA (M-19) 1:100 
CDS Mouse DakoCytomation, Glostrup, Danmark Clone UCHT1 1:5000 
CD4 Mouse DakoCytomation, Gostrup, Danmark Clone MT310 1:1000 
c-kit oncoprotein 
(CD117) Mouse 
Novacastra, Newcastle 
upon Thames, UK 57A5D8 NSS 
mPGES-1 Rabbit Cayman Chemical, Bingham, UK 160140 NSS 
PGE Synthase Rabbit Santa-Cruz Biotechnology Inc, FL-152 NSS 
Phospho-p38 MAP 
Kinase Rabbit 
Cell Signaling 
Technology, Danvers, 
MA, USA 
9211 NSS 
p38 MAP Kinase Rabbit 
Cell Signaling 
Technology, Danvers, 
MA, USA 
9212 NSS 
p38 MAP Kinase 
alpha Rabbit 
Cell Signaling 
Technology, Danvers, 
MA, USA 
9218 NSS 
Nogo-A Mouse GlaxoSmithKiine, Harlow, UK 6D5 
1:160 
1::320 
Nogo 66 receptor Rabbit GlaxoSmithKline, Halow, UK 63774 
1:2000 
1:5000 
Neurofilament 
protein Mouse 
CytoDakomation, 
Glostrup, Danmark 2F11 1:10,000 
Peripherin Mouse Novacastra Newcastle upon Thames, UK PJM50 1:200 
NSS = Non-specific staining 
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Analysis ® FIVE software (Soft Imaging System GmbH. Munster, Germany) 
was used to quantify immunoreactivity of cells or fibres. Analogue images 
were captured via video link (Olympus DP70 Digital Camera) to an Olympus 
BX50 microscope and were converted into a digital monochrome image. 
The grey-shade detection threshold was set at a constant level to allow 
detection of positive immunostaining and the area of highlighted 
immunoreactivity was obtained as a % area of the field scanned. One 
section per specimen was image-analysed at the stated optimum dilution 
(this followed a series of sections immunostained with different antibody 
dilutions). The visual fields were selected at random, avoiding edges of the 
section. The area was 442 pm x 332.8 pm. Five fields per tissue section 
were scanned within the tissue section and the mean value was used in 
subsequent statistical analysis. 
Table 02.02. List of secondary antibodies. 
Antibodies to Donor 
species Source Reference Titration 
Biotlnylated Anti-
Mouse IgG Horse 
Vector Laboratories, 
Peterborough, UK BA-2000 1:100 
Biotinylated Anti-Rabbit 
IgG Goat 
Vector Laboratories, 
Peterborough, UK BA-1000 1:200 
Biotinylated Anti-
IVIouse IgG (Rat 
Absorbed) 
Horse Vector Laboratories, Peterborough, UK BA-2001 1:100 
Biotinylated Anti-Goat 
IgG Horse 
Vector Laboratories, 
Peterborough, UK BA-9500 1:200 
Biotinylated Anti-Rat 
IgG Goat 
Vector Laboratories, 
Peterborough, UK BA-9400 1:200 
Intensity of immunoreaction was assessed in a blinded fashion by two 
observers at two dilutions of antibodies and given a mean score [vision 
inspection scale: 0 = no immunoreaction (-); 1 = weak (+); 2 = medium (++); 
3 = strong (+++)]. 
The number of positive immunoreactive motoneurones was assessed and 
expressed as a percentage (%) of total number of positive cells at two 
dilutions of antibodies. Motoneurones were evaluated by morphological and 
size criteria according to Tomlinson et al. (1973). Cells were considered 
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interneurones if they had a cell body < 25 pm and motoneurones if their cell 
body was > 25 pm (Tomlinson et al., 1973). Also motoneurones could be 
characterised by their distinctive features such as a prominent neuritic 
arborisation and a single long axon-like neurite. 
The number of immunoreactive positive cells was obtained by counting using 
a calibrated microscope eyepiece graticule. Positive immunoreactive cells 
were counted in five fields within the tissue section and within nerve fibres 
using a neurofilament staining on adjacent section as guide. Counts were 
carried on one section per nerve specimen at the stated optimum dilution 
(this followed a series of 5 sections immunostained with different antibody 
dilutions). The visual fields were selected at random, avoiding edges of the 
section. The area was 50[jm x 50|jm. The mean value was used in 
subsequent statistical analysis. 
2.3.2. Double immunostaining 
For double staining in co-localisation studies, tissue sections were incubated 
with two different primary antibodies at the same time, one raised in rabbit 
and the other in mouse. To develop the immunoreaction, the standard ABC 
method, which gives a dark product, was used to reveal the rabbit 
antibodies. Mouse primary antibodies were detected using an alkaline-
phophatase-anti-alkaline-phosphatase (APAAP) complex. After overnight 
incubation at room temperature with primary antibodies, sections were rinsed 
in TRIS (Tris Hydroxymethylaminoethane) buffer pH 7.6, which was used 
instead of PBS also in the antibody diluent to prepare all subsequent 
antibodies. Sections were consecutively incubated in a cocktail of secondary 
antibody composed of biotinylated anti-rabbit (at 1:200 for 40 minutes) and 
non-biotinylated mouse IgG (at 1:25 for 40 minutes), washed in TBS (Tris 
buffered saline), and then incubated in immunoalkaline phosphatase 
(APAAP; 1:25 for 40 minutes). After washing in TBS, incubations in 
secondary antibodies and APAAP were repeated a second time in the same 
sequence as previously stated. Sections were washed well in TBS to 
eliminate any residue of azide and ABC peroxidase was applied for at least 
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40 minutes. After washing, the peroxidase (rabbit-ABC-black product) was 
developed first, as explained before, followed by the alkaline phosphatase 
(mouse-APAAP-red product), developed using Sigma Fast Red reagents 
(red product). The latter reagents came as a kit and manufacturer's 
instructions were followed. For double staining, counterstaining was not 
performed to avoid red nuclei conflicting with red APAAP immunostaining 
product and a xylene free mounting medium was used when cover-slipping 
(see Appendix 1 for list of chemicals and Appendix 6 for list of buffer solution 
used). 
2.3.3. Western blotting 
Nerve extracts and mouse macrophage control extracts (Transduction Labs) 
were processed for Western blotting as previously described (Yiangou et al., 
2001). Briefly, frozen tissues were first pulverised using a mortar and pestle 
pre-cooled in liquid nitrogen. Then ice-cold modified 
radioimmunoprecipitation assay (RlPA) buffer (PBS containing 1% NP40, 
0.5% sodium deoxycholate and 0.1% SDS) containing freshly added 
protease inhibitors (5 mmol/L phenylmethylsuphonyl fluoride, 2 mmol/L 
benzamidine, 1 mmol/L iodoacetamide and 50 mg/mL aprotinin) was added 
to the protein concentrate and left on ice to incubated for 30 min. 
Homogenates were centrifuged at 5000 g for 15 min. The pellet was 
discarded and an aliquot of the supernatant was taken. The total protein was 
measured using a Bradford dye-binding protein assay, according to the 
manufacturer's instructions (Bio-Rad Laboratories). An equal amount of 
protein (~ 25 mg) per homogenate was attempted. Each homogenates were 
then combined with sodium dodecal sulphate (SDS) sample buffer and 
incubated at 100°C for 10 min before loading on an 8% SDS-polyacrylamide 
gel. After electrophoresis, proteins were transferred to pre-wetted 
polyvinylidene difluoride membranes (Hybond P) using a semidry transblotter 
at 200 mA for 16 h at 4°C. Non-specific antibody binding sites were blocked 
by incubating the strips in 5% (w/v) non-fat dried milk in a solution of PBS 
containing 0.1% (v/v) Tween 20 for 1 h. Primary antibody (Cox-2; see Table 
02.01) incubation was 2 h or overnight in block buffer. After washing, sites of 
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attachment of primary antibodies were detected using immunoperoxidase 
reagents. Immunoreactivity was visualized on Hyperfilm autoradiography 
film after treatment with ECL-plus Western blotting detection system 
(Amersham Life Science Ltd) using manufacturer's instructions (see 
Appendix 2 for list of chemicals and Appendix 6 for list of buffer solution 
used). 
Optical density readings of autoradiographs were taken using a Digit-X 
densitometer evenly illuminated on a photography viewer. Background 
readings were determined by measuring optical density outside the sample 
lanes. After subtraction of background, the mean of three consecutive 
readings of protein immunoreactivity at the respective band position for each 
sample lane was obtained. 
Comparisons of control with patient's extracts specimens were performed on 
separate occasions using the same original extracts. Because of inter-gel 
variation, only gels that were performed on the same day were used in 
comparison studies. Inter-gel variation was corrected by comparing the 
optical density of the positive control in each blot and adjusting the optical 
density readings accordingly. This was less than 10%. Because of loading 
limitations due to the number of wells on the comb it was necessary to 
perform more than one Western blot on more than one occasion in order to 
increase the number of extracts for statistical validity. Our results and 
controls were reproducible on each occasion. 
2.3.4. Autoradiography 
Film autoradiography were carried out on unfixed frozen tissue sections 
(human nerve and rat tissue), using custom-synthesised single enantiomer 
[^H] (R) PK11195 - a marker for activated microglia (Banati et al., 1997). 
Tissue sections were first brought at room temperature under a cold stream 
air. They were then incubated in 170 mM TRIS HCI buffer (pH 7.4) 
containing 1 nm of pH] (R) PK11195 (specific activity 53.76 Ci/mmol) for 20 
minutes. The sections were then washed twice for 5 min in the Tris-HCI 
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buffer and quickly dipped in ice-cold distilled water. The sections were dried 
under a stream of cold air and apposed to tritium-sensitive Hyperfilm, 
exposed for 10 days at 4°C. The Hyperfilm was placed 5 minutes in 
developer and then was fixed for one minute. After development, pH] (R) 
PK11195 binding was quantified and a baseline scale established using 
Analyze AVW version 3 (Robb and Hanson, 1991) software package (see 
Appendix 3 for list of chemicals and Appendix 6 for list of buffer solution 
used). 
For the quantification of [^H] (R) PK11195 binding, the Hyperfilm was first 
scanned using standard computer equipment at a high resolution (2,400 dpi) 
and to create an individual black and white digital image for each tissue 
section saved as a tiff file. To establish [^H] (R) PK11195 binding within a 
specific structural region of the tissue section, manual outlining of that 
particular region was carried out using Analyze AVW version 3. Human 
nerve and rat nerve and DRG were outlined to form one region of interest 
(ROI) respectively whilst the rat spinal cord was subdivided into 8 ROI; 1-2: 
Laminae l-ll (left and right respectively); 3-4: Lamina IX (left and right 
respectively); 5-6: Grey Matter (left and right respectively); 7: Central Canal; 
8: White Matter (Figure 03.11). A background region was also defined for 
each individual image sample of similar size as the ROI. A value was 
allocated to each pixel within the ROI depending on the greyness intensity. 
The scale of the greyness intensity ranged from 0 (white) to 255 (black). A 
mean and standard deviation of [^H] (R) PK11195 binding (in fmol/mg of 
tissue) for each ROI were generated. Background levels were subtracted 
from the all the tissue binding potential means prior to statistical analysis. 
2.3.5. Flow Cytometry 
Following surgery (CCI model), serial peripheral blood samples (200 pi 
approximately) were collected from each animal from the rat-tail vein directly 
into K+EDTA plastic Vacutainer tubes after each time point. Tubes were 
inverted 8-10 times to allow thorough mixing of the blood with the 
anticoagulant, dried sprayed on the interior surface of the plastic tube and 
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stored at room temperature (20 to 25°C) till further use. For optimal results, 
the minimum time elapsed as practically possible was strived for between 
blood collection and analysis. The preparation for flow cytometric analysis 
(FACS - fluorescent activated cell sorter) consisted of first transferring SOpI 
of whole blood into a Falcon test tube. Then, 20pl of antibody labelling 
solution was added to each tub. Tubes were vortexed and incubated at 
room temperature for 30 min in the dark. Next, cells were lysed and fixed 
with 0.45ml of FACS Lysing Solution (diluted at 1:10 with deionised water) 
added to each tube (Appendix 4). The FACS Lysing Solution lyses 
erythrocytes under gentle hypotonic conditions while preserving leukocytes. 
Tubes were again vortexed and incubated at room temperature for 30 min in 
the dark. Each tube was thereafter placed onto a four-colour FACSCalibur 
flow cytometer for analysis. Quantification of cells was carried out using 
CellQuest software (Becton Dickinson Immunocytometry Systems). Cells 
were gated using forward- and side-light scattering properties and CD3, 
CD4, CDS and CD45 expression to exclude dead cells and debris. The 
following haematogenous immune cells were isolated: cytotoxic T cells (CD4" 
CD3'"CD8^), T helper cells (CD3'^ CD4+CD8-), neutrophils (CD3-CD4"CD8" 
CD45'), B cells-type like cells (CD3'CD8'^CD45'^), monocytes (CD3"CD8" 
CD4^) and natural killer cells (CD3"CD8''CD4'). 
The following antibodies were used to form a cocktail (antibody labelling 
solution): Allophycocyanin (APC)-conjugated mouse anti-rat CD3 monoclonal 
antibody (Clone 1F4; BD Biosciences Pharmingen, Oxford, UK), Peridinin 
Chlorophyll-a Protein (PerCP)-conjugated mouse anti-rat CD8a monoclonal 
antibody (Clone OX-8, BD Biosciences Pharmingen, Oxford, UK), R-
Phycoerythrin (R-PE)-labelled mouse anti-rat CD4 monoclonal antibody 
(Clone OX-38, BD Biosciences Pharmingen, Oxford, UK) and Fluorescein 
Isothiocyanate (FITC)-conjugated mouse anti-rat CD45RA monoclonal 
antibody (Clone OX-33, BD Biosciences Pharmingen, Oxford, UK). Each 
antibody was diluted at 1:20 with PBS. 
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2.4. Secimen number 
The precise number of tissue specimens (human or rat) will be specified at 
the beginning of each invidual chapter in a subsection called 'Materials'. On 
occasions, not all tissue specimens used in a particular study, especially with 
immunohlstochemical staining methods, reached adequate staining quality 
for quantification analysis purposes. Furthermore, on occasions, not all 
tissue specimens initially reported were always necessary or systematically 
used within a chapter for a particular quantification analysis to reach 
appropriate statistitical significance level. Consequently, at times the number 
of specimens used will be specified in the text or in individual figures when 
different in the quantification analysis from the initial n numbers specified at 
the beginning of the chapter. 
2.5. Statistical analysis 
Descriptive statistics were generated using Microsoft Excel 2000 for 
Windows (Microsoft, Redmond, WA, USA) and GraphPad Prism version 3.00 
for Windows (GraphPad Software, San Diego California, USA). Group 
differences were assessed using a nonparametric test, the Mann-Whitney U 
test (one-tailed), in GraphPad Prism. Correlations were assessed using the 
Pearson's product moment coefficient (parametric test, 2-tailed) in GraphPad 
Prism. Statistical significance was considered when p < 0.05. 
(See Appendix 5 for a list of materials and equipment used in this section) 
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CHAPTER 
Cyclooxygenase-2 (Cox-2) in injured human nerves 
and a rat model of nerve injury 
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3.1. Introduction 
We hypothesize that nerve injury in humans and animal models is associated 
with increased levels of Cox-2 at the site of injury, expressed in non-neuronal 
cells, and that these peripheral changes drive further neuro-inflammatory 
processes in the CNS. These central changes in turn contribute to the 
maintenance of hypersensitivity and chronic neuropathic pain. Activation of 
immune-like glial cells such as astrocytes or microglia has been reported in 
numerous conditions, and may contribute to hyperalgesia, mechanical 
allodynia or chronic inflammatory pain in animal models. Glial activation 
(Figure 01.06) can be induced by substances released from neurones such 
as prostaglandins (PGs), nitric oxide, fractalkine, substance P, excitatory 
amino acids and ATP released from the primary afferents (Watkins et al., 
2001). Glial activation has also been reported following neuronal cell death 
in peripheral sensory nerves and neurodegeneration in the CNS (Watkins 
and Maier, 2002). Glial activation, in turn, leads to the release of numerous 
inflammatory agents such as cytokines, growth factors, kinins, purines and 
amines (Scholz and Woolf, 2002). 
Inflammatory agents have been shown to activate and/or enhance the 
sensitivity of primary afferents and spinal cord neurons (Reeh, 1994, Shu 
and Mendell, 1999, Woolf and Costigan, 1999, Watkins and Maier, 2000). 
Synaptic transmission increase is sustained by transcriptional changes within 
the neurone, resulting in induction of genes such as of Cox-2, which leads to 
PGEz production. The inflammatory agents alter neuronal excitability by 
facilitating pre- and post-synaptic signalling of excitatory neurones, and by 
reducing inhibitory transmission (Yamagata et al., 1993, Kaufmann et al., 
1996, Woolf and Salter, 2000, Scholz and Woolf, 2002). PGs, such as PGE2 
and PGFzo, can also increase the permeability of peripheral microvessels 
and have been linked to alterations in the blood-brain barrier integrity in CNS 
inflammation (Jaworowicz et al., 1998). PGs are known for their involvement 
in the maintenance of the integrity of gastric mucosa and regulation of renal 
blood flow (Smith et al., 2000) often disrupted with current non-steroidal anti-
inflammatory drugs. 
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Tissue damage induces an inflammatory response including production of 
PGs. This paradigm has been developed extensively developed in the first 
chapter. The evidence that prostanoids could sensitise the peripheral nerve 
terminals (Yaksh et al., 2001) has triggered new research in the Cox 
enzymes involved in the biosynthesis of PGs to develop inhibitors (Coxibs) of 
potential therapeutic value. While their role in inflammatory pain is well 
established, a role in clinical neuropathic pain remains uncertain. Currently 
prescribed Cox-1 and Cox-2 inhibitors do not affect animal model or clinical 
neuropathic pain. Further understanding of Cox-2 in chronic pain related 
processes Is therefore necessary, particularly in view of imminent clinical 
trials with a novel Cox-2 inhibitor (GSK) for neuropathic pain, which has 
efficacy when given orally in animal models of neuropathic pain. The 
mechanism of action remains to be determined as yet. However, it is 
speculated that this compound might possibly possess unique CNS 
properties, dissociating it from other existing Cox-2 inhibitors. 
The aim of this study was to investigate further neuronal-inflammatory 
interactions in injured human nerves, and in the chronic constriction nerve 
injury animal model. Cox-2-IR was studied in comparison with a marker for 
microglia/macrophage-like cells (CD68 for humans, 0X42 in rats), and [^H] 
(R) PK11195 for activated microglia/macrophage-like cells. Microglia have 
been identified in an active state by their de novo expression of the 
peripheral benzodiazepine receptor. The ligand isoquinoline carboxamide 
derivative PK11195 was found to be have high affinity to PGR (Banati et al., 
1997, Vowinckel et al., 1997, Banati et al., 2000b). 
3.2. Materials 
3.2.1. Human tissue 
Injured brachial plexus nerve specimens (proximal and distal to the site of 
injury) and control tissue were used in the present study. Samples were 
subdivided into three groups, acute, short-term chronic and long-term chronic 
96 
according to the delay between the date of injury and the tissue collection at 
surgery (Table 03.01). The mean pain scores on a visual analogue scale 
(VAS) were all > 4 out of 10 at the time of surgery, and patients reported this 
or a higher level of pain usually continuously since the time of injury. 
Table 03.01. Patients' characteristics. 
Group injury Duration N Gender Age Range 
Control 13 7 males & 6 females 39-77 years 
Acute 
(< 21 days) 1 . 5 - 1 4 days 6 6 males 20-66 years 
Short-term Chronic 
(>21 days & < 3 months) 28 - 70 days 4 2 males & 2 females 26-66 years 
Long-term Chronic 
(> 3 months) 112-730 days 6 4 males & 2 females 24-35 years 
3.2.2. Rat tissue 
A total of 9 adult male Sprague-Dawley rats (200-250 g) were used in this 
study of which 5 were CCI animals and 4 were controls (sham-operated) 
animals. Left and right sciatic nerve and lumbar spinal cords were collected 
40 days post-operation. 
3.3. Results 
3.3.1. Chronic Constriction Injury (CCI) induced neuropathic 
hypersensitivity 
Unilateral constriction injury to the sciatic nerve resulted in a chronic 
hyperalgesic phenotype. This was manifested as a reduction in paw 
withdrawal threshold ipsilateral to the nerve injury, which was evident at 11 
days, maximal at 20 days and maintained until 40 days post-operation (CCI, 
74.29 ± 5.71 g: n = 7, sham 104.00 ± 7.31 g; n = 5). Following behavioural 
testing on day 40, animals were humanely sacrificed and tissues prepared 
for immunocytochemistry. Sham operation had no significant effect on paw 
withdrawal threshold compared to basal levels. 
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3.3.2. Immunocytochemistry and autoradiography 
3.3.2.1. Human nerves 
Control, uninjured human nerves showed few, scattered 
microglia/macrophage-like, Cox-2 immunoreactive cells throughout (Figure 
03.01 .A - arrowheads). Similar, but more abundant cells were observed in 
both proximal and distal nerve after chronic injury (Figure 03.01.B and 
03.01 .C). Immunostaining for macrophage marker (CD68) showed cells with 
similar morphology and distribution to Cox-2 in controls (Figure 03.01.D), 
with an increase in injured nerves (Figure 03.01.E and 03.01.F). 
Magnification showed, for both immunostaining, typical macrophage 
morphology - foamy fatty vacuole-like structures in the cytoplasm (Figure 
03.01.Cand 03.01.F). 
Co-localisation of Cox-2 and macrophage marker CD68 was shown on one 
human brachial plexus nerve tissue sample (Male, 26 year old, 8 weeks 
injury duration) using a double immunohistochemical technique. This 
particular section showed that most macrophages (in black) were expressing 
Cox-2 (in red, Figure 03.02). 
Image analysis showed a significant increase of Cox-2 immunoreactivity 
(Cox-2-IR; in % area) in short-term (ST) chronic injured proximal human 
nerves (p = 0.0014), in ST chronic injured distal human nerves (p = 0.0028), 
and in long-term (LT) chronic proximal human nerves (p = 0.006) compared 
to the control group. Cox-2-1R in LT chronic distal nerves was not 
significantly different from controls. Cox-2-IR in acute proximal and distal 
nerves was significantly lower statistically (p = 0.0002 two-tailed for proximal 
nerve and p = 0.0418 two-tailed for distal nerve) than in the control nerves 
(Table 03.02 and Figure 03.03.A), but of similar magnitude. 
A time course analysis of injury duration versus Cox-2-1R (% area) showed a 
peak of immunoreactivity at 28-49 days in both proximal and distal nerve 
segments (Figure 03.04.A). A peak at a similar time point was found with 
[^H] (R) PK11195 autoradiography (Figure 03.04.B). 
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Figure 03.01. Cox-2 and CD68 immunoreactivity in human uninjured and 
injured nerves. Uninjured human nerve (control) showed fewer 
microglia/macrophage-like, Cox-2-immunoreactive cells (arrowheads in 
panel A) than proximal chronic injured nerve (B and C). Immunostaining for 
macrophage marker (CD68) showed cells with similar distribution to Cox-2 in 
control (D) and a similar increase in injured nerve (E and F). Magnification 
x110 (A, B, D and E) and x400 (C and F). 
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Figure 03.02. Cox-2 and CD68 co-localisation. Double immunostaining with 
Cox-2 (in red) and with macrophage marker CD68 (in black) and showed that 
most Cox-2-IR cells were of macrophage type. Magnification x400. 
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Binding levels of [^H] (R) PK11195 were significantly higher in ST chronic 
proximal nerves (p = 0.003) and in ST chronic distal nerves (p = 0.0121) 
compared to controls (22.62), but also in acute proximal nerves (p = 0.0175) 
and in acute distal nerves (p = 0.0041) compared to controls (Table 03.02 
and Figure 03.03.B). 
Table 03.02. Cox-2-IR (in % area) and flH] (R) PK11195 binding (Mean ± 
SEM and range) in human nerves. 
Controls 
(n = 9) 
Acute (n = 7) ST Chronic (n = 4) LT Chronic (n = 6) 
Proximal Distal Proximal Distal Proximal Distal 
Cox-2-IR 
(% area) 
0.36 
(0.05) 
0.2-0.6 
0.08 
(0.01) 
0.02-0.14 
0.17 
(0.1) 
0.03-0.74 
2.4 
(0.49) 
1.38-3.56 
1.24 
00.36) 
0.58-2.28 
0.83 
(0.13) 
0.22-1.08 
0.58 
(0.23) 
0.13-1.7 
['H] (R) 
PK11195 
(in fmol/mg) 
22.62 
(1.55) 
16.8-28.3 
31.73 
(3.13) 
23.3-42.7 
33.44 
(2.51) 
22.7-39.1 
58.36 
(6.84) 
46.6-73.61 
41.39 
(6.9) 
26.15-59.5 
28.59 
(4^) 
13-42.45 
27.45 
(3 47) 
12.8-36.8 
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Figure 03.03. Cox-2 immunoreactivity and [^IH] (R) PK11195 binding (Mean 
± SEM) in human uninjured and injured nerves [Control versus Acute (< 
21days), versus ST Chronic (21days to 3 months), and versus LT Chronic (> 
3months); ST = Short-Term and LT = Long-Term]. Cox-2-IR (A) was 
significantly increased in ST chronic proximal and distal nerves (p <0.01) 
and in LT chronic proximal nerves (p < 0.01). Lower levels of Cox-2-IR were 
found in the proximal (p < 0.01) and distal (p < 0.05) nerves from the acute 
group compared to the control group. ** p < 0.01, * p < 0.05. In B, ST 
chronic proximal and distal injured nerves showed significantly showing 
higher levels of [^H] (R) PK11195 binding than controls (p <0.01 and p < 
0.02, respectively). Acute proximal and distal injured nerves also showed 
increased levels of[^H] (R) PK11195 binding than controls, but less than 
seen in the ST chronic nerves (1,5 fold; p < 0.02 and p < 0.01 respectively). 
No significant difference was found in LT chronic injured nen/es compared to 
control nerves. ** p < 0.01, * p < 0.02. 
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Table 03.03. Cox-2 positive cells per 50 pm (l\/fean ± SEI\/1) in human 
nerves. 
Controls 
(n = 9) 
Acute (n = 7) ST Chronic (n = 4) LT Chronic (n = 6) 
Proximal Distal Proximal Distal Proximal Distal 
Mean Cox-2 + 
cells per 50 |jm^ 
14.55 
(1.71) 
10.27 
(4.45) 
10.13 
(6.15) 
77.55 
C5.97) 
62.80 
(11.33) 
38.20 
(8.17) 
26.53 
03.58) 
ST = Short-term, LT= Long-term 
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Figure 03.04. Cox-2 immunoreactivity and fl-i] (R) PK11195 binding time 
course. A peal< of Cox-2-IR occurs between 28-49 days was observed (A) 
while the [ H] (R) PK11195 binding time course (B) showed a similar peal< as 
for Cox-2. Whether Cox-2 and PK11195 binding correlated with pain 
behaviour was not possible to establish as sensory testing was not 
performed but should be included in a future study. 
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Using a different quantification method, cells were counted on the same 
tissue samples. Only minor differences were observed compared to the 
image analysis. Chronic injured nerves showed similar pattern as previously 
reported with the image analysis. However, no significant difference was 
observed for the acute nerves compared to controls (Table 03.03 and Figure 
03.05). The time course revealed an increase in Cox-2 positive cells from 14 
days with a peak at 28 days (Figure 03.06). 
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Figure 03.05. Cox-2 positive cells (Mean ± SEM) in human uninjured and 
injured nerves. [Control versus Acute (< 21 days), versus ST Chronic 
(21days to 3 months), and versus LT Chronic (> 3months); ST = Short-Term 
and LT= Long-Term]. The mean number of Cox-2 positive cells was 
significantly increased in ST chronic proximal and distal nerves (p < 0.002) 
and in LT chronic proximal nerves (p < 0.01). No significant difference was 
found in the proximal and distal nerves from the acute group compared to the 
control group. ** p < 0.002, * p < 0.01. 
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Figure 03.06. Cox-2 positive cells time course. The time course showed that 
Cox-2 positive cells appear to increase from 14 days post injury and peak 
from 28 days. 
3.3.2.2. CCl rat model 
In rat nerve, Cox-2-1R was found in cells similar to those seen in human 
nerve. In controls (sham operated nerve), only a few scattered cells were 
seen within the nerve fascicles (Figure 03.07.A). In all CCl injured rats 
nerves, these cells were numerous proximal to the injury site (Figures 
03.07.B and 03.07.C), and relatively fewer distally. Contralateral, uninjured 
nerves showed a similar immunostaining pattern to sham operated rats. 
Antibodies to the rat macrophage/activated microglia marker (CD11b-OX42) 
gave results similar to Cox-2 with few cells in control nerves (Figure 
03.07.D), and an abundance of cells proximal to the injury site (Figures 
03.07.E and 03.07.F). Left and right nerves from sham operated rats 
showed no difference, both having a normal appearance and few 
immunoreactive cells for Cox-2 or macrophage/activated microglia marker 
(CD11b-OX42). 
Quantification of Cox-2-immunoreactive cells in CCl rats showed a significant 
(p = 0.0079) increase of immunoreactivity in the lesioned nerves (3.73 ± 
0.79; range = 1.48-5.87) compared to sham operated nerves (0.23 ± 0.078; 
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range = 0.13-0.46). The difference between lesioned and contralateral 
nerves in CCI rats was also significant (p = 0.004; Figure 03.09.A). 
Quantification of macrophages (CD11 b-OX42) in rat nerves gave very similar 
results to those obtained with Cox-2 (data not shown). Furthermore, binding 
levels of [^H] (R) PK11195 were significantly higher in the lesioned rat nerve 
(p = 0.0006; 67.83 ± 3.58; range = 56.76-80.01; NF Map) compared to the 
left nerve from sham-operated rats (19.28 ± 3.06; range = 7.58-30.89; Figure 
03.10). 
In rat spinal cord, small, microglial-like, Cox-2-immunoreactive cells, some 
with fine processes, were scattered throughout the grey matter and the white 
matter (Figure 03.08.A). These cells tended to be more prevalent in the grey 
matter and appeared more numerous in CCI rats (Figures 03.08.B and 
03.08.C). In control, sham operated rats, antibodies to the 
macrophage/activated microglia marker (CD11b-OX42) also showed small, 
scattered cells usually with several processes and of similar morphology to 
Cox-2-immunoreactive cells (Figure 03.08.D). These cells appeared to 
increase in number and intensity in the spinal cord on the side of the nerve 
lesion (Figures 03.08.E and 03.08.F). 
Quantification of Cox-2-IR was significantly increased (p = 0.0079) in the 
lesioned side of the spinal cord (0.45 ± 0.05; range = 0.29-0.57) compared to 
sham operated controls (0.22 ± 0.025; range = 0.16-0.28; Figure 03.09.B). 
Similarly, macrophage/activated microglia cells (CD11b-OX42) were 
increased (data not shown). 
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Figure 03.07. Cox-2 and CD11b/OX42 imnnunoreactivity in sham operated 
and CCI rat nerve. Sham operated nerve (control) showed fewer 
microglia/macrophage-like, Cox-2-immunoreactive cells (arrowheads in 
panel A) than CCI nerve (B and C). Immunostaining for macrophage marker 
(CD11b/OX42) showed cells with similar distribution to Cox-2 in control 
(arrowheads in panel D) and a similar increase in CCI nerve (E and F). 
Magnification x110 (A, B, D) and E and x400 (C and F). G, H and I 
respectively show consecutive sections of the same lesioned CCI rat nerve 
with radioligand fH] (R) PK11195- microglia/macrophage marker (G), 
neurofilament immunostaining (H) and 0X42 immunostaining (I). 
Magnification xlO. Cox-2 immunoreactive endothelial cells (arrowhead in 
panel J) in close vicinity to nerve tissue and microglia/macrophage-like cells 
in lesioned CCI rat nerve. Magnification xlQ. 
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Figure 03.08. Cox-2 and CD11b/OX42 immunoreactivity in CCI spinal cord 
(grey matter). Contralateral grey matter showed fewer 
microglia/macrophage-like Cox-2 immunoreactive cells (A) than lesioned 
grey matter in CCI spinal cord (B and C). Immunostaining for macrophage 
marker (CD11b/OX42) showed cells with similar distribution to Cox-2 in the 
contralateral grey matter (D), and a similar increase in CCI lesioned grey 
matter (E and F). Magnification x110 (A, B, D and E), x400 (C and F). 
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Binding levels of [^H] (R) PK11195 were significantly higher in the lesioned 
spinal cord laminae l-ll in the CCI group (p = 0.0129; 67.33 ± 5.79; 47.86-
82.19) compared to the control group (35.42 ± 5.73; range = 26.71-51.86), 
with a significant difference between lesioned and contralateral laminae l-ll 
within the CCI group (p = 0.001; 43.22 ± 6.38; range = 25.07-55.54; Figure 
03.11). The increase between the two groups was nearly two-fold compared 
to normal control grey matter (35.46 ± 4.78). Although not statistically 
significant (p = 0.059), a moderate unilateral increase of [^H] (R) PK11195 
binding above normal grey matter values was noted in Lamina IX of the 
injured group. No significant difference in [^H] (R) PK11195 binding was 
found in the grey matter or central canal compared to controls. 
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Figure 03.09. Cox-2 immunoreactivity (Mean ± SEM) in rat nerve and spinal 
cord. A. Significant increase (p <0.01) in lesioned CCI nerve compared to 
sham operated nerve. B. Grey matter on the side of the nerve lesion 
showed a significant increase (p < 0.01) of Cox-2-IR compared to sham 
operated controls. * p < 0.01. 
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Figure 03.10. fH] (R) PK11195 binding (Mean ± SEM) in sham operated 
and CCI rat nerve. fH] (R) PK11195 binding levels in the nerve were 
generated according to two regions of interest (ROI) outlined on the lesioned 
CCI nerve sections, one according the neurofilament (NF) immunostaining 
(Figure 03.07.H) and referred to as NF map i.e. region of nen/e tissue, and 
the second, according to CD11b/OX42 immunostaining (0X42 map), 
including the whole sample section with nerve and ligation site (p < 0.01; 
Figure 03.07.1). *p>0.01. 
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Figure 03.11. fH] (R) PK11195 binding (Mean ± SEM) in sham operated 
and CCI spinal. Significantly increased levels of[^H] (R) PK11195 binding (p 
< 0.02) were found in laminae l-ll of the CCI spinal cord (nearly 2-fold) on the 
lesioned side compared to the sham operated group (* p < 0.02). [Regions 
of Interest (ROI) outlined in the rat spinal cord 1-2: Laminae l-ll (left and right 
respectively); 3-4: Lamina IX (left and right respectively); 5-6: Laminae lll-VIII 
(left and right respectively); 7: Central Canal; 8: White Matter]. * p < 0.02. 
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5 
Human Nerve Rat Nerve Rat Spinal Cord 
Figure 03.12. [^H] (R) PK11195 autoradiography. A. Control human nerve; 
B. Injured human nerve- 24 days; C. Contralateral CCI rat nerve; D. Sham 
operated left rat nerve; E. CCI lesioned rat nerve; F. Sham operated rat 
spinal cord and G. CCI rat spinal cord. Magnification x10 (A, B, C, D, E) and 
x20 (F and G). 
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3.4. Discussion 
Previous studies have demonstrated that prostanoids sensitise peripheral 
nerve terminals, but are also produced and released in the spinal cord 
following peripheral nerve injury, establishing both PNS and CNS links 
between prostaglandin production and hypersensitivity (Ding and Yaksh, 
1999, Yaksh et al., 2001). Intrathecal administration of NSAIDs and EP1 
receptor antagonists reduce the response to formalin-induced inflammation 
(Malmberg and Yaksh, 1992a, Malmberg et al., 1994). One study has shown 
considerable reduction of mechanical hypersensitivity following intrathecal 
administration of Cox-1 and Cox-2 inhibitors in a model of peripheral nerve 
injury (Ma et al., 2002), but the treatment of neuropathic pain following 
peripheral nerve injury in humans with NSAIDs is generally regarded as 
ineffective, although few systematic clinical trials have been undertaken. 
We have studied the expression of Cox-2 in injured human nerves, and in 
the chronic CCI rat model. In the present study, significantly increased Cox-
2 immunoreactive macrophages were observed in injured human nerves in 
the 28-70 day period after injury, with a peak at around 40 days. Allodynia 
was studied in these patients at the time of surgery as mentioned on page 
81. Moreover, in the CCI rat model, at 40 days post-ligation, increased Cox-
2-1R was demonstrated in the injured nerve and in microglia of ipsilateral 
spinal cord grey matter. Microglial activation was also demonstrated using 
the radioligand [^H] (R) PK11195 in the injured nerve and ipsilateral dorsal 
horn (Lamina l-ll) of the spinal cord of the CCI rats (Figure 03.12). However, 
Cox-2-IR was decreased while PK11195 binding and immunostaining for 
macrophage marker (CD68) was increased in injured human nerves acutely; 
one explanation is that macrophages invading injured nerves increase 
expression of Cox-2 after a delay, and that their expression of Cox-2 is 
induced by factors in the milieu of the injured nerve. Another contributory 
factor could be nerve oedema, since the image analysis recorded % area of 
immunoreactivity. The macrophage marker (CD68) immunostaining on the 
human tissue samples and macrophage/activated microglia marker (CDIIb-
OX42) on the rat tissue samples showed similar cellular distribution pattern 
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to Cox-2 immunostaining in both human and rat chronic tissues, i.e., 
abundance of cells proximal to the injury site in the nerves and increased 
prevalence in the ipsilateral grey matter of the spinal cord in rats. This 
parallel change would suggest an Infiltration of microglla/macrophage-like 
cells at the site of injury, and an increase of proinflammatory prostaglandin 
release via the up-regulation of the Cox-2 enzyme. Ideally a co-localisation 
immunostaining (Cox-2/CD68) study should have been conducted to 
evaluate the number of Cox-2/CD68 positive cells, the number of Cox-2 only 
positive cells and the number of CD68 only positive cells. One of the 
requirement of the APPAP technique, is that one antibody is raised in mouse 
and the other in rabbit. Both markers Cox-2 and CD68 (EBM11) were raised 
in mouse. Commercially available Cox-2 antibody raised in rabbit or a 
macrophage marker raised in rabbit were not available. There is always a 
potential for cross-reactivity interference when antibodies have been raised 
in the same species (Matsumura et al., 1998), and the specificity of the 
results cannot be guaranteed. Consequently, co-localisation of Cox-2 and 
CD68 immunoreactivity was conducted on serial sections with recognized 
markers and immunoreactivity was compared. In this study we have used 
the same macrophage marker (CD68 EBM11) as described in our earlier 
publication (Banati et al., 2000b), where it was co-localised with markers of 
microglia/macrophage activation. We have also recently co-localised Cox-2 
with Ferritin (a microglial marker) in human spinal cord (Yiangou et al., 
2006). When a macrophage marker (CD68) raised in rabbit became 
available, co-localisation of CD68 and Cox-2 using the APAAP technique 
was demonstrated in one human injured nerve tissue sample. Most cells 
were double immunostained with Cox-2 and CD68 consolidating our first 
results i.e. Cox-2 was mainly expressed in macrophages. It is well 
established in the literature that activated macrophages commonly express 
Cox-2 (Luo et al., 2002). Cox-2 has also been shown to be further activated 
via autocrine and paracrine pathways (Dubois et al., 1998, Stack and 
DuBois, 2001, Cao and Prescott, 2002), subsequently attracting further 
microglia/macrophage-like cells at the site of injury, and hence potentially 
exaggerated pain states. 
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Previous reports have shown that Cox-2 immunoreactivity in normal rats can 
be localised to neurons of laminae 11-111, motoneurones of lamina IX and glial 
cells (Goppelt-Struebe and Beiche, 1997, Beiche et al., 1998b). We could 
not detect neuronal associated immunoreactivity in any of the spinal cord 
specimens studied with our antibody and methods, including the control 
spinal cords, in which only a few microglial cells with few processes were 
Cox-2-immunoreactive. In rats, induction of Cox-2 mRNA expression in the 
spinal cord has been demonstrated after intraspinal injections of IL-1a (Tonal 
et al., 1999) or after mechanical injury to the spinal cord (Resnick et al., 
1998): Cox-2 immunoreactivity was found in vascular endothelial cells and 
glial cells after IL-1a challenges (Tonal et al., 1999). Recently, Cox-2 mRNA 
was shown to be up-regulated in ALS spinal cord (Aimer et al., 2001, 
Yasojima et al., 2001). Cox-2 inhibitors have been shown to have a 
therapeutic role in a transgenic mouse model of ALS (PompI et al., 2003). 
These authors showed that prophylactic administration of the preferential 
Cox-2 inhibitor, nimesulide, in the feed resulted in a significant delay in the 
onset of ALS type motor impairment. 
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CHAPTER IV 
Prostaglandin receptor EP1 and Cox-2 in injured 
human nerves and a rat model of nerve injury: a time-
course study 
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4.1. Introduction 
The contribution of prostanoids such as PGE2 or PGE2a in inflammatory 
processes (Bley et al., 1998) and in pain modulation has well been defined 
(Narumiya et al., 1999, Narumiya and FitzGerald, 2001) and reviewed 
(Samad et al., 2002). PGE2 signals via a transmembrane G-protein coupled 
receptor (EP), of which four types (EP1-4) have been identified (Coleman et 
al., 1994). EP1 receptor involvement in pain mechanisms has been 
described in animal studies (Stock et al., 2001, Kobayashi and Narumiya, 
2002). EP receptor antagonists have provided evidence of a role for EP 
receptors in reducing hyperalgesia and allodynia in rodents (Kawahara et al., 
2001). A recent study demonstrated that PGE2, via the prostaglandin 
receptor EP1, contributed to human visceral pain hypersensitivity (Sarkar et 
al., 2003). The emerging general consensus of animal and human studies 
identifies the EP1 receptor as a selective target of therapeutic value, of 
similar analgesic effect as NSAIDs, but with fewer potential side effects 
(Stock et al., 2001). 
The aim of this study was to investigate the time-course of key neuronal-
inflammatory interactions in injured human nerves and ORG, and in the CCI 
rat model. Microglia/macrophage-like cells, EP1 receptor and Cox-2 levels 
were studied, using immunocytochemistry and Western blotting. This study 
will complement the findings from the previous study (Chapter III) by looking 
at microglia/macrophage-like cells and Cox-2 expression over a longer 
period of time after injury in humans and in the CCI model by looking at 
earlier time points as the one previously investigated. 
4.2. Materials 
4.2.1. Human tissue 
In the present study, injured brachial plexus nerve specimens (proximal and 
distal to the site of injury) were subdivided into two groups, acute and chronic 
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according to the delay between the date of injury and the tissue collection at 
surgery. Painful human distal limb neuromas formed a separate group with 
an injury duration much longer than the injured brachial plexus nerve 
specimens. Avulsed DRG specimens were also subdivided into two groups 
in a similar fashion as the injured brachial plexus nerves (Table 04.01). 
4.2.2. Rat tissue 
A total of 32 adult male Sprague-Dawley rats (200-250 g) were used in this 
study of which 16 were CCI animals and 16 were controls (sham-operated) 
animals. To study glial activation and Cox-2 expression, animals were 
sacrificed on days 4, 21, and 30 (n = 4 in each experimental group and for 
each time point) and tissues harvested. Left and right sciatic nerve (nerve 
tissue from 4 days post-operation only was available for this study), and 
lumbar spinal cord were collected. 
Table 04.01. Patients' characteristics. 
Nerve Injury Duration N Gender Age Range 
Control 9 5 males & 4 females 39-77 years 
BP Acute 
(< 21 days) 4 to 14 days 5 5 males 20-66 years 
BP Chronic 
(> 21 days) 28 to 196 days 6 4 males & 2 females 24-35 years 
Neuroma 9 days to 12 years 12 9 males & 3 females 26-63 years 
DRG Injury Duration N Gender Age Range 
Control 7 2 males & 5 females 34-88 years 
Acute 
(< 21 days) 2 to 15 days 5 5 males 18-39 years 
Chronic 
(> 21 days) 28 to 120 days 6 5 males & 1 females 21-39 years 
BP = Brachial Plexus 
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Figure 04.01. EP1 immunoreactivity in human injured brachial plexus nen/es 
and avulsed DRG. EP1-IR was observed in nerve fibres in control nerves 
(A) and appeared more intense in injured nerves (B). EP1-IR was detected 
mainly in small/medium diameter neurones of control (C) and injured human 
DRG (D). Magnification x110. 
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4.3. Results 
4.3.1. Human brachial plexus nerve and DRG 
Both EP1 antibodies showed immunoreactivity in nerve fibres (Figure 
04.01 .A), which appeared more intense in acute injured nerves (Figure 
04.01 .B). The results of image analysis are given below. In human DRG, 
EP1 immunoreactivity (EP1-IR) was detected in small/medium diameter 
neurones of control (Figure 04.01 .C) and injured human DRG (Figure 
04.01 .D). A significant increase of intensity was observed using the visual 
inspection scale in DRG sensory neurones after injury in the acute group 
(surgery delay < 21 days; 3.5 ± 0.34) compared to control DRG (2.57 ± 0.20, 
p = 0.02). Chronic injured DRG were not significantly different (2.83 ± 0.17, 
Figure 04.02). 
Control Acute Chronic 
Figure 04.02. EP1-IR intensity of sensory neurones (Median) in uninjured 
and avulsed DRG. EP1 intensity in small/medium DRG neurones was 
significantly (p < 0.02) increased in the acute group. * p < 0.02. 
EP1 peptide antigen from Cayman Chemicals was used at 10^ to 10"® mg/ml 
and pre-incubated with anti-EPI (Cayman) at 1/1000 on a control DRG. The 
control DRG showed reduced staining at high (10"^  -10"^ mg/ml) 
concentrations of peptide antigen, compared to sections stained in the 
presence of antibody alone. 
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EP1 and NF-immunoreactive nerve fibres were quantified by image analysis 
(% immunopositive area) in control and injured nerves and expressed as the 
ratio EP1 :NF (Figure 04.03). EP1-IR:NF-IR ratio was significantly higher in 
injured acute proximal (0.17 ± 0.05; n = 5; p < 0.03) and distal (0.22 ± 0.69; 
n = 5; p < 0.01) and injured chronic proximal (0.19 ± 0.06; n = 6; p < 0.01) 
and distal (0.33 ± 0.18; n = 6; p < 0.01) nerves compared to controls (0.03 ± 
0.01; n = 5). 
A time course analysis of EP1-iR:NF-IR ratio and Cox-2-IR in human 
brachial plexus nerves showed that EP1 expression preceded Cox-2-IR 
increased levels (Figure 04.04). Similar results were found with both EP1 
markers. 
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Figure 04.03. EP1-IR:NF-IR ratio (Mean ± SEM) in human proximal and 
distal injured nerves. Significant increases of EP1-IR:NF-IR ratios were 
observed in human nerves proximal and distal to injury when compared to 
uninjured nerves. **p <0.01, * p < 0.03. 
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Figure 04.04. EP1-IR:NF-IR ratio and Cox-2-IR in proximal brachial plexus 
injured nerves - time course. The time course of EP1-IR:NF-IR ratio and 
Cox-2-IR showed that EP1 preceded Cox-2-IR increased levels. 
A 70 kDa Cox-2 band was observed in mouse macrophage control and 
human nerve extracts, which was clearly more prominent in the acute nerves 
(Figure 04.05). The optical density of the Cox-2 70kDa band was 
significantly increased (p = 0.02) in the acute group (1.41 ± 0.04, n = 3) 
compared to control nerves (0.55 ± 0.09, n = 4). No statistical significant 
difference was detected for the chronic group (0.61 ± 0.09, n = 5). 
Figure 04.05. Cox-2 70-kDa band by Western blots. Cox-2 70-kDa band in 
control nen/e (A), acute injured nerve (B) and chronic injured nerve (C). The 
Cox-2 70 kDa band was clearly more prominent in the acute nerves. 
Magnification x20. 
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4.3.2. Human painful neuromas 
Few, scattered microglia/macrophage-like Cox-2 immunoreactive cells were 
found throughout the uninjured human nerve tissue (Figure 04.06.A). Similar 
cells, but with more abundance were observed in the painful neuromas 
(Figure 04.06.B). Immunostaining for CD68 showed cells with similar 
morphology and distribution to Cox-2 in controls (Figure 04.06.C), with an 
increase in neuromas (Figure 04.06.D). 
Image analysis showed Cox-2-1R (in % area) to be significantly greater in 
human neuromas (0.79 ± 0.14; n = 12; p = 0.0022) than in controls (0.32 ± 
0.04; n = 13; Figure 04.07). A similar increase was found with the 
macrophage marker CD68. CD68 immunoreactivity (CD68-IR) was 
significantly increased in human limb neuromas (8.96 ± 0.99; n = 12; p < 
0.0001) compared to the control group (0.32 ± 0.04; n = 13). 
A time course analysis of injury duration (time elapsed between the injury 
and the removal of the neuroma) demonstrated an immediate increase in 
CD68-IR, which remained above control levels during the entirety of the time 
course (Figure 04.08). Cox-2-IR increases, as previously described, were 
only apparent from 2 to 3 weeks after injury (Durrenberger et al., 2004), and 
persistent for years. 
Few nerve fibres showed some EP1 immunoreactivity but fibres were too 
sparse to show significant statistical difference (Figure 04.09). 
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Figure 04.06. Cox-2 and CD68 immunoreactive cells in uninjured nerves and 
human neuromas. Very few scattered CD68 and Cox-2 immunoreactive 
cells of similar morphology and distribution were found in uninjured human 
nerve tissue (A and C respectively) compared to human neuromas (B and 
D), where similar cells were observed but with greater abundance. 
Magnification x110. 
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Figure 04.07. Cox-2-IR and CD68-IR (Mean ± SEM) in human painful 
neuromas. Cox-2-IR and CD68-IR (in % area) are significantly increased in 
injured nerves compared to control nerves. ** p < 0.0001, * p < 0.002. 
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Figure 04.08. Cox-2-IR and CD68-IR in human neuromas - time course. 
Rapid increase of CD68 immunoreactive cells was observed, whilst Cox-2-IR 
was only apparent from 2 to 3 weeks as previously described and remained 
persistent over many years. 
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Figure 04.09. EP1 immunoreactivity in tiuman painful neuroma. Only few 
fibres were observed, which were insufficient to conduct a statistical analysis. 
Magnification x110. 
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4.3.3. CCI rat model studies 
Unilateral constriction injury to tine sciatic nerve resulted in a reduction in paw 
withdrawal threshold ipsilateral to the nerve injury, usually evident at 9 days 
and maintained until after 30 days post-operation (in these rats, at 30 days 
post-operation: CCI, 88.12 ± 7.04 g; n = 8, sham 127.5 ± 75.13 g; n = 8, 
Figure 04.10). Following behavioural testing on day 04, 21 and 30, the 
animals were humanely sacrificed and tissues prepared for 
immunocytochemistry. Sham operation had no significant effect on paw 
withdrawal threshold compared to basal levels. 
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Figure 04.10. Time course of development of neuropathy (Mean ± SEM). 
Neuropathy was measured in rats using an algesymeter at 4 days (n = 16 for 
each group), at 9, 11 and 21 days (n = 12 for each group) and at 29 days (n 
= 8 for each group). Significant increase (p < 0.001) in withdrawal of the left 
paw was observed in the CCI group compared to the sham-operated group. * 
p > 0.001. 
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Figure 04.11. Cox-2 and 0X42 immunoreactive cells in sham and CCI rat 
nerve. Very few Cox-2 immunoreactive cells (arrowheads) were observed in 
the left sciatic nerve of sham operated rats (A) compared to CCI rats (B). 
Similarly, sham operated nerves (C) showed much less macrophages in the 
sciatic nerve than CCI nerves (D). Magnification x110. 
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In rat nerve, Cox-2-IR and CD68-IR were found in cells similar to those seen 
in human nerve tissue as previously described (Durrenberger et al., 2004). 
Few scattered Cox-2 positive cells were seen within the nerve fascicles in 
sham-operated or control nerves (Figure 04.11 .A). In CCI nerve, these cells 
appeared more numerous proximal to the injury site (Figure 04.11.B), but this 
was not statistically significant at 4 days; in our previous study, we have 
shown a significant increase at 40 days post-surgery (Durrenberger et al., 
2004). Antibodies to the rat macrophage/activated microglia marker (CD11b-
0X42) showed few positively stained cells in sham-operated or control 
nerves (Figure 04.11.C), and an abundance of positively stained cells in day 
4 post CCI-lesioned nerves (Figure 04.11.D). This was confirmed by image 
analysis where CCI-lesioned nerves at 4 days post-operation showed 
significant increase of 0X42-1R (n = 4, 4.58 ± 0.46, p < 0.015) compared to 
sham-operated nerves (n = 4, 0.26 ± 0.02; Figure 04.12). 
IZJSham Operated 
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Figure 04.12. Cox-2-IR and OX42-IR (Mean ± SEM) in sham-operated and 
CCI lesioned rat nerve at 4 days post-operation. At 4 days post-operation, 
0X42-1R was significantly increased in lesioned nen/es (p < 0.02) compared 
to sham-operated nen/es whilst Cox-2-IR was not significantly increased but 
only showed a trend. * p> 0.02. 
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In the spinal cord of sham-operated rats at all time points, small, microglial-
like Cox-2-immunoreactive cells, with some fine processes, were scattered 
throughout the grey matter and the white matter (Figure 04.13.A). These 
cells tended to be less prevalent in the grey matter of CCI rat spinal cords at 
earlier time points (4, 21 and 30 days; Figure 04.13.B). The 
macrophage/activated microglia marker (CD11b-OX42) showed small, 
scattered cells of similar morphology to Cox-2 immunoreactive cells, usually 
with several processes (Figure 04.13.C). These cells appeared to increase 
in number and intensity in the spinal cord on the side of the nerve lesion, 
mainly in the superficial dorsal horn (Laminae l-ll) and the ventral horn 
(Laminae IX, Figure 04.13.D). 
Quantification of Cox-2-IR in the time course showed significantly (p < 0.02) 
lower levels in the lesioned superficial dorsal horn of the spinal cord 
compared to sham-operated at all three time points (Figure 04.14). 
Quantification of 0X42-1R showed increased significant levels of 0X42-1R 
across the time course (p < 0.03) and across the main three areas in the 
lesioned side of the spinal cord - superficial dorsal horn (Figure 04.14), deep 
dorsal horn (data not shown) and ventral horn (data not shown). 
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Figure 04.13. Cox-2 and 0X42 immunoreactive cells in the superficial dorsal 
horn of CCI rat spinal cord (Laminae l-ll). At 4 days post-operation, Cox-2 
immunoreactive cells were more abundant in controls (A) compared to CCI 
(B), whilst few 0X42 immunoreactive cells were seen in the superficial dorsal 
horn of sham-operated spinal cord (C) compared to CCI (D). Magnification 
x110. 
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Figure 04.14. Cox -2-IR and OX42-IR (Mean ± SEM) in dorsal horn of rat 
spinal cord (Laminae l-ll). Cox-2-IR levels were significantly lower in the 
lesioned superficial dorsal horn of the rat spinal cord compared to the sham-
operated spinal cord at 4, 21 and 30 days post operation. 0X42-1R i/vas 
significantly increased in the lesioned superficial dorsal horn of the rat spinal 
cord across the time course. ** p> 0.02, * p> 0.03. 
4.4. Discussion 
Tissue damage generates an inflammatory response resulting in release of 
inflammatory mediators that in turn causes pain and hyperalgesia. 
Macrophages, other immunocompetent cells, as well as increased levels of 
cytokines have been found in injured nerves and DRG (Wagner et al., 1998, 
Durrenberger et al., 2004, Kleinschnitz et al., 2004). Macrophages have 
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been found to be the predominant source of prostanoid release (Bonney et 
al., 1979, Karck et al., 1996). Prostanoids sensitise peripheral nerve 
terminals, and are also produced and released in the spinal cord following 
peripheral nerve injury, establishing both peripheral and CNS links between 
prostaglandin production and hypersensitivity (Dirig and Yaksh, 1999, Yaksh 
et al., 2001). 
In the present study, the time course of microglia/macrophage-like cell 
activation was studied in comparison with Cox-2 levels and EP1 receptor 
levels in human injured nerves and a rodent model of nerve injury. EP1 
receptor levels were reported for the first time in human nerve fibres and 
DRG, and appeared increased in acutely injured tissues. The greater 
increase distally of EP1 was a trend, and not statistically significant, and 
could be the result of increased EP1 in regenerating or spared fibres. The 
EP1 time course when compared to the previously published time course of 
Cox-2 (Durrenberger et al., 2004) showed rapid elevated levels of EP1 
receptor in proximal nerves. The previous paper reported both proximal and 
distal nerve staining, but only proximal nerve stumps were used to compare 
directly with EP1 immunostaining for the same specimens in this study. In 
accord with our previous report (Durrenberger et al., 2004), Cox-2-IR was 
increased from some weeks after injury, whereas CD68-postive 
macrophages were increased more acutely - in this study, we have 
demonstrated, in addition, that the Cox-2-1R increase in macrophages 
persists over many years in injured human neuromas. After injury nerves 
show rapid swelling and oedema formation. Due to this swelling, the % 
positive areas measured might account for the lower levels of Cox-2-1R with 
image analysis compared to controls - when we analysed our nerves by 
counting positive cell numbers per area, no significant change (i.e. no 
decrease) was observed. A 70 kDa Cox-2 band was significantly increased 
in acute injured human nerve extracts, but not chronic, and are apparently 
discrepant with immunohistochemical findings - this may reflect the time-
points at which limited numbers of nerves were available in sufficient 
quantities to enable Western blotting studies, as only those clustering around 
the broad peak of Cox-2 increase ( 2 - 8 weeks) would be expected, and 
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showed, significant increase. The nerve samples extracts that constitute the 
Western blotting "acute" group represented the later stage of the acute 
phase i.e., 10, 15 and 17 days, and the "chronic" group included 3 out of 5 
samples beyond 10 weeks after injury. 
In the CCI rat model, numerous 0X42-1R microglia/macrophage-like cells 
appeared in the injured sciatic nerves, as well as in the superficial dorsal 
horn of the spinal cord in CCI rats, at 4 days post operation. However, while 
there was a trend, Cox-2-IR was not significantly increased in nerves. A 
similar change was also found at 21 days post-operation in CCI nerve tissue 
in recent different set of animals (data not included): a significant increase of 
Cox-2-IR at 40 days post-injury in CCI nerve was reported by us previously 
(Durrenberger et al., 2004). In this study Cox-2 immunoreactivity just failed 
to reach significance at days 4 and 21 in the CCI rats, possibly because the 
increase was not as robust as at day 40 after injury, and/or due to a smaller 
number of animals in the present study. Two cited papers (Ma and 
Eisenach, 2002, Ma and Eisenach, 2003a) showed an upregulation of Cox-2 
in CCI and partial nerve ligation nerves at 2 and 4 weeks after injury, also in 
macrophages, but they counted Cox-2 positive cells per area in one study 
and a comparison between sham and CCI contralateral sciatic nerve was not 
assessed (Ma and Eisenach, 2003a), whereas we image-analysed % area of 
the sections and conducted statistical comparison, which may account for 
the differences in our studies. When we re-analysed our CCI nerves by 
counting positive cell numbers per area, a trend for an increase was 
observed but this still did not achieve statistical significance (data not 
shown). In another study, when Cox-2 positive cells were compared 
between ipsi- and contralateral sciatic nerve (modified Chung model), not all 
time points (i.e. 3 days) reached levels of significance (Takahashi et al., 
2004). 
In the CCI rat spinal cord, a significant increase of 0X42 immunoreactive 
microglia/macrophage-like cells was observed over the entire time course (4-
30 days) in the lesioned side superficial dorsal horn; however, Cox-2-IR was, 
surprisingly, found to be decreased at all these time points. Sufficient tissues 
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were not available for Western blotting of Cox-2 in rat spinal cord, but are 
necessary to substantiate present findings. The underlying mechanisms and 
significance of this decrease remain hence uncertain; it should be noted that 
we have previously reported using the same methods that Cox-2 
immunoreactive macrophage-IIke cells In the nerves and in the lesioned 
superficial dorsal horn of the CCI rats were increased above normal levels at 
40 days post operation, suggesting a delay In the expression of Cox-2 
(Durrenberger et al., 2004). Structural reorganisation in the spinal cord after 
peripheral nerve injury (Woolf et al., 1995) could account for the delayed 
expression of Cox-2 in microglia/macrophage-like cells. 
A number of other studies have described Cox-2 changes in different cell 
types in animal models of nerve injury. Using a modified Chung model, 
where only L5 was severed (Kim and Chung, 1992, Li et al., 2000), different 
stages of Cox-2 expression were observed in the sciatic nerve, with an early 
or first phase (after 1 day), where Cox-2-IR was co-localised with a Schwann 
cell marker, followed by a second phase, involving macrophages (Takahashi 
et al., 2004). In the spared nerve injury (SNI) model (Decosterd and Woolf, 
2000), a small increase in Cox-2 mRNA protein was demonstrated in the 
dorsal horn at 24 hours post surgery, returned to sham levels at 72 hours, 
and was decreased at 7 days (Broom et al., 2004). Furthermore, Cox-2-IR 
was shown by immunohistochemical methods to be only slightly increased in 
the deeper layers of the L4-L5 dorsal horn of the spinal cord at 10 hours post 
surgery. In this study pain behaviour in the rats was apparent from 9 days 
and maintained until 30 days post operation, which suggests that the 
neuropathic pain behaviour tested was not correlated, at the time-points 
studied, with significantly increased Cox-2 expression, in accord with the 
findings of some other investigators (Colburn et al., 1997). 
In a rodent partial nerve ligation study, EP1-IR was found near the sciatic 
nerve ligation site, in nuclei of cells co-expressing the macrophage marker 
EDI (Ma and Eisenach, 2003b). However, in the present study, we found 
EP1 receptors to be mainly expressed in axons and cell bodies of human 
sensory neurones. The regulation of EP1 receptors in injured sensory 
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neurones and inflammatory cells deserves further investigation. The 
molecular regulators of EP1 expression in DRG neurons are unknown -
trauma and initial inflammatory response (shown by rapid increases of 
CD68-IR) may lead to increased EP1 levels, to which PGs may contribute. 
Later, Cox-2 expression in macrophages may be involved in the persistence 
of pain. The time-course of Cox-2 expression also suggests a role in the 
processes of Wallerian degeneration and regeneration. Further 
investigations are required, including studies of chronic non-painful human 
neuromas, to establish a link between EP1 and Cox-2 levels with pain. The 
relationship between prostaglandins expression and EP1 up- and down-
regulation is not known but deserves further investigating. 
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CHAPTER V 
Cyclooxygenase-1 (Cox-1) in injured human nerve 
and a rat model of nerve injury 
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5.1. Introduction 
Cox-1 as well as Cox-2 Is also involved in the biosynthesis of prostanoids. 
Mostly found at basal levels, this constitutive Cox-1 enzyme has been mainly 
associated with homeostatic regulatory functions such as mucosal integrity 
(Vane et al., 1998, Smith et al., 2000). Since the discovery of the inducible 
Cox-2 isoform and its role in inflammation, Cox-1 received very little attention 
and the ability of this isoform to modulate an immune response has been 
overlooked (Tilley et al., 2001). However new accumulating evidence 
associated also this isoform with inflammatory processes, underrated its role 
in pathophysiological conditions (Schwab and Schluesener, 2003). It was 
suggested that prostanoid profile at site of inflammation is dependent on the 
differential Cox enzyme expression from the immune cells present at the site 
of injury or inflammation. For instance the prostanoid response during early 
stages of the inflammatory response is Cox-1 dependent while prostanoid 
production during the later stages is Cox-2 dependent. It is known that mast 
cells mainly release PGD2 while macrophages generate PGE2 and TXA2. 
However prostanoid profile release from the same cell can change upon 
activation. At this stage Cox-1 or Cox-2 cannot be linked to specific 
prostanoid production within a specific cell at a specific moment (Tilley et al., 
2001). Animal and human studies focusing on the inflammatory component 
in AD, for instance, found that administration of selective Cox-1 inhibitors 
(indomethacin or ibuprofen) reduced considerably AD related symptoms 
such as plaque formation or inflammation (Lim et al., 2000, Wyss-Coray and 
Mucke, 2000, McGeer and McGeer, 2003, Hoozemans and O'Banion, 2005). 
Furthermore, Cox-1 expression has also been recently investigated in animal 
models of inflammatory and neuropathic pain which has been reviewed in 
the main introduction (Section 1.6.1.3). Most of these studies concluded that 
selective blocking of Cox-2 may not be sufficient in suppressing spinal 
prostaglandin production. Cox-1 expression, to our knowledge, has not as 
yet been investigated in chronic human pain states. 
The aim of this study was to investigate Cox-1 expression in human brachial 
plexus nerves (proximal only) and in the CCI rat nerve, DRG and spinal cord. 
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5.2. Materials 
5.2.1. Human tissue 
Uninjured and injured proximal brachial plexus nerves were used for the 
purpose of this study. The mean pain scores on a visual analogue scale 
(VAS) were all > 4 out of 10 at the time of surgery, and patients reported this 
or a higher level of pain usually continuously since the time of injury. 
Table 05.01. Patients' characteristics. 
Group Injury Duration N Gender Age Range 
Control 9 8 males & 1 females 14-73 years 
Acute 
(<21 days) 
4 days to 8 days 7 5 males & 2 females 14-54 years 
Chronic 
(> 21 days) 
4 weeks to 5 years 10 8 males & 2 females 20-38 years 
5.2.2. Rat tissue 
A total of 32 adult male Sprague-Dawley rats (200-250 g) were used in this 
study of which 16 were CCl animals and 16 were controls (sham-operated) 
animals. To study glial activation and Cox-2 expression, animals were 
sacrificed on days 4, 21, and 30 (n = 4 in each experimental group and for 
each time point) and tissues harvested. Left and right sciatic nerve (nerve 
tissue from 4 days post-operation only was available for this study), and 
lumbar spinal cord were collected. 
5.3. Results 
5.3.1. Human nerve 
Control, uninjured human nerves showed few, scattered Cox-1 
immunoreactive cells throughout the nerve (Figure 05.01 .A). The Cox-1 
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immunoreactive cells were most likely of macrophage morphology as 
morphology and distribution was similar to the immunostaining for 
macrophage marker (CD68: Figure 03.01.D and 03.01.E). Similar, but more 
abundant positive cells were observed in proximal nerves after chronic injury 
(Figure 05.01 .B). Identical staining was produce with the mouse monoclonal 
anti-Cox-1 antibody from Cayman. 
The mean number of Cox-1 positive (Cox-1+) cells was significantly 
increased in chronic proximal injured nerves (74.36 ± 8.93; n = 10; p < 0.005) 
compared to controls (43.7 ± 10.94; n = 9). Acute proximal injured nerves 
(49 ± 7.7; n = 7) did not show any significant difference. There was also a 
significant difference (p < 0.01) between the acute and the chronic group 
(Figure 05.02). 
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Figure 05.02. Number of Cox-1 positive cells (Mean ± SEM) in uninjured 
and injured nerves. A significant increase in the number of positive Cox-1 
cells i/i/as observed in chronic injured nerves (p < 0.05) only. ** p < 0.005, * p 
< 0.01. 
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Figure 05.01. Cox-1 immunoreactivity in human uninjured and injured 
nerves. Uninjured human nerve (control) showed fewer Cox-1 positive cells 
(A) than proximal chronic injured nerves (B). Magnification x110. 
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Figure 05.03. Cox-1 positive cells in sham and CCI rat nerve. An increased 
number of Cox-1 expressing cells, most likely of macrophage morphology 
were observed near the site of injury of the lesioned nerve (B) compared to 
the sham operated nerve (A). Magnification x110. 
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5.3.2. CCI rat model 
In the sham operated nerve very few Cox-1+ cells were observed (Figure 
05.03.A). In the CCI nerve, numerous Cox-1+ cells were observed mostly 
near the site of injury and most likely of macrophage morphology (Figure 
05.03.B). 
Semi-quantitative analysis (visual inspection) showed a significant increase 
(p < 0.02; Figure 05.04) in the number of positive Cox-1+ cells in the 
lesioned CCI nerves compared to sham-operated nerves at 4 days post-
operation. No C0X-I+ cells were observed in the contralateral nerves of both 
CCI and Sham-operated rats. 
Sham 
Figure 05.04. Number of Cox-1 expression cells (Median) in the rat nerve. 
Visual inspection analysis of the number of Cox-1 positive cells in the 
lesioned nen/e of CCI and sham operated nerves at 4 days post-operation, 
p < 0.02. 
In the DRG, few positive Cox-1 cells of microglia/macrophage-like 
morphology most likely were observed scattered throughout the DRG as well 
as in the rootlets with no clear difference between lesioned and contralateral 
side. 
In the spinal cord, very few Cox-1 + cells were seen scattered throughout the 
white and grey matter with no distinction in number between lesioned and 
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contralateral side in the CCI rat spinal cord. Cox-1 positive cells presented 
several processes characteristic of microglial morphology (Figure 05.05). 
5.4. Discussion 
We have studied the expression of Cox-1 in injured human nerves, and in 
the CCI rat model. In the present study, we have shown for the first time 
Cox-1 expressing cells in human injured nerves. Significant increases of 
Cox-1 expressing cells, immune cells most likely, were found in chronic 
injured nerves only. The distribution pattern was similar to the one seen with 
Cox-2 immunoreactivity. The CCI rat model revealed increased Cox-1 
expressing cells near the site of injury only in the lesioned nerve in the acute 
stage (04 days post-operation). No significant difference between ipsilateral 
and contralateral in the number of Cox-1 expressing cells was found in the 
rat ORG or in the rat spinal cord. Positive Cox-1 cells in the CCI rat spinal 
cord showed several processes typical of microglial morphology and as seen 
previously with Cox-2 (Durrenberger et al., 2004). 
The number of Cox-1 expressing cells increased gradually over time after the 
transient Cox-2 peak and remained above basal levels over many years. 
Evidence suggests that Cox activity is generated by a transient Cox-2 up-
regulation (Figure 05.06) and by infiltrating Cox-1 expressing inflammatory 
cells (Mattson, 1998). As already mentioned, the involvement of these 
enzymes in the production of prostanoid is cell dependent and time 
dependent (Tilley et al., 2001). Only further studies, establishing explicit cell 
phenotype as well as prostanoid profile will shed further light on the specific 
role of Cox-1 in injured peripheral nerves from patients with post-traumatic 
painful neuropathy. Furthermore, the Cox-1 distribution pattern in the human 
injured nerves was similar to one seen with Cox-2 and, in the CCI spinal 
cord, Cox-1 positive cells showed typical microglial morphology which 
strongly suggests that Cox-1 expressing cells were of microglia/macrophage-
like morphology. However, double immunostaining techniques should be 
carried out to support these preliminary findings. 
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Figure 05.05. Cox-1 positive cells in the CCI rat spinal cord. Numerous Cox-
1 positive cells presented processes characteristic of microglial morphology 
(bipolar processes; black arrows). But no significant difference in number in 
the grey matter could be observed between ipsilateral and contralateral side 
on the CCI rat spinal cord. Magnification x200. 
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In the CCI rat model, at 04 days post-ligation, increased Cox-1 
immunoreactive cells were observed in the injured nerve but concentrated 
mainly near the site of injury. Furthermore, no significant difference in the 
number of Cox-1 expressing cells was observed between the ipsilateral and 
contralateral in the spinal cord grey matter at all time points (04, 21 and 30 
days post-operation). The results from the CCI rat nerve, in the present 
study, do not reflect the findings of the human injured nerves. One plausible 
explanation is that the CCI data were able to demonstrate localisation of 
Cox-1 expressing inflammatory cells near the site of injury acutely. With the 
human tissue samples, it is difficult to establish how close or far the sections 
on which the analysis was conducted on were from the site of injury. Human 
nerve tissue samples were in constant use for continuous different research 
projects and consequently some tissue sections of acute injured nerves 
might have not originated from the immediate proximity of the site of the 
injury. Furthermore, it was only possible to assess Cox-1 expression at 04 
days post-operation, as later time points were not available for the purpose 
of this study. Finally, various animal models of peripheral nerve injury, 
contrary to the findings in the present study found increased Cox-1 
expression in the spinal cord i.e. superficial dorsal horn ipsilateral to the 
lesion. The use of different animal model could account for the divergence in 
results. Some of the variability in results, using various animal models of 
neuropathic pain, appeared to be depended on whether a ligation or a 
transection model was used with the latter models inflicting a more severe 
injury than the ligation models consequently generating a more pronounced 
inflammatory response. Also, as demonstrated previously, increased levels 
of Cox-2 were only observed in the superficial ipsilateral spinal cord at 40 
days post-operation (Durrenberger et al., 2004). If the Cox-2 peak in the 
spinal cord is only from 40 days and if following the pattern of Cox-1/Cox-2 
activation in the peripheral nervous system and the pattern previously been 
published (Schwab and Schluesener, 2003), then it would be reasonable to 
assume that significant increase of Cox-1 expression in the spinal cord would 
only appear after that peak. However, only further research will be able to 
confirm this view. 
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In conclusion, the increased levels of Cox-1 expression in the peripheral 
human injured nerve were primarily observed at the chronic stage and over 
many years after injury. Targeting the transient increase of Cox-2 observed 
in human injured nerves with specific Cox-2 inhibitor at around 40 days 
would also possibly be of therapeutic value in reducing long term increased 
levels of Cox-1 as well as Cox-2 assuming that Cox-1 is also involved in 
generating and maintaining chronic pain states. 
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Figure 05.06. Cox activity time course after injury (From Schwab and 
Schluesener, 2003). 
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CHAPTER VI 
Prostaglandin receptor EP1 and Cox-2 in normal and 
diseased human spinal cord 
145 
6.1. Introduction 
CNS inflammatory processes, neuronal loss or regeneration inhibition could 
not be studied in patients with brachial plexus nerve injury as no spinal cord 
specimens were available. Instead post-mortem spinal cord from patient 
with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) were 
used, as post-mortem tissue was available. Both conditions present 
elements of neuroinflammation and neurodegeneration. MS is a chronic, 
immune-mediated disorder of the central nervous system. MS patients may 
be affected by a relapsing-remitting form of the disease, but a large 
proportion of patients will progress to a secondary progressive form of the 
disease, which results in a gradual and progressive loss of neurological 
function. The underlying pathophysiological mechanisms remain to be fully 
elucidated as yet, however evidence suggests that atrophy in MS is the 
result of a dynamic inflammatory processes involving demyelination, axonal 
injury, neuronal loss, Wallerian degeneration and possibly iron deposit 
(Minagar et al., 2004). Progression of neurological dysfunction is also a 
characteristic of ALS - a rapidly progressive motor neurodegenerative 
disorder (MND) with poor prognosis due to a lack of molecular markers and 
fatal within 5 years after onset (Al-Chalabi and Leigh, 2000). Selective loss 
of the upper and lower motoneurones is the main pathological hallmark in 
this disorder. The cellular mechanism to account for the loss of 
motoneurones remains to be fully explained. However, several mechanisms 
have been proposed such as oxidative stress, glutamate excitotoxicity and 
apoptosis. The involvement of several mechanisms to account for the 
selective and progressive degeneration of the motoneurones would suggest 
that onset is more likely to be multifactorial (Eisen, 1995, Al-Chalabi and 
Leigh, 2000, Cleveland and Rothstein, 2001, McGeer and McGeer, 2002). 
While new treatments have shown some efficacy in MS and ALS (Bensimon 
et al., 1994, Johnson et al., 1995, Jacobs et al., 1996, Miller et al., 2003), 
more effective therapies are required to slow progression and reduce 
disability and mortality. 
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The contribution of prostaglandins such as PGE2 or PGEaa in inflammatory 
processes and in pain modulation has been described previously. 
Prostaglandins once released from the cell act on specific plasma membrane 
receptors via an autocrine or paracrine pathway. For instance, EP (1-4) 
receptors respond preferentially to PGE2 (Bley et al., 1998, Narumiya et al., 
1999). In the previous chapter (Chapter IV), we mainly investigated EP1 
receptor expression and its involvement in the modulation of pain in the PNS 
(Durrenberger et al., 2005). However, PGs have additional sites of action 
both in the spinal cord and in the brain to generate hyperalgesia (Hori et a!., 
1998, Ito et al., 2001, Vanegas and Schaible, 2001, Kobayashi and 
Narumiya, 2002). A number of studies have shown a central role of EP1 
receptor in PGEg-induced pain response. For instance, administration of 
NSAIDs directly into the rat spinal cord reduced thermal hyperalgesia 
induced with a subcutaneous injection of formalin in the hindpaw responsible 
of the activation of spinal glutamate and substance P receptors (Malmberg 
and Yaksh, 1992b). An autoradiographic study demonstrated high density of 
[^H]PGE2 binding sites in the dorsal horn of rat spinal cord following dorsal 
rhizotomy (Matsumura et al., 1995). The central effects of PGs on 
nociception was further demonstrated by intracerebroventricular injection of 
PGE2 which induced in rats thermal hyperalgesia through EPS receptors and 
analgesia through EP1 receptors (Oka et al., 1994). In order to establish 
which PGE receptor subtype is involved in the generation of hyperalgesia, 
one particular study using EP1- and EPS-deficient mice demonstrated that 
intrathecal administration of PGE2 induced allodynia in the wild type and in 
EPS-deficient mice but not in EP1-deficient mice (Minami et al., 2001). 
These studies clearly demonstrated the implication of EP1 receptor in central 
nociception modulation. Nevertheless, the explicit role of PGs spinal 
receptors in neuropathic pain remains to be fully understood. 
The prostaglandin PGE2 can reduce the sensitivity threshold of nociceptive 
nerves. After intrathecal administration, it can affect central terminals of 
nociceptors and increase the sensitivity of dorsal horn neurons. These 
effects are produced via the G-protein coupled prostanoid receptors EP1-4. 
The EP1 receptor in particular seems to have a major but not exclusive role 
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in the central peripheral sensitisation of nerves and in mediating pain and 
inflammation. EP1 antagonists could be, therefore, of potential therapeutic 
value in alleviating pain (Stock et al., 2001). 
Cox-2 as previously described is an enzyme involved in the production of 
prostaglandins. Cox-2 expression is increased by a number of pro-
inflammatory cytokines, including IL-1 and TNF-a, as well as by other factors, 
including endotoxin, hypoxia, ischemia, epidermal growth factor and 
transforming growth factor beta 1. Cox-2 expression is increased in spinal 
cord neurones following peripheral inflammation (Goppelt-Struebe and 
Beiche, 1997). Inflammation produces robust increases in Cox-2 expression 
diffusely in the rat brain, especially in and around blood vessels. 
Prostaglandins derived from Cox-2 expression in cerebral vessels appear 
important in the generation of fever. Focal or global cerebral ischemia 
dramatically induces Cox-2 expression (Sairanen et al., 1998). Inhibition of 
both Cox-1 and Cox-2 may contribute to spinal analgesic and anti-
hyperalgesic actions of non-steroidal anti-inflammatory drugs (Willingale et 
al., 1997). Cox-2 inhibitors have also recently been suggested (Badie et al., 
2003) as possible alternatives to glucocorticoids in the treatment of 
peritumoural oedema in patients with malignant brain tumours, as they 
showed that glioma-infiltrating microglia are a major source of PGE2 
production through the Cox-2 pathway. 
Furthermore, Cox-2 mRNA was shown to be up-regulated in ALS spinal cord 
(Aimer et al., 2001, Yasojima et al., 2001). Cox-2 inhibitors have been 
shown to have a therapeutic role in a transgenic mouse model of ALS 
(Pompi et al., 2003). These authors showed that prophylactic administration 
of the preferential Cox-2 inhibitor, nimesulide, in the feed resulted in a 
significant delay in the onset of ALS type motor impairment. 
In this study, we have used antibodies to EP1 to investigate its distribution in 
normal controls and diseased (MS or ALS, respectively) human spinal cord. 
There is increasing evidence for shared cellular mechanisms that may affect 
disease progression in CNS disorders, particularly glial responses, we have 
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studied tine expression of key mechanisms in the neuro-inflammatory 
cascade, Cox-2, and the distribution and activation of microglia/macrophage-
like cells in MS and ALS post-mortem human spinal cord using markers 
CD68 (Collo et al., 1997), [^H] (R) PK11195 (Banati et al., 2000b) and ferritin 
(Peudenier et al., 1991). 
6.2. Materials 
Segments of deep frozen human spinal cord from patients with MS and ALS 
and from control patients with no neurological signs or symptoms were used 
for the purpose of this study. The mean disease duration for ALS was 34 
months, ranging from 7-84 months. The patient's characteristics from the 
entire cohort used across this study can be found in the table below (Table 
06.01). The full cohort was not always available for each invidual experiment 
within this chapter. Therefore, specific number of cases used for each study 
can be found in the text or in individual figures. 
Table 06.01. Patient's characteristics. 
Spinal Cord PM delay N Gender Age Range 
Control 0-92 hours 12 3 males & 9 females 63-80 years 
MS 5-11 hours 19 7 males & 12 females 38-79 years 
ALS 04-87 hours 09 4 males & 5 females 41-80 years 
PM = Post Mortem 
No clinical or other neuropathological information was available for the 
diseased spinal cord samples. 
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6.3. Results 
6.3.1. Prostaglandin receptor EP1 
6.3.1.1. Dorsal horn 
All spinal cords showed strong EP1-immunoreactive nerve cell bodies and 
fibres in the superficial laminae of the dorsal horn (Figures 06.01 .A and 
06.01 .D). In specimens where the nucleus intermediate-lateralis was 
present, intense EP1 immunoreactivity in cells and fibres was also found 
(Figures 06.01 .B and 06.01 .E). There was no obvious difference in EP1 
immunostaining in dorsal horn between control and pathological groups. 
6.3.1.2. Ventral horn 
Ventral horns showed generally some strong fibres and positive tracts 
through the white matter towards the ventral roots (Figure 06.01.C and 
06.01 .F). Motoneurones in control spinal cords were mostly negative with 
only 2 specimens showing few positive cells with EP1 immunostaining of 
low/medium intensity. However, both MS and ALS cords showed generally 
strong EP1 immunostaining in an increased proportion of motoneurones 
(Figure 06.02). 
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Figure 06.01. EP1 immunoreactivity in diseased spinal cord. Transverse 
section of MS spinal cord showing EP1 immunoreactivity in cells and fibres in 
the dorsal horn (A and D). Transverse section ofALS spinal cord showing 
EP1 immunoreactivity in cells and fibres in the nucleus intermediate-lateralis 
(B and E). Transverse section of MS spinal cord showing EP1 
immunoreactivity in large calibre fibres in the ventral horn (C and F). D, E 
and F are higher magnification (x400) of boxed regions in A, B and C (x55), 
respectively. 
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Figure 06.02. EP1 immunoreactivity in motoneurones of normal and 
diseased spinal cord. Control (A), MS (B) and ALS (C) spinal cord ventral 
horn immunostained with antibodies to EP1 showed an increased number of 
EP1 positive motoneurones in diseased spinal cord. Magnification x110. 
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6.3.1.3. Image analysis 
For the quantification of EP1 positive (EP1+) motoneurones in the ventral 
horn, EP1 positive and negative motoneurones were counted in 2 tissue 
sections from each of the 5 controls, 5 MS and 5 ALS spinal cords. The 
number of EP1+ motoneurones was expressed as a percentage (%) over the 
total number of motoneurones counted in each specimen. 
The analysis showed a significant increase of EP1+ motoneurones in MS 
and ALS spinal cords compared to control spinal cord (one-tailed Mann-
Whitney U test; p < 0.03; Figure 06.03). 
Control 
(n = 5) 
Figure 06.03. Quantitative assessment of EP1-immunoreactive 
motoneurones (Mean) in human spinal cord. A significant increase ofEP1+ 
motoneurones vi/as observed in both MS and ALS. **p < 0.004, * p < 0.03. 
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6.3.2. [^ H] (R) PK11195, Cox-2 and CD68 
6.3.2.1. Autoradiography 
Regional increases of PK11195 binding were found in MS plaques and 
associated white matter tracts (Figure 06.04.A) and closely matched the 
spatial distribution of activated microglia/macrophage-lil<e cells 
immunostained by CD68 antibodies (Figure 06.04.B, 06.04D and 06.04.E). 
Regional increases of [^H] (R) PK11195 binding were found along the 
corticospinal tract region in ALS spinal cord (Figure 06.05.A) and closely 
matched the distribution of activated microglia/macrophage-like cells 
immunostained with CD68 antibodies (Figure 06.05.B, 06.05.D and 06.05.E). 
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Figure 06.04. Cox-2 expressing microglia/macrophage-like cells in MS spinal 
cord. Cox-2-IR was predominantly observed in microglia/macrophage-like 
cells. (A) Autoradiographic localisation of[^H] (R) PK11195 in a spinal cord 
from a patient with MS (A) and co-located with CD68 (D). The square 
indicates the area where subsequent CD68 and Cox-2 images were taken 
from. Microglia/macrophage-like cells immunostained with CD68 antibody in 
B and E. Microglia/macrophage-like cells immunostained with Cox-2 in C 
and F. Magnification x55 (A and D), magnification x110 (B and C) and 
magnification x400 (E and F). 
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Figure 06.05. Cox-2 expressing microglia/macrophage-like cells in ALS 
spinal cord. Cox-2-IR was predominantly observed in 
microglia/macrophage-like cells in the white matter. Autoradiographic 
localisation of^[H] (R) PK11195 in a spinal cord from a patient with ALS (A), 
co-located with CD68 (D). The square indicates the area where subsequent 
CD68 and Cox-2 images were taken from. Microglia/macrophage-like cells 
immunostained with CD68 antibody (B and E). Microglia/macrophage-like 
cells immunostained with Cox-2 (C and F). Magnification x55 (A and D), 
magnification x110 (B and C) and magnification x400 (E and F). 
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Figure 06.06. Cox-2 and CD68 immunoreactivity in normal spinal cord. 
Microglia/macrophage-like cells in control spinal cord immunostained with 
antibodies to Cox-2 (A) and CD68 (B). Magnification x400. 
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6.3.2.2. Immunocytochemistry 
In control tissue, antibodies to Cox-2 were immunoreactive with scattered, 
small, nucleated cells with some cells showing fine short processes typical of 
microglia/macrophage-like cells (Figure 06.06.A). Similar staining was 
obtained with antibodies to CD68 (Figure 06.06.B) which is known to be a 
marker of microglia/macrophage-like cells. The distribution of Cox-2 positive 
cells was very similar to CD68 staining. 
All MS spinal cord samples showed glial-like cells, mostly bipolar with short 
processes scattered throughout the tissue. The processes appeared longer 
in MS spinal cord compared to the ones seen in ALS spinal cord. MS spinal 
cord specimens also appeared to have a greater density of glial-like cells, 
particularly around plaques (Figure 06.04.C and 06.04.F) and this was 
confirmed by image analysis (Figure 06.07). 
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Figure 06.07. Cox-2 immunoreactivity (Mean) in normal and MS spinal 
cords. Cox-2 immunoreactivity is increased significantly (p < 0.03) in MS 
spinal cords (n = 10) compared to controls (n = 7). The horizontal line 
indicates the median value from each group. * p = 0.025. 
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In MS spinal cord specimens, witii antibodies to CD68, strong 
immunoreactivity was observed in microglia/macrophage-lil<e cells located 
mostly in affected regions. The CD68 positive cells were bipolar with long 
processes (Figure 06.04.B, 06.04.D and 06.04.E). There was no overall 
difference between the groups [Control spinal cord, n = 7, 3.54 (mean), 2.79 
-4 .99 (range) and MS spinal cord, n = 10, 3.92 (mean), 2.51 - 6.68 (range), 
p = 0.6 (not significant)]. 
All ALS samples showed glial-like cells, mostly bipolar with short processes 
scattered throughout the tissue. The process appeared slightly longer in 
ALS spinal cord (but not as long as observed in the MS spinal cords) and 
also appeared to have greater density of glial-like cells compared to controls 
(Figure 06.05C and 06.05.F). This was confirmed in the dorsolateral white 
matter but not in the grey matter or dorsal columns by image analysis (Figure 
06.08). In contrast, there was no difference between these regions in control 
cords. 
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Figure 06.08. Cox-2 immunoreactivity (Mean ± SEM) in normal and MS 
spinal cords. Cox-2 is significantly (p < 0.002) increased in the dorsolateral 
white matter of ALS spinal cord. * p = 0.0012. 
In all ALS spinal cords, with antibodies to CD68 at a titre of 1:750, very 
intense staining was observed in microglia/macrophage-like cells. Some 
CD68 positive cells presented long processes (Figure 06.05.B, 06.05.D and 
06.05.E). Staining was almost exclusively localized to the dorsolateral white 
matter (Figure 06.05.D) and significantly increased compared to grey matter 
in ALS (p = 0.0022) and dorsolateral white matter of controls (p = 0.0012) 
using image analysis (Figure 06.09). 
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Figure 06.09. CD68-IR (Mean ± SEM) in normal and ALS spinal cord. CD68 
expression is significantly (p < 0.05) increased in the dorsolateral white 
matter of ALS spinal cord. *p = 0.0047. 
6.3.2.3. Western blotting 
Spinal cords from 11 control and 11 MS patients were available for the 
Western blotting study. Only a limited number of ALS spinal cord tissue was 
available and was insufficient for statistical purposes. A 70 kDa Cox-2 band 
was observed in mouse macrophage control and human MS spinal cord 
extracts, which was significantly (p < 0.001) more prominent in the MS spinal 
cords (Figure 06.10). There was a significant positive correlation (XY pairs = 
10, r = 0.89, P = 0.0011) between the Cox-2-IR (in % area) and the optical 
density of the Cox-2 70 kDa band obtained in the MS group (Figure 06.11). 
No significant correlation was obtained between the Cox-2 70-kDa optical 
density readings and the controls. 
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Figure 06.10. Cox-2 70-kDa band by Western blots (Mean) in normal and 
MS spinal cord. Top panel representative Western blots of the Cox-2 70-kDa 
band in control (lanes 1 - 6), in MS (lanes 7-11) and in lane 12 the mouse 
macrophage positive control. Bottom panel, optical density readings of Cox-
2 70-kDa bands in control (n = 11) and MS spinal cords (n = 11). * p = 
0.0004. 
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Figure 06.11. Cox-2 protein expression and Cox-2 70 kDa band optical 
density correlation. A significant correlation was established between the 
Cox-2 immunoreactivity and the Cox-2 70-kDa optical density readings from 
MS spinal cords. Number of XY pairs 10. 
6.3.2.4. Co-localisation studies 
Immunostaining with a mixture of antibodies to Cox-2 and ferritin in MS 
(Figure 06.12.A) and in ALS (Figure 06.12.B) showed that the majority of 
cells with red immunoproduct (Cox-2) also contained black immunoproduct 
(ferritin), indicating the presence of Cox-2 in microglia/macrophage-like cells. 
163 
r- mitm 
' V '7^ ' 
• ^ 4 i .. 
» *r 
* , « * » 
IK. 
X 
« . 1 
Figure 06.12. Co-localisation of Cox-2 and ferritin in MS and ALS spinal 
cord. Double immunostaining with Cox-2 (in red) and with the microglia 
marker ferritin (in black) showed that most Cox-2 positive cells were also 
positive with ferritin suggesting that most Cox-2 expressing cells were of 
microglia/macrophage-like morphology MS (A) and in ALS (B) spinal cord. 
Magnification x110. 
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6.4. Discussion 
With this study, we report that prostaglandin receptor EP1 and Cox-2 
expressing microglia/macrophage-like cells are present in the human spinal 
cord and more so in neurological conditions with elements of 
neuroinflammation and neurodegeneration. Since microglial activation has 
been shown in the CCl animal model (Durrenberger et al., 2004), EP1 
antagonists and selective CNS-penetrant Cox-2 inhibitors, in addition to 
inflammatory pain, could be also of potential therapeutic value in neuropathic 
pain. However our findings should be interpreted with caution as microglial 
activation may be non-pathogenic with respect to pain, or indeed in some 
circumstances may even be beneficial. 
We, hereby, are, to our knowledge, the first to show EP1 receptor expression 
using immunohistochemical technique in human spinal cord. EP1 receptor 
was strongly expressed in nerve cell bodies and fibres in the superficial 
laminae of the dorsal horn as well as in cells and fibres in the nucleus 
intermediate-lateralis of the spinal cord. Finally, EP1 receptors were also 
expressed on motoneurones in the ventral horn and more so in diseased 
spinal cord than in controls suggesting possibly that the spinal production of 
prostaglandins is increased in conditions with an inflammatory component. 
As we have established up to know the importance of an inflammatory 
component in the PNS of patients with post-traumatic painful neuropathy 
(Durrenberger et al., 2004, Durrenberger et al., 2006), it is most likely that 
neuronal-inflammatory interactions extend beyond the PNS to the CNS since 
prostaglandin receptor EP1 is expressed in the spinal cord, as we have 
observed presently. However, further studies are necessary to evaluate to 
what extend central prostaglandin receptors are involved in the generation or 
maintenance of chronic pain states. Nevertheless, numerous animal studies 
have demonstrated that prostaglandin EP1 receptor plays an important role 
in mediating nociception and that consequently EP1 antagonists might be of 
potential therapeutic value. 
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Furthermore, the studies reported here demonstrate that MS spinal cord 
contained increased levels of Cox-2 receptor in affected regions compared to 
control spinal cords. The immunohistochemical studies showed a greater 
number of microglia/macrophage-like cells expressing Cox-2 in MS 
compared to control spinal cord. In MS cords, Cox-2 positive cells often had 
long processes characteristic of microglia morphology, particularly when 
located within active plaques. In ALS spinal cord, Cox-2 was also elevated 
in regions known to be affected in this condition when compared to control 
spinal cord, as previously reported (Aimer et al., 2001). No specific 
microglial marker exist to date, nevertheless, the use of radioligand [^H] (R) 
PK11195 and ferritin have proven to reliably detect the presence of activated 
microglia/macrophage-like cells in the diseased CNS (Banati et al., 1997, 
Banati et al., 2000b, Durrenberger et al., 2004). The use of those two 
markers confirmed that most Cox-2 expressing cells were of microglial 
morphology in diseased (MS and ALS) spinal cord. Finally, no Cox-2 
immunoreactivity was found in the grey matter as in neurones. 
The increased Cox-2 immunoreactive microglia/macrophage-like cells were 
localised in the affected regions of the spinal cord, such as dorsolateral white 
matter with corticospinal tract degeneration, and not in the dorsal columns, 
which are spared in this condition. In other studies Cox-2 mRNA and protein 
were found to be significantly elevated in ALS cord, but the location of this 
increase was not reported (Yasojima et al., 2001). Cox-2 over-expression in 
the spinal cord of patients with ALS has also been shown to be present in 
neurones and glial cells of the CNS (Maihofner et al., 2003) and some 
reports have shown that Cox-2 immunoreactivity in normal rats is localised to 
neurons of laminae ll-lll, motoneurones of lamina IX and glial cells (Goppelt-
Struebe and Beiche, 1997, Beiche et al., 1998a). In support of this we have 
found Cox-2 immunoreactivity in our studies of human and rat peripheral 
nerves using the same methods and antibodies as the present study 
(Durrenberger et al., 2004, Durrenberger et al., 2006). We did not detect 
neuronal associated Cox-2 immunoreactivity in any of the spinal cord 
specimens studied including the control spinal cords, in which only a few 
microglia/macrophage-like cells with few processes were Cox-2 -
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immunoreactive. These contrasting results between laboratories may reflect 
differences in methods (antigen retrieval) and/or reagents. In rats, induction 
of Cox-2 mRNA expression in the spinal cord has been demonstrated after 
intraspinal injections of IL-1a (Tonai et al., 1999) or after mechanical injury to 
the spinal cord (Resnick et al., 1998). Cox-2 immunoreactivity was also 
found in vascular endothelial cells and glial cells after 1L-Ia challenges 
(Tonai et al., 1999). 
It has been shown recently that peripheral benzodiazepine receptor ligand 
PK11195 inhibits the lipopolysaccharide-induced Cox-2 expression in human 
microglia/macrophage-like cells (Choi et al., 2002). This suggests that the 
binding of this ligand to the PBR site on the mitochondrial outer membrane of 
microglia/macrophage-like cells could serve an anti-inflammatory function in 
the CNS. Thus, the development of drugs that can bind the mitochondrial 
outer membrane of microglia/macrophage-like cells, or even the peripheral 
benzodiazepine receptor ligand PK11195 itself, may be of use in the 
treatment of some patients with MS and/or ALS. Inhibition of Cox-2 has 
indeed been shown to prevent or attenuate disease progression, in an ALS 
animal model (PompI et al., 2003). 
Glial activation, including microglial cells/macrophages, is a major 
histopathological feature of MS and ALS, and may reflect the severity of the 
disease process. The precise mechanisms of glial activation in these 
diseases are not fully understood; recent observations implicate a purinergic-
signalling pathway (Schipke et al., 2002, Yiangou et al., 2006). In accord 
with the acknowledged role of microglia as the brain's endogenous immune 
effector cells (Kreutzberg, 1996, Kim and de Vellis, 2005), their presence in 
inflammatory and degenerative processes may underlie the commonality of 
pathological mechanisms, which may be targeted to modify disease 
progression, irrespective of the primary cause. 
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CHAPTER VII 
Prostaglandin receptor EP4 in injured human nerves 
and dorsal root ganglia 
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7.1. Introduction 
The prostaglandin receptor EP1 is not the only prostanoid receptor subtype 
affected by inflammatory mediators (Tilley et al., 2001). The use of gene 
knockout studies suggested that the EP4 receptor may play a potential role 
in inflammation and immune functions (Regan, 2003). Further animal 
studies appear to support this paradigm. For instance, spinal application of 
specific EP (1-4) agonist in an inflammatory rat knee joint model increased 
the response of dorsal horn neurones to mechanical stimulation (Vasquez et 
al., 2001). It was demonstrated that inflammatory pain was generated by 
sensitisation of peripheral and central neurones and that EP1, EP2 and EP4 
agonists generated spinal hyperexcitability similar to PGE2 (Vasquez et al., 
2001, Bar et al., 2004). Another study found that activation of EP4 has an 
inhibitory effect on pro-inflammatory cytokine production by immune cells. 
Intracapsular administration of an EP4 agonist in a rat model of arthritic pain 
showed effective inhibition of mechanical and thermal hyperalgesia and in 
the inflammatory response. It was proposed that EP4 agonist could be of 
potential therapeutic value in inflammatory arthritic pain (Omote et al., 
2002a). The EP4 receptor was found to be up-regulated as well as EP1, 
EP2 and EPS receptors in the injured nerve at 2 and 4 weeks after partial 
sciatic nerve ligation (Seltzer model). The EP4 immunoreactive cells were 
macrophages in 30% of the cases since they co-expressed macrophage 
marker EDI and other immune cells for the rest. No EP4-IR cells did co-
express Schwann cell marker SI 00. Furthermore, perineural injection of 
ketorolac, a non-selective COX inhibitor, effectively reversed tactile allodynia 
and reduced EP1 and EP4 expression in the injured nerve (Ma and 
Eisenach, 2003b). More studies are required to define the exact involvement 
of this receptor in inflammatory and more importantly in chronic neuropathic 
pain before any specific role or therapeutic value could be attributed to this 
particular EP receptor in neuropathic pain. 
The aim of this study was to investigate EP4 receptor expression in injured 
human nerves and in DRG following peripheral nerve injury as well as in 
control tissue. 
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7.2. Materials 
Table 07.01. Patients' characteristics. 
Nerve Injury Duration N Gender Age Range 
Control 10 8 males & 2 females 14-73 years 
BP Acute 
(< 21 days) 
3 to 16 days 7 5 males & 2 females 14-53 years 
BP Chronic 
(> 21 days) 
28 days - 5 years 11 8 males & 3 females 24-39 years 
Neuroma 1 to 19 years 16 10 males & 6 females 15-59 years 
DRG Injury Duration N Gender Age Range 
Control 7 2 males & 5 females 34-88 years 
Acute 
(< 21 days) 
2 to 15 days 9 8 males & 1 female 18-39 years 
Chronic 
(> 21 days) 
28 to 120 days 4 4 males 21-39 years 
BP = Brachial Plexus 
In the present study, injured brachial plexus nerve specimens (only proximal 
to the site of injury) and avulsed DRGs were used as well as their respective 
controls. Injured groups were subdivided into two groups, acute (<21 days) 
and chronic (> 21 days) according to the delay between the date of injury 
and the tissue collection at surgery (Table 07.01). The mean pain scores on 
a visual analogue scale (VAS) were all > 4 out of 10 at the time of surgery, 
and patients reported this or a higher level of pain usually continuously since 
the time of injury. 
7.3. Results 
EP4 antibodies showed very little immunoreactivity in control nerve fibres 
(Figure 07.01 .A). Increased number of EP4 positive fibres were observed in 
acute injured nerves (Figure 07.01.B) and more so in chronic nerves (Figure 
07.01 .C). In human DRG, EP4 immunoreactivity (EP4-IR) was detected in 
small/medium diameter neurones of controls (Figure 07.01.D). The EP4-IR 
appeared less intense in human injured acute and chronic DRG (Figures 
07.01.E and 07.01.F, respectively) with the appearance of some positive 
nerve fibres. 
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Figure 07.01. EP4 immunoreactivity in human proximal brachial plexus 
nerves and DRG. EP4-IR was very weak in control nerve fibres (A) and 
appeared more intense in acute injured nerves (B) and increased further in 
chronic injured nerves (C). In the sensory neurones, EP4-IR appeared to 
decease acutely (E) and chronically (F) compared to controls (D). 
Magnification x110. 
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EP4 peptide antigen from GSK/Cayman Chemicals was used at 10^ to 10"® 
mg/ml and pre-incubated with anti-EP1 at 1/1000 on a control DRG and at 
1/2000 on an acute injured DRG. Both control and injured DRG showed 
inhibition at high (10'^  - 10'^  mg/ml) concentrations of peptide antigen. 
EP4 and NF-immunoreactive nerve fibres were quantified by image analysis 
(% immunopositive area) in control and injured nerves (acute, chronic and 
neuromas) and expressed as a ratio (Figure 07.02). EP1-IR:NF-IR ratio was 
significantly increased in injured acute proximal (n = 7; 0.07 ± 0.015; p < 
0.02), in injured chronic proximal (n = 11; 0.14 ± 0.05; p < 0.01) and even 
further increased in neuromas (n = 16; 0.21 ± 0.29; p < 0.0001) compared to 
controls (n = 10; 0.03 ± 0.01; Figure 07.02). 
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Figure 07.02. EP4-IR:NF-IR ratio (Mean ± SEM) in human uninjured and 
injured proximal nerves. Significant increases of EP1-IR:NF-IR ratios were 
observed in human proximal injured nerves when compared to uninjured 
nerves. *** p < 0.001, ** p < 0.01, * p < 0.02. 
The time course analysis of EP4-IR:NF-IR ratio in human brachial plexus 
nerves did not reveal any thing in particular. 
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In human DRG, decreased Intensity of EP4-IR was observed using the visual 
inspection scale in DRG sensory neurones after injury in the acute group 
(surgery delay < 21 days; n = 9; 1.72 ± 0.09) and in the chronic group 
(surgery delay > 21 days; n = 4; 1.87 ± 0.12) compared to control DRG (n = 
7; 2.86 ± 0.09, p < 0.005). Acute and chronic injured DRG were not 
significantly different (Figure 07.03). 
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Figure 07.03. EP4-IR (Median) intensity of sensory neurones in uninjured 
and avulsed DRG. EP4 intensity in small/medium DRG neurones was 
significantly (p < 0.005) decreased in acute and chronic group. * p < 0.005. 
7.4. Discussion 
EP4 receptor expression levels were investigated and reported for the first 
time, to our knowledge, in human injured nerves and avulsed DRG. EP4-IR 
was found to be increased in injured peripheral nerves (acute, chronic and 
neuromas) while decreased in injured DRG sensory neurones (acute and 
chronic) suggesting a translocation of the protein from the soma on to the 
proximal nerve axon after injury. The EP4 receptor was exclusively 
expressed on nerve axons and soma contrary to some animal studies 
localising this particular on immune cells such as macrophages, mast cells 
and lymphocytes (Tilley et al., 2001 for a review). EP receptors and 
especially EP1 involvement in pain have been previously discussed and will 
173 
be further considered. The preliminary findings from the present study would 
suggest that most of our knowledge on EP1 gained herein would be 
transferable to EP4 since both receptors showed similar expression following 
peripheral nerve injury in patients with post-traumatic neuropathy, i.e., 
immediate increase after injury. The evidence on EP1 receptor expression 
suggested that the receptor was activated by prostaglandins released by 
inflammatory cells mostly macrophages in response to injury (Durrenberger 
et al., 2006). With the present findings we demonstrate that more than one 
EP receptor might be involved in the generation and maintenance of pain. 
However to which extent each of those EP receptors may play a role in 
chronic neuropathic pain remains to be fully determined and deserves further 
investigation as targeting these receptors, individually or in combination, 
could offer or present different therapeutic options for patients. 
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CHAPTER VIII 
Cathepsin S and lymphocyte expression in injured 
human nerves 
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8.1. Introduction 
Infiltration of macrophages represents only one aspect of an inflammatory 
response. The immune response is composed of many stages. A detailed 
description of these stages is beyond the scope of this project. However, 
recent attention was given to the presentation of antigens by the major 
histocompatibility complex class II (MHC II) molecules, which is an important 
step in the activation of the CD4'' T cells-mediated immune response that in 
turn activate other parts of the immune system. Antigen presenting cells 
(APCs) such as dendritic cells, B cells and macrophages internalise engulfed 
antigens through phagocytosis and bind antigen peptides to the MHC II 
molecule that is subsequently exported to the cell surface (Goldsby, 2003, 
Male, 2004). The MHC II molecule is assembled in the endoplasmic 
reticulum where enzymes such as lysosomal cysteine protease also known 
as cathepsins play a crucial role for normal MHC II presentation and 
immunity (Riese et al., 1998, Honey and Rudensky, 2003). Cathepsins 
present also some extracellular role. Activated macrophages and microglia 
can release cathepsin S which have been shown to play a role in degrading 
myelin basic protein and amyloid (3 protein (Liuzzo et al., 1999). 
Eleven human cathepsins have been isolated and some functions have been 
established. Specific inhibitors have also been developed. Only one of 
those enzymes is of interest, i.e. cathepsin S (CatS), as this enzyme is 
mainly expressed in APCs (Petanceska et al., 1996) while other cathepsins 
such as B, D and L are more generally expressed (Katunuma et al., 2003, 
Nakanishi, 2003, Hsing and Rudensky, 2005). Little is known about the 
exact function of CatS in health and disease. It was suggested, however, 
that Cats might be implicated in the degradation of the extracellular matrix 
leading to the pathology of various inflammatory diseases including 
rheumatoid arthritis and atherosclerosis (Liu et al., 2004, Yasuda et al., 
2005). Very few studies have been conducted to date to investigate the 
expression and inhibitory effects of this enzyme. Gene knockout studies 
showed that CatS deficient mice were found to be healthy but exhibited 
immune function deficits (Shi et al., 1999). Several reports showed that CatS 
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inhibitors effectively reduce inflammation in animal inflammatory pain 
models. For instance, using a rat adjuvant-induced arthritis model, cysteine 
protease activity and consequently inflammation was significantly reduces 
with a protease inhibitor (Biroc et al., 2001). Furthermore, it was 
demonstrated that CatS deficient mice showed reduced susceptibility to 
collagen-Induced arthritis (Nakagawa et al., 1999). Cathepsin S inhibitors 
have also proven to be effective in treating a murine model for Sjogren 
syndrome - an autoimmune disorder associated with defective T cell function 
(Saegusa et al., 2002). Finally, some preclinical unpublished data suggested 
that Cats inhibitors were effective in animal inflammatory and neuropathic 
pain models. Although only few reports have to date shown the 
effectiveness of cathepsin S inhibitors as immunosuppressive agents, further 
investigations are required using other animal pain models with an 
inflammatory component to evaluate cathepsin S as a promising target for 
the development of novel therapeutic approaches for various inflammatory 
disorders including neuropathic pain. 
Cats is involved in the normal presentation of antigens by antigen presenting 
cells which activate the T cells-mediated immune response. T lymphocyte 
cells possess specific receptors, i.e., T-cell receptors (TCR - identified with 
the CDS marker) that recognise the MHC/peptide complex. The CDS plays a 
crucial role in the transduction of intracellular antigen-recognition signals and 
in regulating the cell surface expression of the TCR complex (Hsing and 
Rudensky, 2005). Briefly, T cells mature in the thymus where they develop 
their TCR. T cells are subdivided into two main subset populations, the T 
helper cells (TH) mostly expressing the CD4 marker (also referred to as 
CD4'') and the T cytotoxic cells expressing the CDS marker (CDS"^ ). TH cells 
are further subdivided (THI and TH2) according to their cytokine profile 
production. TH1 appear to release proinflammatory cytokines resulting in 
macrophage, neutrophils and natural killer cells activation. On the other 
hand, TH2 were found to produce mostly anti-inflammatory cytokines 
responsible to down-regulate the activity of inflammatory cells (London et al., 
1998). The main function of lymphocytes is however to recognise antigens 
within a host. T cytotoxic cells (Tc) have the ability to destroy cells while TH 
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facilitate B cells division, differentiation and antibody production via the 
release of various cytokines (Goldsby, 2003, Male, 2004). 
The role of T lymphocytes following neuronal injury has been mostly 
investigated using the rat facial nerve paradigm (Jones et al., 2005) where 
CD4^ and not CD8^ T cells appear to play a neuro-protective role in neuronal 
survival and/or peripheral nerve regeneration (Armstrong et al., 2004). 
Increased infiltration and recruitment of CDS'" lymphocytes after peripheral 
nerve injury was observed in the rodent brain 7-21 days with a peak at 14 
days suggesting a retrograde inflammatory response (Raivich et al., 1998, 
Raivich et al., 2003). Lymphocyte expression was also investigated in 
several rat models of mononeuropathy. For instance, using 
immunohistochemical method and a CPA induced sciatic nerve injury rat 
model, CD4'' and CDS'" lymphocytes were observed 3-4 days post-operation. 
It was suggested that the lymphocyte inflammatory response was 
responsible for the neuritis-evoked neuropathic pain (Eliav et al., 1999). 
Another study, using the Bennett, Seltzer and Gazelius models as well as the 
complete sciatic nerve axotomy model, demonstrated a significant increase 
in the number of CD4 positive cells (up to tenfold above baseline levels) at 
14 days post-operation in all rat models (Cui et al., 2000). Finally, the 
number of T cell was found to be significantly increased in the sciatic nerve 
(CCI or Bennett model) at 14 days post-operation where the increased level 
of lymphocytes was linked with the generation of hypersensitivity, THI more 
so than TH2 (Moalem et al., 2004). 
In human studies, lymphocyte expression has mostly been investigated in 
relation to immune-mediated diseases of the nervous system, e.g., 
demyelinating neuropathies such as MS and their central role has been well 
documented (Archelos and Hartung, 2000, Moalem and Tracey, 2005). T 
cells were found to play a role in the inflammatory component of these 
neurodegenerative diseases with increased expression in lesions (Bitsch et 
al., 2000, Bonetti et al., 2003, Aboul-Enein et al., 2004). Only one study 
appears in the literature to have investigated using immunohistochemistry 
the expression of T cells in sural nerve biopsies from patients with vasculitic 
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neuropathy, chronic inflammatory demyelinating neuropathy and with non-
inflammatory chronic axonai neuropath. Although the focus of this study was 
more on cytokine expression (IL-I3, IL-6 and TNF), they demonstrated 
significant increases of epineurial rather than endoneurial T cell 
immunoreactivity in patients with vasculitic neuropathy (Lindenlaub and 
Sommer, 2003). 
Using antibodies to the enzyme Cathepsin S, to CDS (marker for all 
lymphocytes irrespective of subset) and to CD4 (marker for TH), we have 
investigated the distribution of CatS and the presence of lymphocyte 
expression in normal and injured nerves of patients with post-traumatic 
neuropathic pain. 
8.2. Materials 
For the purpose of the present study, control nerves, injured brachial plexus 
nerve specimens (only proximal to the site of injury) and neuromas were 
used. Injured brachial plexus nerves were subdivided into two groups, acute 
(< 21 days) and chronic (> 21 days) according to the delay between the date 
of injury and the tissue collection at surgery. Neuromas formed a separate 
group with an injury duration much longer than the chronic group (Table 
08.01). 
Table 08.01. Patients' characteristics. 
Nerve Injury Duration N Gender Age Range 
Control 7 5 males & 2 females 15-73 years 
BP prox Acute <21 days 8 6 males & 2 females 14-54 years 
BP prox Chronic > 21 days 12 9 males & 3 females 20-38 years 
Neuromas 1 to 19 years 16 9 males & 7 females 15-59 years 
BP = Brachial Plexus 
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Figure 08.01. Cathepsin S expression in uninjured and injured nerves. 
Control nen/es (A) showed some positive CatS immunoreactive cells of 
mononuclear/macrophage-like morphology. More of these cells could be 
observed in acute specimens (B) and their number appeared to decrease in 
chronic specimens (C). Magnification x110. 
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8.3. Results 
8.3.1. Cathepsin S (CatS) 
All nerves showed CatS immunoreactivity (CatS-IR) in large cell bodies 
(amoeboid- and round shaped) of mononuclear/macrophage-like morphology 
scattered throughout the nerve fibres. More positive cells could be seen in 
acute nerves compared to control and chronic nerves (Figure 08.01). CatS 
immunoreactivity with the same antibody as been previously shown and 
described in human brain tissue (Flannery et al., 2003). 
Image analysis showed a significant increase of CatS expression in acutely 
injured nerves (p < 0.001) and significant lower levels of CatS expression in 
chronically injured nerves (p < 0.002) and neuromas (Table 08.02 and Figure 
08.02). 
Table 08.02. CatS-IR (Mean ± SEM and N) in uninjured and injured nen/es. 
Controls Acute 
(< 21 days) 
Chronic 
(21 days - 1 year) 
Neuromas 
(1 to 19 years) 
N 7 8 11 16 
Mean 0.64 1.27 0.2 0.21 
SEM 0.09 0.10 0.038 0.03 
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Figure 08.02. CatS-IR (Mean ± SEM) in human uninjured and injured 
nerves. Increased immunoreactivity was found in acute proximal brachial 
plexus nerves and below baseline levels in chronic nen/es (including 
neuromas). ** p < 0.001, * p < 0.002. 
A time course analysis showed immediate increases above control levels of 
Cats expression with a decrease below baseline levels after 14 days (Figure 
08.03). As described previously, macrophage marker (CD68) showed also 
an early increase of immunoreactivity above baseline level and remained 
elevated above control levels during the entirety of the time course (Chapter 
IV). Finally, was shown that Cox-2 expression remained below normal levels 
during the acute phase, peaked at 28 days to 70 days, to decrease thereafter 
but remain above baseline levels (Chapter III). The combined time course of 
Cox-2, CD68 and CatS would suggest, in the first instance, an immune 
response generated by antigen presenting cells including macrophages at 
the site of injury resulting in a gradual recruitment and infiltration of further 
macrophages expressing Cox-2. 
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Figure 08.03. Cox-2-IR, CD68-IR and CatS-IR in uninjured and injured 
nerves - a time course. When CatS-IR i^as compared with previously found 
Cox-2 and CD68 expression on a time course, it appears that the transient 
Cats increase was immediate after peripheral nerve injury and generated a 
steady influx of further macrophages expressing Cox-2. 
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Figure 08.04. CD3* lymphocyte expression in uninjured and injured nerves. 
More positive cells were seen in injured nerves (B & C) compared to normal 
nerves (A) where very few cells could be detected. More cells were seen in 
the chronic stage (C) than in the acute stage (B). Magnification x110. 
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8.3.2. CD3* lymphocyte expression 
Very few positive CDS"" lympliocyte cells were seen in control nerves (Figure 
08.04.A). Their number was observed to increase considerably in injured 
nerves, more so in the chronic stage (Figure 08.04.B and C). The mouse 
monoclonal anti-human CDS is a well established lymphocyte marker and 
according the manufacturer data sheet, specificity has been confirmed by 
many laboratories. 
Cell counting revealed a significant increase in the mean number of CDS 
positive cells in injured nerves. The highest significant increase was seen in 
the chronic injured nerves (n = 12; S2.80 ± 3.27; p < 0.001). Acute injured (n 
= 8; 11.88 ± S.35; p < 0.005) and neuromas (n = 16; 12.6 ± S.66; p < 0.005) 
showed similar CDS'" lymphocyte expression compared to controls (n = 6; 
2.47 ± 0.52; Figure 08.05). 
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Figure 08.05. Number of 003"^ lymphocytes (Mean ± SEM) in uninjured and 
injured nerves. A significant increase was determined in injured nerves 
compared to normal nerves. ** p < 0.0001, * p < 0.005. 
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8.3.3. CD4''lymphocyte expression 
As with CDS expression, CD4 positive (CD4+) cells were very scarce in 
normal nerves (Figure 08.06.A). Their number was observed to increase 
considerably in injured nerves, more so in the chronic stage (Figure 08.06.B). 
The mouse monoclonal anti-human CD4 is a well established marker and 
according the manufacturer data sheet, specificity has been confirmed by 
many laboratories. 
Quantification revealed a significant increase in the mean number of CD4 
positive cells in injured nerves. As with CDS'" lymphocyte expression, the 
highest significant increase with CD4'^  lymphocytes was also seen in the 
chronic injured nerves (n = 12; 6.63 ± 1.43; p < 0.005) as well as in 
neuromas (n = 16; 4.2 ± 1.6; p < 0.002) while acute injured nerves (n = 8; 
3.65 ± 1.95; p = 0.0539) showed only a trend while compared to controls (n = 
6; 0.43 ± 0.2; Figure 08.07). 
A time course analysis (Figure 08.08) showed similar increases in 
macrophage and lymphocytes, mostly CD3VCD4", following peripheral nerve 
injury. CD4"' lymphocytes appeared to increase above baseline levels only 
half way through the acute phase (6 days onwards) and their number 
remained elevated over the whole time course. 
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Figure 08.06. CD4^ lymphocyte expression in uninjured and injured nerves. 
More positive cells were seen in injured nerves (B) compared to normal 
nerves (A) where very few cells could be detected. More cells were seen in 
the chronic stage than in the acute stage that only showed a trend to 
increase. Magnification x110. 
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Figure 08.07. Number of CD4^ lymphocytes (Mean ± SEM) In uninjured and 
injured nerves. A significant increase was determined in chronic injured 
nerves compared to normal nerves. ** p < 0.002, * p < 0.005. 
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Figure 08.08. CatS-IR, macrophage (CD68) and lymphocyte expression in 
injured nerves - a time course. Elevated levels of Cats (in orange) were 
immediately observed after peripheral nerve injury as well as a rapid influx of 
macrophages (in green) and lymphocytes (in red and blue). A subset of 
lymphocytes (004" lymphocytes in red) appeared in the injured nerves only 
halfway through the acute phase. lymphocyte (in blue) appeared 
immediately after injury and lingered in the endoneurium of peripheral nerves 
for many years. 
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8.4. Discussion 
In this study, with the presence of the lysosomal cysteine protease. Cats, we 
were able to demonstrate the presence and activity of professional ARC in 
human peripheral nerves after injury. Cats expression was only expressed 
above baseline levels in acute injured nerves. CatS-1R was immediate and 
lasted only for a period of 2 weeks. Furthermore, although APC could also 
include B cells, mast cells or dendritic cells, it is thought that most the CatS 
producing APC are of mononuclear/macrophage phenotype as the pattern of 
positive Cats cell distribution in the injured nerve is very similar to the 
positive CD68 (macrophage marker) cell distribution observed in injured 
human nerves as previously shown (Chapter 111 and Chapter IV). However, 
to fully determine the specific distribution and phenotype of the CatS 
expressing professional APC present in injured nerves, further investigations 
will be required using double immunostaining techniques with specific 
markers for macrophages (CD68 as previously described), dendritic cells 
(e.g. HLA-DR), B lymphocyte cells (e.g. CDS or CD20) and for mast cells 
(e.g. c-kit/CD117). Nevertheless, we are confident to support the view with 
this preliminary data, that the transient activity of professional APC is 
responsible for the second wave of infiltrating macrophages and the latter 
increase of Cox-2. 
Finally, the Cox-2, CD68 and CatS time course suggests the involvement of 
Cats in the recruitment of Cox-2 expression macrophages around 2-3 
weeks. Very little is know about the exact role of CatS in neuropathic pain as 
the only studies conducted to date have investigated this enzyme in 
inflammatory pain where administration of CatS inhibitors showed reduced 
inflammation (Biroc et al., 2001). With the findings above, it is premature to 
assume that CatS is a novel mediator for neuropathic pain and a target for 
therapeutic intervention. Nevertheless, as we have demonstrated so far, 
there is an important inflammatory component in patients with post-traumatic 
painful neuropathy which has been already associated in the generation and 
maintenance of hyperalgesia. It is therefore reasonable to assume that any 
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attempt at taming or inhibiting this inflammatory response at any stage might 
be of potential value in reducing chronic pain experienced by these patients. 
Very few systematic studies have investigated lymphocyte expression in 
patients with neuropathic pain. We, hereby, have demonstrated for the first 
time the presence of T lymphocytes using a CDS marker and a CD4 marker 
(identifying a subset of lymphocytes - T helper cells) with 
immunohistochemical methods in patients with painful post-traumatic 
neuropathy. The time course analysis showed rapid infiltration of CD37CD4" 
T cells with an increase of CD4'' lymphocytes only after one week of injury 
duration suggesting that the present lymphocytes prior to the appearance of 
T helper cells might have been T cytotoxic cells (CD8^). 
Although, some animal studies were confident in associating T cell infiltration 
with pain behaviour (Moaiem et al., 2004), their specific role in the generation 
and maintenance of pain within this cohort of patients would need to be still 
fully determined as T helper cell subtypes have not been assessed as yet. 
As mentioned earlier, other animals studies allocated to T cells a beneficial 
role in the survival and regeneration of nerves following peripheral nerve 
injury (Raivich et al., 1998, Armstrong et al., 2004). It is therefore imperative 
to assess the exact T cell type and/or subtype present in the injured 
peripheral nerves before any final conclusion can be reached. Since two 
subtypes of T helper cells have been identified - one producing pro-
inflammatory cytokines and the other producing anti-inflammatory cytokines, 
it would be useful to establish with further studies which subtype or cytokines 
would be present in patients with post-traumatic neuropathies. Nevertheless, 
more and more new evidence converge towards a role played by immune 
cells as well as glial cells in the development and maintenance of 
neuropathic pain (Watkins and Maier, 2002). An inflammatory component 
has been demonstrated in an increased number of neuropathic pain 
syndromes (Bennett, 1999, DeLeo and Yezierski, 2001, Sommer and Kress, 
2004). In addition, a number of animal studies have directly or indirectly 
linked T cell derived cytokines with the generation of pain behaviour 
(Michaelis et al., 1998, Sommer et al., 2001, Schafers et al., 2003). Finally, 
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one particular study reduced T lymphocyte proliferation and pain behaviour 
in CCI rats after the administration of tramadol - a centrally acting analgesic 
drug (Tsai and Won, 2001). It is therefore of value to investigate further the 
involvement of pro-inflammatory producing T cells in neuropathic pain and 
understand their exact involvement in the contribution of persistent pain. 
192 
CHAPTER IX 
Immune cell profile in the peripheral blood of a rat 
model of nerve injury 
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9.1. introduction 
Immunohistochemical studies with human injured nerves showed increased 
expression of different immune cells following peripheral nerve injury. Using 
the CCI rat model, it would be of interest to investigate whether such immune 
profile could be detected in the peripheral blood and be used as a potential 
biomarker. 
Previous studies (unpublished data) have shown that in the established CPA 
model of inflammatory pain there was a significant decrease at 24hr in 
circulating T-cells, monocytes and B cells (possibly due to their accumulation 
in the inflamed paw), and an increase in neutrophils compared to blood from 
vehicle-injected rats. Although CCI is not an inflammatory pain model, the 
neuropathic damage that causes pain in these rats is induced via a local 
inflammation and oedema around the nerve. It is therefore possible that 
some reflection of an inflammatory condition might be detectable in the 
peripheral blood profile of CCI rats. Understanding the latter might not only 
shed light on the pathological events involved in this model of neuropathic 
pain, but could also provide indication of a potentially useful peripheral 
biomarker. 
The present study aimed to determine whether or not there are any 
significant changes in the immune profile detectable at different time points in 
the peripheral blood taken from the rat after peripheral nerve injury using the 
CCI model of neuropathic pain. 
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9.2. Materials 
A total of 16 adult male random bred hooded rats (200-250 g) were used In 
this study of which 8 were CCI animals and 8 were controls (sham-operated) 
animals. To study the phenotype of haematogenous immune cells, animals 
were tested for pain behaviour on days 3, 16 22 and 28. Serial blood 
sampling was carried. 
9.3. Results 
9.3.1. Behavioural testing 
Unilateral constriction injury to the sciatic nerve resulted in a reduction in paw 
withdrawal threshold ipsilateral to the nerve injury, usually evident rapidly 
with a peak at 9 days and maintained over time (Table 09.01 and Figure 
09.01). Following behavioural testing on day 03, 16, 22 and 28, blood 
samples were collected for flow cytometry. Sham operation had no 
significant effect on paw withdrawal threshold compared to basal levels. 
Table 09.01. Means (SEM) of left paw withdrawal threshold. 
24 hours 
pre-surgery 
Post operation (in days) 
03 16 22 28 
Sham 321.25 
(± 11.25) 
286.25 
(± 8.44) 
291.25 
(+ 15.86) 
327.5 
(± 14.97) 
271.25 
(±21.33) 
CCI 315 
(± 9.64) 
187.5** 
(± 9.02) 
180 ** 
(± 7.32) 
196.25 ** 
(± 3.24) 
168.75* 
(± 8.95) 
{** p < 0.0001 and * p = 0.0023) 
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Figure 09.01. Time course of development of neuropathy in rats (Mean ± 
SEM). An algesymeter was used to assess the development of neuropathy 
at 24 hours before the CCI operation and at 03, 16, 22 and 28 days post 
operation (n = 8 for each group). Significant increase in withdrawal of the left 
paw was observed rapidly after injury in the CCI group compared to the 
sham-operated group and was maintained over this time course. No 
difference was observed between experimental groups prior to surgery. ** p 
< 0.0001, *p < 0.003. (PWT = paw withdrawal threshold). 
9,3.2. Flow Cytometry 
Overall, there was little evidence of any major changes in the immune profile 
of peripheral blood from CCI rats when compared to sham controls. At the 
time points 03, 22 and 28 days post operation no differences in the number 
of leukocytes were observed (Figure 09.02, Figure 10.04 and Figure 09.05). 
However, at 16 days post-operation (Figure 09.03) there was a significant 
small elevation in cytotoxic T cells (p < 0.03) and B-like cells (p < 0.05). 
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Figure 09.02. Leukocyte profile in peripheral blood at 03 days post-operation 
(CTC = cytotoxic T cells, TH = T helper cells, Neut = neutrophils, BC= B 
cells, Mon = monocytes and NK = natural killer cell). 
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Figure 09.03. Leukocyte profile in peripheral blood at 16 days post-
operation. A minor significant increase in cytotoxic T cells and B cell-like 
cells was observed. ** p < 0.03, * p < 0.05. 
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Figure 09.04. Leukocyte profile in peripheral blood at 22 days post-
operation. 
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Figure 09.05. Leukocyte profile in peripheral blood at 28 days post-
operation. 
198 
Further analysis were conducted to asses for possible significant changes 
over time in the numbers of cytotoxic T cells and B cell-like cells using a 
One-way AN OVA (non parametric; Friedman Test). 
9.3.2.1. Cytotoxic T cells 
The mean number of cytotoxic T cells for each group at all time points was 
compared (Table 09.02 and Figure 09.06). A on-way AN OVA (non 
parametric; Friedman Test) showed no significant main effect of mean 
number of cytotoxic T cells over time in the CCI group but showed a 
significant main effect (p = 0.0181) of mean number of cytotoxic T cells over 
time in the sham operated group. Number of haematogenous cytotoxic T 
cells in the sham group was observed to increase and peak at 22 days with a 
slow decrease over the rest of the time course. Post hoc analysis (Dunn's 
Multiple Comparison Test) showed a significant difference (p < 0.05) 
between day 03 and 22 in the sham group. 
Table 09.02. Mean (SEM) number of cytotoxic T cells for all time points. 
Post operation (in days) 
03 16 22 28 
Sham 1160 1230 1464 1266 
(± 90.23) (± 37.72) (± 64.15) (± 37.12) 
CCI 1163 1473* 1276 1134 
(± 86.34) (± 96.87) (± 88.19) (± 60.07) 
(* p = 0. 0249) 
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Figure 09.06. Cytotoxic T cell profile in peripheral blood - time course. A 
significant difference in the number of cytotoxic T cells between sham 
operated and CCI rats was found at day 16. * p < 0.03. 
9.3.2.2. B cell-like cells 
The mean number of B cell-like cells for each group at all time points was 
compared (Table 09.03 and Figure 09.07). An on-way AN OVA (non 
parametric; Friedman Test) showed no significant main effect of mean 
number of cytotoxic cells over time in the CCI group and in the sham 
operated group. 
Table 09.03. Mean (SEM) number of B cell-like cells for all time points. 
Post operation (in days) 
03 16 22 28 
Sham 1822 
(±118.9) 
1536 
(± 104.3) 
1663 
(± 150.4) 
1619 
(± 43.93) 
CCI 2124 
(± 168.2) 
2038 * 
(± 200.8) 
1440 
(± 168.4) 
1609 
(±108.7) 
(* p = 0. 0415) 
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Figure 09.07. B cell-like cell profile in peripheral blood - time course. A 
significant difference in the number of B cell-like cells between sham 
operated and CCI rats was found at day 16. * p < 0.05. 
9.4. Discussion 
Minor changes were seen in the leukocyte profile of peripheral blood 
samples taken from random hooded rats at 3, 16, 22, or 28 days following 
CCI. There was a significant elevation in the number of circulating cytotoxic 
T cell and B cell-like cells. However these changes were evident only at 16 
days post-surgery and were relatively limited in magnitude with also some 
variability in the baseline levels. It is concluded that an immune component 
of CCI is not detectable as a major feature of the peripheral blood profile in 
this animal model. 
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CHAPTER X 
Nogo-A and Nogo-66 receptor in Multiple Sclerosis 
and Amyotrophic Lateral Sclerosis spinal cord and 
injured human peripheral nerves 
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10.1. Introduction 
Plasticity and neuro-degenerative processes are thought to play an important 
role in generating abnormal pain such as hypersensitivity or allodynia 
(Scholz and Woolf, 2002). Regeneration of nerve growth and structural 
plasticity after injury are limited in the adult CNS compared to the PNS (Ide, 
1996, Schwab and Bartholdi, 1996, Olson, 1997, Bregman, 1998). It was 
quickly established that rather than the absence of growth-promoting 
molecules it was the presence of axon growth-inhibitor molecules that limited 
regeneration (Schwab and Caroni, 1988, Niederost et al., 1999). Since 
inhibitors of neurite outgrowth have become a focus of attention. The neurite 
growth inhibitory membrane protein Nogo-A is a myelin-associated molecule 
with known inhibitory functions on axon regeneration. Only cloned in 2000 
(Chen et al., 2000, GrandPre et al., 2000, Prinjha et al., 2000), Nogo-Nogo-
66 receptor have since generated a considerable amount of interest in the 
literature (Fouad et al., 2001, Grandpre and Strittmatter, 2001, Fournier et 
al., 2002, Woolf and Bloechlinger, 2002, Woolf, 2003, Schwab, 2004, Teng 
and Tang, 2005). Mainly expressed by oligodendrocytes in the rodent CNS, 
Nogo-A is however also expressed by neuronal tissue such as DRG, 
sympathetic neurons, and a subsets of motoneurones (Liu et al., 2002b) from 
both intact and injured nerves in rodent PNS (Josephson et al., 2001, Huber 
et al., 2002, Wang et al., 2002, Hunt et al., 2003). The receptor to Nogo-A, 
Nogo-66 receptor, is on the other hand, mainly expressed on subpopulations 
of neurones (Fournier et al., 2001). Spatial distribution of Nogo-A in humans 
was found to be similar to rodents (Buss et al., 2004). Evidence that this 
molecule was responsible for preventing nerve regeneration was supported 
by the fact that oligodendrocytes or myelin removal (Schwab and Bartholdi, 
1996), or using neutralising Nogo-A antibodies such as IN-1 (Schnell and 
Schwab, 1990, Brosamie et al., 2000, Chen et al., 2000, Fiedler et al., 2002), 
or experimental vaccination (Huang et al., 1999, Sicotte et al., 2003) resulted 
to nerve growth. 
Peripheral and central Nogo-A and its receptor after injury on axonal 
regeneration have been investigated. For instance, delayed axon 
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regeneration was observed in transgenic mice (higher expression of Nogo-A) 
7 days after freeze-crush lesions of the sciatic nerve (Pot et al., 2002). In 
humans, autoantibodies directed against CNS myelin antigens have been 
investigated in patients with MS and other neurological diseases (Bernard et 
al., 1997, Reindl et al., 1999, Archelos and Hartung, 2000, Cross et al., 
2001). Autoantibodies directed against Nogo-A were found in elevated 
levels in patients with MS and acute neurological diseases (Reindl et al., 
2003). There is a strong consensus in the literature linking the presence of 
anti-myelin antibodies with CNS tissue repair and that blocking interactions in 
the Nogo-Nogo receptor system present some benefits for nerve 
regeneration (Schnell and Schwab, 1990, Schnell and Schwab, 1993, 
Bregman et al., 1995, Brosamie et al., 2000, Buffo et al., 2000, Warrington et 
al., 2000, Bieber et al., 2001, Merkler et al., 2001, Warrington et al., 2001, 
Mitsunaga et al., 2002, Papadopoulos et al., 2002, Sicotte et al., 2003, 
Wiessner et al., 2003). A strong T cell response with detection of specific 
antibodies to the epitope as well as amelioration of induced MS-like 
symptoms was observed after immunisation with Nogo-A-derived peptides in 
experimental autoimmune encephalomyelitis (EAE) susceptible rats - animal 
model developed to investigate pathophysiological and therapeutic insights 
into the human disease MS (Fontoura et al., 2004). Moreover, myelin 
associated proteins including Nogo-A have been shown to persist for many 
years in oligodendrocytes cell bodies along spinal cord nerve tracts following 
degeneration distally to injury thus preventing successful re-innervation 
(Buss et al., 2005). Finally, increased levels of Nogo-A genes have been 
shown in lumbar spinal cord of symptomatic transgenic mice with ALS-like 
pathology (Dupuis et al., 2002). 
The Nogo-Nogo receptor system appears not to have been investigated in 
animal models of neuropathic pain as yet, including de-afferentation, and 
subsequently no association has been raised so far with chronic pain states. 
Little is known about the distribution of Nogo-A and Nogo-66 receptor in 
human CNS and PNS disorders. Our aim was to examine the distribution of 
Nogo-A and its receptor Nogo-66 in control and diseased human spinal cord 
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(MS and ALS) and in liuman uninjured and injured dorsal root ganglia and 
nerves. 
10.2. Materials 
In tine present study, liuman spinal cord from patients with MS and ALS and 
from control patients, control and avulsed DRG (acute and chronic), control 
nerves, injured proximal brachial plexus nerve specimens (acute and 
chronic), and painful human distal limb neuromas were used for the purpose 
of this study (Table 10.01). 
Table 10.01. Patients' characteristics. 
SC PM delay N Gender Age Range 
Control SC 5-92 hours 5 2 males & 3 females 57-85 years 
MS SC 5-11 hours 4 2 males & 2 females 38-79 years 
ALS SC 16-87 hours 5 3 males & 2 females 41-80 years 
DRG ^ Injury Duration N Gender Age Range 
Control 8 3 males & 5 females 45-91 years 
Acute 
(< 21 days) 
2 to 15 days 9 8 males & 1 females 18-27 years 
Chronic 
(> 21 days) 
28 to 120 days 5 5 males 9-38 years 
Nerve Injury Duration N Gender Age Range 
Control 8 5 males & 3 females 1-73 years 
BP Acute 
(< 21 days) 
4 to 16 days 10 8 males & 2 females 14-66 years 
BP Chronic 
(> 21 days) 
28 to 196 days 7 5 males & 2 females 20-38 years 
Neuroma 2 to 12 years 8 8 males 15-57 years 
SC = Spinal cord; PM = Post Mortem; BP = Brachial Plexus 
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Figure 10.01. Nogo-A (A-C) and Nogo-66 receptor (D-F) in human spinal 
cord. An increased number of positive motoneurones to Nogo-A were seen 
in MS spinal cord (B) and ALS (C) compared to controls (A). 
Immunoreactivity to the Nogo-66 receptor was more intense in 
motoneurones from MS spinal cord (E) than in control (D) and in ALS spinal 
cord (F). Magnification x110. 
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10.3. Results 
10.3.1. Nogo-A in spinal cord 
All spinal cords showed strong Nogo-A-immunoreactive nerve cell bodies 
and/or cells bodies of glial-type morphology scattered throughout the white 
and grey matter as well as some positive nerve fibres (Figure 10.01.A-C). 
For quantification of Nogo-A positive motoneurones in the ventral horn, 1 
control specimen showing too few motoneurones for adequate quantification 
was omitted from the analysis. Nogo-A positive and negative motoneurones 
were counted in both sides of the spinal cord from each of the 4 controls, 4 
MS and 5 ALS spinal cords. The number of Nogo-A positive motoneurones 
was expressed as % of total for each specimen. The analysis showed a 
significant increase in numbers of positive motoneurones in both MS (n = 4, 
70.25 ± 4.66, p < 0.02) and ALS (n = 5, 66.24 ± 7.78, p < 0.01) spinal cords 
compared to controls (n = 4, 33.32 ± 2.53, Figure 10.02). 
Control 
(n = 4) (n = 4) (n = 5) 
Figure 10.02. Nogo-A-IR (Mean ± SEM) in human normal and diseased 
spinal cord. A significant increase in the number of positive motoneurones to 
Nogo-A was observed in MS (n = 4, 70.25 ± 4.66, p < 0.02) and ALS (n = 5, 
66.24 ± 7.78, p < 0.01) spinal cord compared to controls (n = 4, 33.32 ± 
2.53). ** p> 0.01, * p> 0.02. 
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10.3.2. Nogo-66 receptor in spinal cord 
All spinal cords showed positive Nogo-66-receptor immunoreactive nerve cell 
bodies and/or cells bodies of glial-type morphology scattered throughout the 
white and grey matter (Figure 10.01.D-F). Positive and negative 
motoneurones to Nogo-66 receptor were counted in a similar fashion as for 
Nogo-A. The analysis showed a small significant increase in numbers of 
Nogo-66 receptor positive motoneurones in MS spinal cord only (n = 4, 67.36 
± 0.69, p < 0.03) compared to control spinal cord (n = 4, 58.15 ± 4.17, Figure 
10.03). 
- -
Control 
n = 5) (n = 4) (n = 4 
Figure 10.03. Nogo-66 receptor positive motoneurones (Mean ± SEM) in 
normal and diseased spinal cord. A significant increase in the number of 
positive motoneurones to Nogo-66 receptor was observed in MS spinal cord 
only compared to control spinal cord. * p > 0.03. 
Nogo-66 receptor immunoreactivity intensity of motoneurones was 
established from both sides of the spinal cord from each of the 5 controls, 4 
MS and 5 ALS spinal cords. A significant increase of intensity was observed 
using the visual inspection scale in motoneurones in MS (n = 4, 2.42 ±0.16, 
p < 0.005) and in ALS (n = 5, 1.93 ± 0.17, p < 0.05) compared to control (n = 
5, 1.44 ± 0.2, Figure 10.04). 
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Control 
n = 4) n = 4) (n = 5) 
Figure 10.04. Nogo-66 receptor immunoreactivity intensity in motoneurones 
(Mean ± SEI\/J) in normal and diseased spinal cord. A significant increase in 
intensity to Nogo-66 receptor was observed in diseased spinal cord. ** p < 
0.005, *p < 0.05. 
10.3.3. Motoneurones in spinal cord 
The number of motoneurones was tallied for each patient from two separate 
tissue samples by two independent observers, and a mean with SEM was 
generated for each group. Controls (n = 4, 30.92 ± 5.25) and ALS (n = 5, 
30.36 ± 4.74) showed similar number of motoneurones control whilst 
MS tissue samples presented less motoneurones (n = 4, 19 ± 2.57, Figure 
10.05). ALS should have presented less motoneurones compared to 
controls and MS. However such was not the case. Most likely the ALS 
samples were no longer representative of adequate lumbar sections where 
most of the neuronal loss occurs (Stephens and McMacken, 1997, Maihofner 
etal., 2003). 
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Control MS 
(n = 4) (n = 5) 
Figure 10.05. Number of motoneurones (Mean ± SEM) in normal and 
diseased spinal cord. 
10.3.4. Nogo-A and Nogo-66 receptor in DRG 
Nogo-A antibodies gave strong immunostaining of fibres and sensory 
neurons of all size with most cells positive in control DRG (Figure 10.06.A) 
and some weak or negative cells mainly in injured DRG (Figure 10.06.B). 
Significant decrease in the percentage of large Nogo-A-positive neurons was 
observed in injured acute DRG (n = 9, 67.58 ± 5.94, p < 0.03) compared to 
controls (n = 8, 83.38 ± 3.7, Figure 10.07). 
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Figure 10.06. Nogo-A in uninjured and avulsed DRG. Nogo-A was present 
in most sensory neurons and fibres in control (A) but lesser large positive 
neurones were observed in injured DRG (B). Despite the decrease of Nogo-
A positive neurons in acute injured DRG, there were still plenty of intensely 
positive, small and large calibre nerve fibres with some neurons showing 
weak soma but with intense axonal hillock and axon (insert). Magnification 
x110 (insert in B x400). 
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Nogo-66 receptor was seen in a few small/medium sensory somata whilst 
most large somata were negative. No change of Nogo-66 receptor 
immunoreactivity in DRG after injury. 
Control Acute Chronic 
Figure 10.07. Percentage of large Nogo-A positive sensory neurones (Mean 
± SEM) in control and avulsed DRG. A significant increase in large Nogo-A 
positive sensory neurones was observed in injured acute DRG compared to 
controls. * p < 0.03. 
10.3.5. Nogo-A and Nogo-66 receptor in nerves 
Nogo-A was present in nerve fibres of all calibre in control nerve, neuromas 
and proximal and distal injured nerves (Figure 10.08). The ratio of Nogo-A 
and NF positive fibres close to one for most samples, indicating that the 
majority of fibres express Nogo-A. No obvious change in density or intensity 
of Nogo-A immunostaining after injury. Nogo-66 receptor immunoreactivity 
was seen in a subset of fibres in all samples with no change after injury. 
When Nogo-A antibody was pre-incubated with Nogo-A fusion protein at 
3|ig/mL, staining was completely inhibited. Nogo-A positive neurons and 
fibres started to appear when antigen at concentration less than 0.3 
micrograms/mL was pre-applied with antibody (data not shown). 
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Figure 10.08. Nogo-A in nerve fibres of uninjured and injured human nerve. 
A similar patter of immunoreactivity was seen in controls (A) and in injured 
nerves (B). Magnification x110. 
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10.4. Discussion 
All spinal cords showed strong Nogo-A-immunoreactive nerve cell bodies 
and/or cells bodies of glial-type morphology scattered throughout the white 
and grey matter as well as some positive nerve fibres. Diseased spinal cord 
showed however increased expression of Nogo-A and of Nogo-66 receptor 
in motoneurones compared to controls. The abundance of Nogo-A (the 
strong intensity of its immunostaining) makes it difficult to detect any change 
in the synthesis of Nogo-A protein after nerve rupture by 
immunohistochemistry and image analysis of the proximal stump of the 
lesioned nerves, adding also the possible translocation and accumulation of 
the protein from the soma on to the proximal nerve axon. Motoneurone 
count showed no loss of motoneurones in our ALS cohort as would be 
expected. Therefore ALS results should be interpreted with caution. 
Nevertheless, these preliminary findings would support the proposal that 
blockade of Nogo-A and its receptor are potentially of therapeutic value in 
neurodegenerative and neuro-inflammatory CNS disorders, including MS 
and ALS. 
Previous studies have shown that the neurite outgrowth inhibitor Nogo-A is 
involved in autoimmune-mediated demyelination. EAE-susceptible mice 
(MS-like disease animal model) were vaccinated against Nogo-A prior the 
induction of EAE. Immunisation reduced the incidence and severity of EAE 
as well as the production of antibodies to Nogo-A. Moreover, using Nogo-
deficient mice, it was shown that the clinical course of EAE could be altered 
such as delayed onset, reduction in duration of illness and milder clinical 
symptoms compared to the wild-type (Karnezis et al., 2004). Functional 
recovery in spinal cord injured rats was investigated after administration of 
Nogo-A neutralising antibodies. It was shown that monoclonal antibody 
(mAb) IN-1 treatment was beneficial in locomotor function recovery after 
lesioned spinal cord and it was suggested that this type of treatment was 
responsible for allowing new outgrowth of uninjured as well as injured nerve 
fibres. In this study, Nogo-A neutralisation presented apparent regenerative 
and structural plastic capabilities in the CNS by rewiring the motor systems 
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(Merkler et al., 2001). Sprouting and structural reorganisation of injured and 
uninjured nerve fibres has been further demonstrated in adult rats at a level 
that is usually only observed after perinatal lesions (Thallmair et al., 1998, 
Z'Graggen et al., 1998, Z'Graggen et al., 2000). 
The underlying mechanism to account for the increase in the Nogo-A 
molecule as its receptor in neurodegenerative and neuro-inflammatory CNS 
disorders remains to be explained. It could be argued that inflammatory 
agents could play a role in the increase of the Nogo-Nogo receptor system, 
since an inflammatory response is present in MS pathophysiology (Bruck 
and Stadelmann, 2003) and is a potential candidate in ALS pathogenesis 
(McGeer and McGeer, 2002, Malaspina and de Belleroche, 2004). 
Microglia/macrophage type cells have been shown to support regeneration 
not only by removing debris via phagocytosis but also by producing agents to 
create a favourable neuronal environment (Lotan et al., 1994, Barron, 1995). 
One particular study investigated several potential inflammatory-related 
axonal CNS regeneration cytokines and neurotrophic factors in differentiated 
human neurones but failed to found any effect on Nogo-A mRNA expression 
(Satoh and Kuroda, 2002). 
The Nogo-Nogo receptor system appears not to have been investigated in 
animal models of neuropathic pain as yet and subsequently no association 
has been raised so far with chronic pain states. Plasticity in neuropathic pain 
is thought to play an important role in generating abnormal pain such as 
hypersensitivity or allodynia (Scholz and Woolf, 2002). Changes to normal 
nociception function such as neurochemical changes (post-translational and 
transcriptional changes) and structural changes (synaptic connectivity) in the 
dorsal horn of the spinal cord can dramatically alter threshold, excitability 
(ectopic excitability) and transmission properties of nociceptors, contributing 
to pain hypersensitivity and spontaneous pain (Woolf and Mannion, 1999, 
Scholz and Woolf, 2002). Peripheral nerve injury can result in spontaneous 
ectopic activity (Wall and Gutnick, 1974a, Wall and Devor, 1983). It is 
thought that this response to the injury-discharge evoked or excitotoxic 
changes can lead to the death of local inhibitory cells in the dorsal horn 
215 
(Sugimoto et al., 1987, Hamaetal., 1996). Over-activity of sensory A-fibres 
using glutamate as a transmitter was shown to result in the loss of 25% of 
neurones in lamina III, main site of termination of Ap-fibres. It was 
suggested that stimulation-induced neuronal cell death in the dorsal horn of 
the adult rat spinal cord might contribute to the development of chronic pain 
(Coggeshall et al., 2001). Since glutamate is a potential candidate 
responsible for central sensitisation in neuropathic pain (Willis, 2001), 
inhibition of glutamatergic activity was investigated in an animal model of 
neuropathic pain, the chronic constriction injury model. The mGlu5 
glutamate receptor was directly associated with neuronal cell death 2-3 days 
post operation and administration of an antagonist provided sufficient 
neuroprotection to alleviate thermal and mechanical hyperalgesia. It was 
concluded that this receptor was crucial in neuropathic pain pathogenesis 
(de Novellis et al., 2004). 
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CHAPTER XI 
DISCUSSION 
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11.1. Introduction 
It was only recently that the immune system was also considered to play a 
part in the development and maintenance of neuropathic pain (Watkins and 
Maier, 2002). As discussed previously, inflammatory pain and neuropathic 
pain were considered to be separate categories with only a small overlap 
representing the neuro-inflammatory mechanisms. New evidence has 
however blurred the margins of this overlap and a new conceptual approach 
to inflammatory pain and neuropathic pain has emerged. Instead, a 
continuum, with each one on either side of the spectrum, was postulated 
(Backonja, 2003). Several clinical cases of neuropathy have since been 
associated with inflammation of the peripheral nervous system. For 
instance, complex regional pain syndromes has been suggested to be the 
result of neurogenic inflammation (Bennett, 2001, Weber et al., 2001), the 
acute inflammatory neuropathy Guillain-Barre syndrome is associated with 
chronic pain sensations (Moulin et al., 1997, Hughes et al., 1999), in 
vasculitis neuropathies it was suggested that the attack of the immune 
system on peripheral nerve blood vessels was the cause of chronic pain 
states (Said and Lacroix, 2005) and inflammatory mediators released by the 
damaged disc have been found to be the culprit in generating low back pain 
following herniated discs (Ahn et al., 2002, Burke et al., 2002). With the 
evidence from this project and summarised thereafter, post-traumatic 
neuropathic pain should most likely be added to above list of neuropathies 
associated with inflammation. 
Animal models of nerve trauma support the notion that the immune system 
might play a more important role than initially thought in pain. As discussed 
in length across this project, studies have demonstrated that several 
inflammatory cell types (mostly macrophages and microglia) play a 
considerable role in the development and maintenance of neuropathic pain. 
The paradigm that the activation of immune cells, discussed previously in 
detail (see Figure 01.06), may contribute to development and/or the 
maintenance of pain has been now well been accepted (Watkins et al., 
2001). The main impetus behind this considerable body of evidence was to 
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increase tine effectiveness of treatment strategies in patients with chronic 
pain. One of the main difficulties in finding adequate treatment protocols for 
clinicians was that treatment was focused on alleviating symptoms rather 
than targeting specific mechanisms. Within one neuropathic pain syndrome 
numerous heterogeneous patterns of symptoms can be found, each 
generated by a specific pain mechanism (Dworkin, 2002). The identification 
of specific pathophysiological mechanism is therefore of great importance in 
order to better target treatment. The evidence herein would support a shift 
towards the trend of a mechanism-based classification of pain (Craig, 2003). 
11.2. Main findings and their significance 
The first insights into the neuro-inflammatory mechanism in patients with 
post-traumatic neuropathic pain were proposed and presented in this thesis. 
Previous efforts in finding the cause of chronic neuropathic pain as well as 
new treatment options were essentially focused on the nervous system. 
Several mechanisms of neuronal dysfunction have been determined and 
helped to advance the understanding of pathophysiological mechanisms in 
neuropathic pain. However, even with the contribution of these novel 
mechanisms, numerous therapeutic strategies failed to provide adequate 
relief for most patients. The main finding of this work was the presence of a 
significant inflammatory component in the peripheral nerves of patients with 
post-traumatic neuropathic pain. With the tissue samples available, we were 
able to cover a wide range of illness duration i.e. time elapsed between the 
injury and the collection and were able to establish the presence of 
macrophages immediately after injury and remaining present over many 
years. Cox-2, an enzyme involved in the biogenesis of prostaglandins was 
found to be expressed, mostly in macrophages, from 2-3 weeks with a peak 
at 40 days and also over many years. Another isoenzyme, Cox-1 was 
expressed mostly during the chronic stage. Findings from the chronic CCI 
rat model were in support of the human studies and also showed an increase 
in microglia/macrophage-like Cox-2 immunoreactive cells in the ipsilateral 
spinal cord grey matter (Lamina l-ll) at 40 days post-operation. 
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Prostaglandin receptors EP1 and EP4 were found to be expressed in human 
injured peripheral nerves immediately after injury, and over many years. The 
increase of EP1 preceded the Cox-2 peak. EP1 receptor appeared also 
elevated in acute sensory DRG while the EP4 receptor expression was 
decreased in sensory DRG suggesting a translocation of this receptor from 
the soma to the nerve axons. Finally, EP1 receptor and Cox-2 expressing 
microglia/macrophages cells were observed in inflamed human spinal cord. 
Further immune activity was found to be present in human peripheral nerves. 
Cathepsin S, an enzyme involved in the antigen presentation was mostly 
expressed acutely. The presence of this enzyme suggest the recruitment of 
further macrophages or other APC as well as other immuno-competent cells 
including lymphocytes which were also found to be present immediately after 
injury and over a long period of time. A subset of lymphocytes, T helper cells 
{CD4^), appeared only half-way through the acute stage and remained above 
baseline levels over the entire time course. It is believed that the 
lymphocytes (CD3''/CD4") present prior to the appearance of T helper cells 
must have been T cytotoxic cells and must have assisted macrophages and 
contributed to the removal of damaged tissue. An attempt was made using 
the chronic CCI rat model to assess whether changes in the immune profile 
could be detected in the peripheral blood in view to be used as a potential 
biomarker in humans but too little significant results emerged from this trial to 
pursue this line of investigation. Finally, an increase of the Nogo-Nogo 
receptor system in inflamed human spinal cord was demonstrated. It was 
suggested that the peripheral immune response might play a role in delayed 
axonal regeneration and in the maintenance of chronic pain. 
11.3. Cox-2 and EP1 as therapeutic targets 
The successful treatment of neuropathic pain following peripheral nerve 
injury with NSAIDs remains under debate as few clinical trials examined their 
effectiveness in humans. Further investigations are required, including 
studies of chronic non-painful human neuromas, to establish a link between 
EP1 and Cox-2 levels with pain in patients with post-traumatic neuropathic 
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pain. Potential therapeutic window opportunities for presumed optimal trial of 
specified treatment remains to be fully investigated and are summerised in 
the figure below (Figure 11.01). 
EP1 Inhibition 
Cats inhibition 
Cox-2 Inhibition 
EP4 Inhibition 
Cox-1 Cox-1 Inhibition 
Cox-2 
Cats 
2 weeks 1.5 month Months Years 
Figure 11.01. Potential therapeutic window opportunities proposal. This 
schematic representation shows time after injury and inflammatory markers 
and the presumed optimal time for trial of specified treatment. 
However, a number of clinical and animal model pharmacological studies 
suggest that Cox-2 and EP1 are key therapeutic targets in inflammatory and 
neuropathic pain. 
More recent research with the use of a new generation of NSAIDs selective 
to the second isoform of the cyclooxygenase enzyme (Cox-2) has shown, as 
far as the effectiveness was concerned, confounding results to date. For 
instance, one study showed considerable reduction of mechanical 
hypersensitivity following intrathecal administration of a Cox-1 inhibitor 
(ketorolac) and two Cox-2 inhibitors (piroxicam & NS-398) in a model of 
peripheral nerve injury. Once the agents were intrathecally delivered at 
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different time points 4 weeks post partial sciatic nerve ligation, paw 
withdrawal threshold to mechanical stimulation (von Frey filaments) was 
quantified. One i.t. injection of ketorolac alleviated mechanical 
hypersensitivity for nearly one week. NS-398 i.t. showed a much shorter 
duration of anti-hypersensitivity whilst piroxicam was ineffective. They 
concluded that prostaglandins were important in the maintenance of 
hypersensitivity following peripheral nerve injury. Thus, Cox inhibition with 
prolonged duration of action by ketorolac could present potential therapeutic 
benefits for some neuropathic pain sufferers (Ma et al., 2002). 
The selective GlaxoSmithKline Cox-2 inhibitor, GW406381X, was shown to 
be effective in reducing mechanical allodynia in the CCI rat model, and 
thermal hyperalgesia in the mouse partial ligation model, both animal models 
of neuropathic pain. GW406381X was also effective in reducing pain 
behaviour when given intrathecally and orally to rats with capsaicin-induced 
inflammatory pain (Bingham et al., 2004). The selective Cox-2 inhibitor, 
etodolac, administered orally, reduced heat-evoked hyperalgesia in rats with 
chronic constrictive sciatic nerve injury (Suyama et al., 2004). Other Cox-2 
inhibitors such as celecoxib and rofecoxib, however, are effective in 
inflammatory pain but did not alter neuropathic pain behaviour. 
Intraperitoneal injection of Rofecoxib, a selective cox-2 inhibitor, did not 
prevent the development of allodynia and hyperalgesia in the spared nerve 
injury model (Broom et al., 2004). 
EP1 antagonists may also be effective in neuropathic, inflammatory and 
incisional pain models. In the CCI model, oral administration of an EP1 
antagonist from 8 to 14 days post-operation effectively reduced CCI-induced 
mechanical hyperalgesia and allodynia (Kawahara et al., 2001). In another 
animal model of neuropathic pain (partial ligation of the sciatic nerve), 
mechanical and thermal hyperalgesia was reversed with a EP1 receptor (SC-
19220) antagonist (Syriatowicz et al., 1999). EP1 receptor antagonists 
reduced the response to formalin-induced inflammation (Malmberg and 
Yaksh, 1992a, Malmberg et al., 1994). Spinal application of EP agonists (7-
11 hours post peripheral inflammation) in an inflammatory rat knee joint 
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model demonstrated that EP1 (ONO-DI-004), EP2 (butaprost) and EP4 
(ONO-AE1-329) agonists all generated spinal hyperexcitability similar to 
PGE2 (Bar et al., 2004). In a rat model of postoperative pain administration 
of an EP1 antagonist (ONO-8711) generated analgesic effects on 
mechanical evoked pain (Omote et al., 2001, Omote et al., 2002b). Similar 
inhibitory effects on mechanical hyperalgesia with the same EP1 antagonist 
were shown in a carrageenan-induced inflammatory model further 
strengthening the link between increased PGE2 levels and persistent pain 
(Nakayama et al., 2002). The second phase, but not the first phase, of 
formalin-induced flinching behaviour in the paw was effectively inhibited by 
spinally administered EP1 receptor antagonists (SC-51089 and SC-51234A, 
Malmberg et al., 1994). Importantly, the involvement of PGE2 in sensitisation 
via the EP1 receptor has also been shown in human oesophageal pain 
hypersensitivity, with the successful use of an EP1 antagonist (Sarkar et al., 
2003). 
Very few systematic studies have been undertaken to date investigating the 
specific role of EP4 receptor in animal models of peripheral nerve injury. A 
number of selective EP4 agonist have been described (Maruyama et al., 
2001, Maruyama et al., 2002, Billot et al., 2003, Wilson et al., 2006). Finding 
potent and effective selective EP4 receptor antagonists has proven to be 
more difficult - one reason most likely being that EP4 present, in 
pharmacology terms, close resemblance to EP2. Nevertheless, a small 
number of EP4 receptor have been described to date such as EP4A 
(Machwate et al., 2001), ONO-AE2-227 (Mutoh et al., 2002), the 
diphenyloxazole 'compound 8' and the N5-Z-0rnithine 'compound 11' 
(Hattori et al., 2005) and GW627368X (Wilson et al., 2006). Furthermore, 
since this receptor was predominantly associated with the immune system, 
most investigations with EP4 receptor in pain were mostly carried out using 
inflammatory pain models. For instance, using a collagen-induced arthritis 
mouse model, inflammation was significantly reduced with an EP2 agonist 
and an EP4 agonist (ONO-AE3-208) combined (Honda et al., 2006). 
Moreover, in a study mentioned previously in relation to EP1, it was shown 
that PGE2 induced central sensitisation was achieved, in a similar fashion, 
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with spinal application of the EP4 agonist (ONO-AE1-329). However, the 
lack of available EP4 specific antagonists left this study inconclusive as the 
specific role of EP4 in inflammatory-evoked central sensitisation was 
concerned (Bar et al., 2004). Using mice lacking an opioid receptor and its 
endogenous llgand (noclceptin or orphanin FQ) showed that EP4 agonist 
(ONO-AE1-329) induced allodia through the intermediate of the endogenous 
ligand in the spinal cord (Okuda-Ashitaka et al., 2006). EP4 agonist was 
also investigated in an NMDA-induced brain excitotoxicity mouse model 
since activation of intracellular signal molecules such as protein kinase C 
and activation of the arachidonic acid cascade can lead to the excitability of 
postsynaptic cells through activation of NIVIDA receptors and consequently to 
overexpression of cyclooxygenase (Chen and Huang, 1992, Miller etal., 
1992, Nishizawa, 2001). EP4 agonist (ONO-AE1-329) significant decreased 
the NMDA-induced neurotoxicity effect in mouse brain (Ahmad et al., 2005) 
Positive EP4 cells were observed in the contralateral sciatic nerve after 2 
and 4 weeks post partial sciatic nerve ligation (Seltzer model). The staining 
was found to be nuclear. About 30% of EP4+ cells were co-localised with a 
macrophage marker (EDI) and 50% of the macrophages co-expressed the 
prostaglandin receptors EP1 and EP4. It was proposed that the PGE2 
overproduction by infiltrating macrophages may be involved in the 
pathogenesis of pain and that PGE2 can act in an autocrine and paracrine 
fashion via EP1 and EP4 receptors on macrophages (Ma and Eisenach, 
2003b). Further investigations demonstrated that PGE2 was also involved in 
an increase of IL-6 occurring in infiltrating macrophages via the EP4 receptor 
and the protein kinase C signalling pathway and that IL-6 release could be 
suppressed with a selective EP4 receptor antagonist L-161982 (Ma and 
Quirion, 2005). Several other lines of research using cell culture techniques 
established that PGE2 suppressed production and release of a number of 
chemokines in human macrophages such as matrix metalloproteinases and 
IL-8 through the activation of the EP4 receptor. EP4 receptor antagonist was 
able to reverse the PGE2-mediated suppression of chemokine production 
(Takayama et al., 2002, Takayama et al., 2006). 
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11.4. Methodological considerations 
Efforts in standardising immunoliistochemical methods have considerably 
increased over the last years as more immunohistochemical methods are 
used as a diagnostic tool (Taylor, 2000, O'Leary, 2001, Grube, 2004). Some 
of the pitfalls and limitations in immunohistochemical methods were 
previously briefly reviewed (Dalquen et al., 1993, Leong, 1996, Leong, 2004). 
While the highest standards with adequate controls (negative and internal) 
were observed to maintain a reliable method of quantification and 
immunohistochemical staining throughout this work, methodological 
shortcomings were encountered. One of the limitations has been discussed 
in chapter III. For the co-localisation of Cox-2 and CD68, serial sections 
method was used rather then double immunostaining technique. The 
APAAP technique requires that one antibody is raised in mouse and the 
other in rabbit. Such combination was not always available when conducting 
the study therefore Cox-2-1R and CD68-IR was assessed on serial sections. 
Constant efforts were made during this project to find Cox-2 and CD68 
markers raised in rabbit. When a rabbit polyclonal antibody to human CD68 
became available, double immunostaining was conducted on one injured 
nerve and corroborated existing data. 
COX-2/CD68 co-localisation on serial sections presented an additional 
advantage over the double staining method. The visualisation of 
immunohistochemical reactivity in the standard immunohistochemical 
protocol used throughout this project was nickel-enhanced, generating a 
black stain. The APPAP technique in addition to the black chromogen 
(antibody raised in rabbit) used a red chromogen as the standard second 
staining for the antibody raised in mouse. Consequently, CD68-IR appeared 
in black and Cox-2-1R in red. CD68 antigen is expressed in the cytoplasm on 
lysosome (Company data sheet) whilst Cox-2 is localised on the nuclear 
membrane and on the ER (Regier et al., 1995). On some occasions the 
CD68 staining covered the Cox-2 staining in red rendering co-localisation 
difficult to assess (Figure 03.02). 
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A number of controls are used to validate tine interpretation of 
immunohistochemical stains (O'Leary, 2001). For instance, specific antigen-
antibody reaction of primary antibody can be confirmed by either using 
corresponding target antigen or by replication of staining with other similar 
commercially available antibody from a different company preferably. Some 
other markers such as the mouse monoclonal anti-CD68 and mouse 
monoclonal rat anti-CD11b (0X42) are well established and described in 
numerous previous publications. Two goat polyclonal anti-Cox-2 antibodies, 
mouse monoclonal anti-Cox-1 were especially purchased to replicate 
staining of prior antibodies (Table 02.01). Specificity of the primary antibody 
can also be confirmed by other immunohistochemical techniques such as 
Western blotting. 
Furthermore, not all antibodies purchased for purpose of the present 
research project achieved acceptable staining quality. Another enzyme 
involved in the production of prostaglandin, PGE synthase, and several p38 
MAP Kinase proteins involved in the intracellular signalling pathway of Cox-2 
transduction, were also investigated. All antibodies to PGE synthase and to 
p38 showed non-specific staining. No changes to the immunohistochemical 
protocol were applied to maintain consistent and reliable immunostaining 
across experiments. Another outcome (Chapter VIII) depends on the 
availability and the avidity of specific cell markers. Markers to identify 
dendritic cells (e.g. HLA-DR), B lymphocyte cells (e.g. CDS or CD20) and 
mast cells (e.g. c-kit/CD117) will be required to determine the exact profile of 
Cats expressing professional APC present in the injured nerves. A marker 
to identify mast cells (c-kit/CD117) was acquired and tested but showed non-
specific staining. 
Antibodies availability was not the only factor imposing a limitation on the 
outcome of an experimental investigation. Tissue availability was another 
factor that could influence or impede the course or/and the outcome of a 
research project. Access or availability is sometimes limited. In chapter IV, 
the limited number of nerve samples available for Western blotting was a 
contributing factor in the differential finding of Cox-2 expression across 
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methodologies. Furthermore, motoneurone quantification in chapter XI 
revealed that the ALS spinal specimens were no longer representative of the 
disease process and no other ALS spinal cord became available in time to 
repeat some of the evidence. However, since the findings and interpretation 
were based on diseased spinal cord which also included suitable MS spinal 
cord, the data should not be discarded, but instead considered as preliminary 
until results are duplicated. Despite presenting some restrictions, 
immunohistochemical staining is a widely used and accessible laboratory 
technique that enabled, via specific antigen-antibody interaction, rapid and 
cost-effective visualisation of the distribution, localisation and quantity of 
proteins and cells in tissue. 
11.5. Future directions 
A number of further investigations would contribute in confirming some of the 
evidence presented here, and advance knowledge on chronic neuro-
inflammatory neuropathic pain mechanisms. Future research could 
overcome some of methodological considerations encountered and 
mentioned above, i.e. availability of new markers and/or additional human 
tissues. Furthermore, other techniques could be investigated. Identification 
of gene expression profile has been conducted in different rat models of 
peripheral nerve injury, and has identified a number of differentially 
expressed genes (Xiao et al., 2002, Schmitt et al., 2003). Newer 
methodologies such DNA oligonucleotide microarrays are currently in use 
and cover the whole human genome (Moran et al., 2006). Identification of 
differentially expressed genes in peripheral nerves from patients with post-
traumatic painful neuropathy could contribute in isolating novel 
pathophysiological pathways and could provide potential novel targets of 
therapeutic value. Confocal microscopy and the use of fluorescent dyes are 
currently the technique par excellence to assess distribution pattern of two 
different proteins within one location or one cell in co-localisation studies. 
Co-localisation studies between Cox-2 and CD68 (macrophage marker) or 
other markers using light fluorescent microcospy or confocal microscopy 
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could benefit from those more advanced techniques whenever available. 
Moreover, since prostaglandin production and release appears to be cell 
dependent and time dependent (Tilley et al., 2001), it would be useful to 
assess prostaglandin profile over time in neurones and other cells such 
macrophages or microglia using a cell culture injury model in order to assess 
whether the prostaglandins released are, in fact, friend or foe in chronic pain 
states. Finally, specific T helper cell subtypes with their cytokine profile 
(pro- or anti-inflammatory) remains to be determined in injured peripheral 
nerves from patients with post-traumatic painful neuropathy. 
11.6. Conclusion 
In conclusion, it was hypothesized that nerve injury in humans and animal 
models is associated with increased levels of Cox-2 at the site of injury, 
expressed in non-neuronal cells, and that these peripheral changes drive 
further neuro-inflammatory processes in the CNS. These central changes in 
turn contribute to the maintenance of hypersensitivity and chronic 
neuropathic pain. Increased levels of Cox-2-1R in the peripheral injured 
nerve, and in the ipsilateral spinal cord in rodents, were observed primarily in 
microglia/macrophage-like cells. The peak of Cox-2 expression found in the 
human injured nerve, at around 40 days, would invite selection of patients at 
this possible window of therapeutic efficacy for controlled clinical trials of 
specific Cox-2 inhibitors to treat and prevent the development of persistent 
pain. 
Furthermore, a rapid increase of EP1 receptor levels in injured human 
sensory neurones was found to precede Cox-2 expression in infiltrating 
macrophages. Chronic painful human neuromas showed persistence of 
EP1-IR in nerve fibres and increased Cox-2-1R in macrophages. EP1 
antagonists may show therapeutic effects in acute and chronic neuropathic 
pain, in addition to inflammatory pain. 
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Finally, the number and intensity of Nogo-A and Nogo-66 receptor positive 
motoneurones were significantly increased in MS and ALS spinal cord. The 
data supports blockade of Nogo-A and its receptor as being potentially 
therapeutic in neurodegenerative and neuro-inflammatory disorders. The 
marked presence of Nogo-A with low Nogo-66 receptor levels in peripheral 
nerves indicate additional roles, such as axonal guidance, in the developing, 
adult and regenerating peripheral nervous system. 
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APPENDICES 
Appendix 1. List of chemicals used in immunohistochemistry 
Product Name Company name, 
City, Country 
Code 
Poly-L-Lysine hydrobromide 
(CeHizNzO HBr)n 
MolWt (150,000-300,000) 
SIGMA, Gillingham, 
UK 
P-1399 
OCT Embedding Medium Raymond A Lamb, 
Eastbourne, UK 
4583 
Paraformaldeliyde GPR 
(H.CHO)n 
VWR International 
Ltd, Poole, UK 
294474L 
Sodium Chloride 'AnalaR' 
(NaCI = 58.44 g/mol) 
VWR International 
Ltd, Poole, UK 
102415K 
Potassium dihydrogen orthophosphate 
'AnalaR' 
(KH2PO4 = 136.09 g/mol) 
VWR International 
Ltd, Poole, UK 
102034B 
Sodium dihydrogen orthophosphate 
di hydrate GPR 
(NaH2P04.2H20 = 156.01 g/mol) 
VWR International 
Ltd, Poole, UK 
3013240 
Spirit Methylated Industrial GPR 
Industrial Methylated Spirit 
VWR International 
Ltd, Poole, UK 
30244 DN 
Hydrogen Peroxide solution about 30% 
H2O2 GPR 
VWR International 
Ltd, Poole, UK 
285194F 
Donor Horse Serum TCS Biosciences Ltd, 
Botolph Claydon, UK 
HA002 
Donor Goat Serum TCS Biosciences Ltd, 
Botolph Claydon, UK 
GS008 
Albumin Bovine 
Fraction V minimum 96% 
(electropheris) 
SIGMA, Gillingham, 
UK 
A-9647 
Sodium Azide VWR International 
Ltd, Poole, UK 
301114Y 
di-Ammonium nickel(ii) sulphate 6-
hydrate GPR (ammonium nickel 
sulphate) 
(NH4)2S04.NiS04.6H20 
M.W.394.97 
VWR International 
Ltd, Poole, UK 
271894F 
3,3'-diaminobenzidine tetra-
hydrochloride di hydrate, 97% 
ALDRICH, 
Gillingham, UK 
261890-
25G 
D-(+)-Glucose (C6H12O6) Dextrose: 
Corn sugar 
SIGMA, Gillingham, 
UK 
G-7528 
Glucose Oxidase SIGMA, Gillingham, 
UK 
G-2133 
Ammonium Chloride 'AnalaR' 
NH4CL 
VWR International 
Ltd, Poole, UK 
100173D 
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M.W.53.49 
Acetic Acid Glacial 'ARISTAR' 
CH3COOH M.W.60.05 
VWR International 
Ltd, Poole, UK 
450015K 
Neutral red Gurr Certistain for 
microscopical staining 
VWR International 
Ltd, Poole, UK 
340564A 
Sodium Acetate 3-hydrate GPR 
CHs.COONazO M.W. 136.08 
VWR International ^ 
Ltd, Poole, UK 
301034J 
Xylene low in sulphur GPR 
C6H4(CH3)2 M.W. 106.17 
VWR International 
Ltd, Poole, UK 
305756G 
SIGMA FAST'^ FAST RED 
TR/NAPHTHOL AS-MX TABLESTS 
SETS 
SIGMA, Gillingham, 
UK 
F4648 
APAAP 
Appendix 2. List of chemicals used in Western blotting 
Product Name Company name, 
City, Country 
Code 
ProtoGel Stacking Buffer National 
Diagnostics, Hessle, 
UK 
EC-893 
ProtoGel Buffer 
4x ProtoGel Resolving Buffer 
National 
Diagnostics, Hessle, 
UK 
EC-892 
Ammonium Persulfate National 
Diagnostics, Hessle, 
UK 
EC-504 
Aprotinin 
(Protease Inhibitor) 
SIGMA, Gillingham, 
UK 
A-6279 
TEMED 
Tetramethylethylenediamine 
National 
Diagnostics, Hessle, 
UK 
EC-503 
Phenylmethylsulfonyl Fluoride (PMSF) 
C7H7FO2S F.W.I74.2 
SIGMA, Gillingham, 
UK 
P7626 
Methanol 'AnalaR' 
Methyl Alcohol 
CH3OH M.W.32.04 
VWR International 
Ltd, Poole, UK 
101586B 
Tris(hydroxymethyl)aminomethane 
ECL Plus Western Blotting Detection 
Reagent 3000cm^ 
Amersham 
Biosciences UK Ltd, 
Little Chalfont, UK 
RPN2133 
Protogel National 
Diagnostics, Hessle, 
UK 
EC-890 
Butan-2-ol 'AnalaR' 
CH3.CH2.CH(0H).CH3 M.W.74.12 
VWR International 
Ltd, Poole, UK 
103165P 
20% SDS solution Ultra Pure National 
Diagnostics, Hessle, 
EC-974 
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UK 
NP-40 
(non-ionic detergent to extract proteins) 
492016-
100 
Non-Fat Dried IVIilk Powder 
Blotting Grade Blocl<er 
BioRad, Hemel 
Hemstead, UK 
170-6404 
Tween 20 Ultra Pure National 
Diagnostics, Hessle, 
UK 
EC-607 
Sodium Deoxycholate 
C24H3904Na M.W.414.56 
VWR International 
Ltd, Poole, UK 
430353P 
Ethylenediaminetretraacetic Acid 
Disodium Salt Dihydrate (EDTA) 
CioHi4N2Na208 • 2H2O F.W.372.2 
SIGMA, Gillingham, 
UK 
E4884 
Ponceau S 'Electran' VWR International 
Ltd, Poole, UK 
440832H 
Bio-Rad Protein Assay 
Dry Reagent Concentrate 
BioRad 
Laboratories GmbH, 
Munich, Germany 
500-0006 
TRIS/Glycine/SDS 10X Ultra Pure 
(Electrophoresis Running Buffer) 
National 
Diagnostics, Hessle, 
UK 
EC-870 
Appendix 3. List of chemicals used in autoradiography 
Product Name Company 
name, City, 
Country 
Code 
TRIZMA® BASE 
(Tris[hydroxymethyl]aminomethane) 
C4H11NO3 M.W.121.14 
SIGMA, 
Gillingham, UK 
T-1503 
Hydrochloric Acid 'AnalaR' 
Specific Gravity 1.18 
HCI M.W.36.46 
VWR 
International Ltd, 
Poole, UK 
101256J 
R-[N-methyl-H^] PK 11195 ethanol 
solution, specific activity 3.11 TBq/mmol 
84Ci/mmol 
Amersham 
Biosciences UK 
Ltd, Little 
Chalfont, UK 
Custom 
synthesised 
Developer 
llford PQ Universal 
llford Imaging 
UK Limited, 
Mabberley, UK 
65B028 
Fixer 
llford Hypam 
llford Imaging 
UK Limited, 
Knutsford, UK 
63A004 
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Appendix 4. List of chemicals used in flow cytometry 
Product Name Company name, City, Country Code 
FACS"^ Lysing Solution 
10X Concentrate 
Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA 
349202 
Appendix 5. List of materials and equipment 
Apparatus Company name, City, Country Code 
OFT 5000 Cryostat Bright Instruments Co Ltd, 
Huntington, UK 
Superfrost Microscope 
Slides (76 x 26 mm) 
VWR International Ltd, Poole, 
UK 
631-0117 
Cover Glass (22 x 50 mm, 
Thickness No. 1) 
VWR International Ltd, Poole, 
UK 
631-0137 
Petri Dish (standard style, 
150 mm of diameter) 
VWR International Ltd, Poole, 
UK 
Hyperfilm - ''H 
(18 X 24 cm) 
Amersham Biosciences UK Ltd, 
Little Chalfont, UK 
RPN535B 
Autoradiographic [^H] 
Microscale 
(0.111-4.07kBq/mg, 3-
lOOnCi/mg) 
Amersham Biosciences UK Ltd, 
Little Chalfont, UK 
RPA506 
Autoradiographic [^H] 
Microscale 
(3.7-592Bq/mg, 0.1-
16nCi/mg) 
Amersham Biosciences UK Ltd, 
Little Chalfont, UK 
RPA507 
Hypercassette' 
(18 X 24 cm) 
Amersham Biosciences UK Ltd, 
Little Chalfont, UK 
RPN13642 
Hamilton Microlitre Syringe 
(lOOgl) 
Mini-PROTEAN 11'^  Vertical 
Electrophoresis System 
BioRad, Hemel Hemstead, UK 
Trans-blot SD Semi-Dry 
Transfer Cell 
BioRad, Hemel Hemstead, UK 
Four-colour FACSCalibur 
flow cytometer 
Becton Dickinson 
Immunocytometry Systems, San 
Jose, CA, USA 
Hyperfilm ECL'^ Amersham Biosciences UK Ltd, 
Little Chalfont, UK 
RPN3103K 
Hybond-P 
Membrane optimised for 
protein transfer 
Amersham Biosciences UK Ltd, 
Little Chalfont, UK 
DPX mounting Medium RA Lamb, Eastbourne, UK A/E020-C 
Faramount Aqueous 
Mounting Medium 
DakoCytomation, Ely, UK S3025 
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Digit-X densitometer X-Ograph Ltd, Wiltshire, UK 
Photography viewer 
K+EDTA plastic Vacutainer 
tubes 
Becton Dickinson, Oxford, UK 
Falcon test tube Becton Dickinson Lab ware 
Europe, Meylan, France 
Appendix 6. List of buffer solutions 
Solutions Protocol 
4% formalin fixative Paraformaldehyde was prepared in the fume 
cupboard. 40g were dissolved in 1L of PBS under 
heat. 
Phosphate buffer 
saline (PBS) 
A stock solution (10x concentrate) was prepared 
using NaCI (1740g), KH2PO4 (54.4g) and Na2HP04 
(227g) in 20L of purified water. The pH of 1x PBS 
was then checked and should be 7-7.3. Stock 
solution was diluted 1:10 in purified water when 
needed. 
TRIS buffer To prepare 0.05 M TRIS-buffered saline (pH 8), 
400ml of distilled water were added to 500ml of 
0.1 M Tris pH 7.5 (assay buffer). Solution was 
adjusted to pH8 with 10M NaOH, 8.7grams of NaCI 
were added and the final volume was brought to 1 
litre with water. 
Horse serum buffer For 25 ml of PBS, added 0.1% of albumin bovine 
serum, 1 ml of normal horse serum and 0.01% of 
sodium azide. 
Goat serum buffer For 25 ml of PBS, added 0.1% of albumin bovine 
serum, 1 ml of normal goat serum and 0.01% of 
sodium azide. 
ABC buffer 0.1% of albumin bovine diluted in PBS 
Glucose solution 4 g of glucose per 10 ml of purified water. Add 
water onto the powder rather than reverse it will 
dissolve better. Leave in oven for complete 
dissolution. 
Glucose oxidase 
solution 
Stock solution of lOOmg of glucose oxidase in 1mL 
of purified water was prepared and stored at -20C. 
Ammonium chloride 
solution 
Concentration 3.2 g of ammonium chloride per 20 
ml of purified water. 
Neutral red solution 50pg of neutral red + % litre of purified water 
DAB Solution 3,3'diaminobenzidine tetrahydrochloride dihydrate 
was dissolved in purified water, at 25mg/1ml, then 
aliquoted and stored frozen (-20 °C). 
Developer solution Acetate buffer was diluted in water (1:10). di-
Ammonium Nickel (II) Sulfate 6-hydrate (7 grams) 
was dissolved in 400mL of sodium acetate 0.1 M 
and then 1 ml of a glucose solution, 0.5 ml of 
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ammonium chloride solution and 4 ml of DAB stock 
solution were added. The enzyme glucose oxidase 
(40 ml in 400 ml of developer) was added to the 
developer solution immediately before or just after 
immersion of sections to initiate the reaction. 
Acetate buffer (1M) Sodium acetate 1M, brought at pH 6.0 with acetic 
acid. 
RlPA Buffer PBS with 1% NP-40, 0.5% sodium deoxycholate 
and 0.1% SDS 
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